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Abstract 
Osteoarthritis is a debilitating disease that is predicted to affect 130 million people 
worldwide by 2050. Despite being a global problem, there is no cure for osteoarthritis. 
Therefore, there is a need for cell therapies to repair injured cartilage. Delivering and 
localising cells at the injury site is a major challenge, the use of hydrogels as cell carriers may 
overcome this challenge. Fibrin is a natural hydrogel and is formed by the proteolytic action 
of thrombin on fibrinogen creating a fibrous network of fibrin fibres. Cell encapsulation in 
fibrin has been demonstrated, these natural gels suffer from batch and manufacturer 
variability. Haemostatix Ltd. have developed novel cross-linked fibrinogen gels by attaching 
the active fibrinogen binding sequence (GPRP) to different molecules. This active sequence 
binds to fibrinogen without the need for thrombin, creating a multi-branched fibrin-like gel. 
This has the potential to provide opportunities to tailor gel properties for cell delivery. The 
aim of this research was therefore to investigate the potential use of the novel fibrinogen gels 
for the encapsulation and culture of chondrocytes and mesenchymal stem cells (MSCs).  
The cell encapsulated fibrinogen gels were cultured under chondrogenic conditions for 
twenty-one days, fibrin gels were used as a reference material. This research has shown that 
chondrocytes and MSCs exhibited good survival and differentiation in both fibrinogen and 
fibrin gels. Chondrocytes remained in encapsulation throughout, and extracellular matrix 
(ECM) deposition was detected by measuring glycosaminoglycan (GAG) content and 
Toluidine blue staining. MSC’s behaved differently, with evidence for cell migration from 
the fibrinogen and fibrin gels and degradation of the gels. This behaviour was inhibited by 
incubation with aprotinin. Gel degradation and MSC migration also occurred in serum-free 
culture conditions. In the presence of aprotinin, cell activity and GAG deposition suggested 
that the encapsulated MSCs survived and differentiated in the fibrinogen and fibrin gels.  
The fibrinogen gels were comparable to fibrin for both chondrocyte and MSC 
encapsulation for cell activity and ECM deposition. The MSC migration and gel degradation 
was inhibited by aprotinin and therefore was most likely due to the activation of plasminogen. 
Removing plasminogen i.e. serum from the culture conditions resulted in gel degradation and 
MSC migration, suggesting that an aprotinin sensitive serine protease was produced that had 
activated fibrinogen and degraded the fibrinogen gels. The fibrinogen gels were comparable 
to natural fibrin, but offer the distinct advantage that the cross-linking density may easily be 
modified making the fibrinogen gel more versatile for use in different applications.  
In conclusion, this novel fibrinogen system supported chondrocyte and MSC survival and 
differentiation, and these new biomaterials show great promise for use in cell encapsulation 
and delivery for cartilage regeneration. 
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1.0 Introduction 
Articular cartilage is a highly specialised connective tissue providing structural 
support and absorbing compressive energy. Articular cartilage covers the ends of bones 
of diarthrodial joints. The main function of articular cartilage is to provide a smooth, near 
frictionless surface for joint articulation and to act as a biological “shock absorber” to 
protect articulating bones by absorbing the forces produced during movement. Articular 
cartilage has viscoelastic properties which enable it to withstand the forces placed on the 
joint due to every day movement. Cartilage is predominately avascular and aneural, 
therefore receiving nutrients and removing waste products is largely carried out by 
diffusion through the synovial fluid. This limits the regenerative capacity of articular 
cartilage because a typical cellular response of most tissues to injury usually involves 
vascularisation. Defects in articular cartilage due to trauma e.g. by sports injuries, may 
not heal and can result in eventual degeneration of the surrounding cartilage [1]. This 
process is considered the first step in a patient developing osteoarthritis.  
Osteoarthritis is the commonest degenerative arthritis affecting joints of the body 
including the hand, feet, hip, shoulder and knee joints. Osteoarthritis places a huge 
economic burden and costs 1-2 % of GDP in developed countries [2] for treatment 
including assistive devices, medicine, and surgery but also for the time required for the 
patient to be off work [3].  Approximately 8.75 million people have requested treatment 
for osteoarthritis in the UK alone [4]. It is estimated that 8.3 million people aged 45 and 
over will have osteoarthritis of the knee alone by 2035, in the UK, placing a huge 
economic burden on the National Health Service [4]. Osteoarthritis is a global problem 
and it is predicted that by 2020 osteoarthritis will be the fourth leading cause of disability 
worldwide [5]. Further to this, by 2050 it is estimated that 130 million people will suffer 
from osteoarthritis worldwide [6]. Trauma, age and obesity are the highest risk factors 
associated with osteoarthritis [7] and affects a greater number of woman compared to men 
[8]. With an ever increasing aging population and obesity predicting to affect 11 million 
people in the UK by 2030 [9] osteoarthritis is going to continue to be a burden. Joint 
replacements are far from ideal as a solution to the disease particularly for younger 
patients. This is because the device loosens over time requiring revision surgery every ten 
to twenty years. Therefore, there is a huge need to find alternative treatment options for 
sufferers.         
Regenerative medicine and tissue engineering technologies are focussed on 
stimulating tissue regeneration and repair of damaged tissues and tissue defects.  One area 
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of focus of these technologies is that of the methodologies of delivering cells to a site of 
injury to aid in the regeneration of damaged tissue. Currently, one such area of cell 
delivery research is that of autologous chondrocyte implantation (ACI). ACI is 
undergoing clinical trials and has been successful in reducing pain and regaining joint 
mobility in patients with cartilage injuries [10]. By ACI becoming successful a cell 
delivery system must be researched in order to provide the cells with the optimum 
environment for cellular growth and differentiation. The extracellular matrix (ECM) of 
most tissues is a hydrogels and this is one of the reasons hydrogels are being investigated 
for cell encapsulation and delivery.  
Many hydrogels are under investigation for cell encapsulation and delivery 
applications including fibrin. Fibrin is the first natural scaffold cells come across during 
the wound healing cascade and is a popular research material. Clinically, fibrin is used as 
a haemostat and has been used to encapsulate a variety of different cell types in vitro.   
However, due to fibrin being a natural material it suffers from batch and manufacturer 
variability. It is also difficult to alter the cross-linking density of fibrin gels. There are 
very few commercially available hydrogels with the advantages of natural materials and 
the tailorability of synthetic materials. Haemostatix Ltd. have developed a novel 
fibrinogen gel that takes advantage of the fibrinogen binding system. A synthetic 
molecule is linked to the active fibrinogen binding sequence (GPRP) that is available to 
bind to natural fibrinogen molecules. This creates a gel with the advantages of natural 
components and the tailorability of synthetic materials.  
Therefore, the aim of this project was to investigate the potential of the novel cross-
linked fibrinogen hydrogels provided by Haemostatix Ltd. for the cell encapsulation and 
delivery of chondrocytes and bone marrow-derived mesenchymal stem cells for the 
regeneration of articular cartilage. This novel cross-linked fibrinogen hydrogel was 
compared with the main competitor fibrin and agarose hydrogels.  
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2.0 Literature review 
The literature review describes the structure and function of cartilage, the effects of 
osteoarthritis on patients, clinical current treatments and treatments in research for 
cartilage injury repair. The need for cell therapies and a novel delivery system will also 
be outlined. This will provide an overview of the background of the research allowing the 
impact of this work to be shown. 
 
2.1 The structure and function of cartilage 
Cartilage is a specialised connective tissue. There are four forms of cartilage: hyaline 
cartilage, fibrocartilage, elastic cartilage, and hypertrophic cartilage [11]. Hyaline 
cartilage is the most abundant type of cartilage within the body and can be found in the 
nose, trachea and at the ends of long bones. Elastic cartilage can be found in the ear and 
epiglottis, its main function is to provide support and be flexible whilst maintaining its 
shape. Fibrocartilage has the ability to absorb high levels of compressive energy and 
provides strength and support. This type of cartilage can be found in the spine as 
intervertebral discs and as the menisci in the knee joint.  
Articular cartilage is classified as a hyaline cartilage, and is located on the ends of 
bones in diarthrodial joints.  The main functions of articular cartilage are to 1) provide a 
smooth, low-friction surface for articulation and 2) to protect the bones by absorbing the 
compressive forces produced by joint movement, i.e. it acts as a biological ‘shock 
absorber’ [12]. Cartilage is made up of a sparse population of cells (chondrocytes) 
embedded in a dense ECM. The ECM of articular cartilage is composed predominantly 
of water which makes up approximately 80 % of its wet weight [13]. The remaining 20 % 
of the wet weight of the ECM is composed of proteins and proteoglycans and the 
oligoscaccharide hyaluronan. The major protein component of the ECM is collagen with 
90 – 95 % of collagen in articular cartilage being collagen type II [14], collagen I, IV, V, 
VI, IX and XI make up the remaining collagen and contribute towards stabilising the 
collagen type II network [13]. Proteoglycans form a dense ECM [13] with aggrecan 
making up the majority of the proteoglycans, and comprises of a protein core bound to 
glycosaminoglycan (GAG) chains of chondroitin sulfate or keratan sulfate by covalent 
bonds [15] [13]. Its main function is to provide osmotic properties [13] and compressive 
strength [15] but also binds to hyaluronic acid via a protein linker to form a 
macromolecular aggregate [13]. The only cell type in cartilage is the chondrocyte and are 
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derived from mesenchymal stem cells (MSCs) [12]. MSCs secrete cartilage matrix and in 
doing this are known as chondroblasts which become surrounded in ECM known as the 
pericellular region. By chondroblasts being trapped in lacunae they are then known as 
chondrocytes. Chondrocytes are surrounded by a specialised ECM called the pericellular 
matrix [16]. This is important in protecting the chondrocytes during compressive loading 
and is involved in cell-ECM signalling and detection of compressive loads [16]. The 
pericellular matrix is formed from collagen fibrils of (mainly type VI collagen) and a 
dense proteoglycan matrix, providing protection to the chondrocytes during loading onto 
the joint [17]. The chondrocytes and surrounding pericellular matrix is known as a 
chondron. The territorial region of ECM surrounds the pericellular region protecting 
chondrocytes from mechanical forces.  
Articular cartilage is composed of three different zones: superficial, middle and deep 
zones, see Figure 2.1 [13]. The superficial zone, approximately 10 – 20 % of articular 
cartilage, is the outermost zone and is in contact with the synovial fluid, its function is to 
protect the cartilage from shear stresses and tensile and compressive forces. The middle 
zone’s main function is to resist compressive strength, this zone makes up 40 – 60 % of 
cartilage and is located between the superficial and deep zone. The deep zone is 
approximately 20 % of the total cartilage and provides the most resistance to compressive 
forces due to the organisation of collagen fibres, a low water concentration and high 
proteoglycan content. The mechanical properties of cartilage are due to the organisation 
of collagen fibrils in the interterritorial region, the ECM of the middle zone. The 
organisation of collagen fibrils differs in each zone: the collagen fibres run parallel to the 
surface of cartilage in the superficial zone; obliquely in the middle zone and perpendicular 
in the deep zone. Above the deep zone is calcified cartilage which contains hypertrophic 
chondrocytes and is separated from the deep zone by a tidemark. The function of the 
calcified cartilage is to adhere the articular cartilage to subchondral bone.  
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Cartilage, unlike other connective tissues, is mostly avascular and aneural. Therefore, 
cartilage receives oxygen and nutrients, and waste products are removed by diffusion 
through the synovial fluid and matrix. Compression and regular movement of the joint is 
essential for the metabolism of the articular cartilage [18]. It is thought that the 
avascularity of cartilage is the cause of the limited capacity of the tissue to repair. Focal 
loss of articular cartilage causes lesions in the tissue and ultimately if the cartilage loss is 
severe, can lead to bone on bone grinding in the joints causing pain, discomfort and 
restricted articulation. Osteochondral defects consists of the full thickness of the cartilage 
and injuring the subchondral bone, in doing this bone marrow MSCs are released into the 
defect and begin to regenerate the cartilage. Unfortunately, this regeneration leads to the 
formation of fibrocartilage which has inferior properties to hyaline articular cartilage [19].  
 
2.2 Cartilage injury and disease 
Articular cartilage is an essential tissue for smooth, low friction joint articulation but 
this can be affected by injury or disease of the cartilage. The three major challenges 
associated with cartilage are: injury, rheumatoid arthritis and osteoarthritis. Cartilage 
injury is commonly associated with sports injuries and occurs in younger patients [20]. 
Three main types of cartilage injury can occur: matrix disruption, partial thickness and 
full thickness defects [21]. Matrix disruption is a small defect minimally injuring the 
articular surface. Partial thickness defects cause injury to the middle zone of the articular 
cartilage and full thickness defects injure the cartilage to the subchondral bone. Due to 
the limited capacity in which cartilage can repair itself these injuries do not heal, and 
currently the only treatment option for severe cartilage injuries is a joint replacement. Due 
Tidemark 
Articular surface 
Subchondral bone 
Deep zone 
Middle zone 
Superficial zone 
Figure 2.1 A schematic diagram of the structure of cartilage to show the morphology and 
distribution of chondrocytes (front of the diagram) and the orientation of collagen fibres (right 
hand side of the diagram) 
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to patients with injuries to cartilage typically being younger, joint replacements are not a 
suitable treatment option, as discussed in more depth in section 2.3. But if the injury is 
not treated osteoarthritis may develop [22].  
The main diseases affecting articular cartilage are osteoarthritis and rheumatoid 
arthritis. Both diseases result in the loss of articular cartilage from the diarthrodial joints 
causing decreased joint mobility and chronic pain. Rheumatoid arthritis is an autoimmune 
disease that results in the inflammation of diarthrodial joints [23]. Osteoarthritis is the 
loss of articular cartilage from diarthrodial joints which may be a result from previously 
untreated cartilage injuries, as previously stated.  
The challenges of cartilage injury and disease requires intervention to aid in the repair 
of articular cartilage. There is a clear link between injury of the cartilage and osteoarthritis 
[24] and therefore osteoarthritis will be discussed in more depth below, section 2.2.1.  
 
2.2.1 Osteoarthritis 
Osteoarthritis is a debilitating complex disease which is characterised by loss of the 
articular cartilage. This leads to an increase in the friction coefficient, and loss of the 
ability of the diseased areas to withstand compressive loading which together, results in 
difficult and painful articulation of the joint. Age, obesity, sports injuries and trauma are 
risk factors for osteoarthritis [7]. It is still unknown as to why age is a contributing risk 
factor however, the majority of suffers are aged over 45. 49 % of women and 42 % of 
men aged over 75 have required treatment for osteoarthritis, these statistics suggest that 
age is contributing factor. Previously, it was suggested that osteoarthritis was an 
inevitable part of growing older this is because there is a general reduction of collagen 
synthesis contributing to other health problems such as cardiovascular disease [25].  
However, it is now considered that osteoarthritis takes many years to develop into a 
symptomatic disease with a need for clinical intervention [26]. Obesity is a risk factor due 
to the increased weight being placed on the joint. A lack of exercise and sufficient 
movement and loading onto the joint may also cause cartilage degradation [13]. This is 
because regular movement and joint loading is required for metabolic activity. It is widely 
known that changes in the biomechanical and biochemical properties of the articular 
cartilage contribute towards the progression of the disease, these changes are still 
unknown and therefore it is difficult to find a cure. A defect may occur in the cartilage 
due to a disruption in chondrocyte metabolism affecting the chondrocyte – matrix 
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interactions [15] or due to chondrocyte apoptosis. Apoptosis occurs during the normal 
developmental stages of skeletal growth [27] but releases ECM degradative factors which 
can lead to the breakdown of the cartilage creating a defect [28]. Chondrocytes may 
respond to mechanical stress by synthesising proteinases involved in the degradation of 
the matrix [15] causing a defect in the cartilage. Once a defect has been established, the 
articular cartilage surface becomes much weaker so the injury can easily worsen. Synovial 
fluid MSCs are easily accessible to cartilage and it has been shown that they are present 
in a healthy joint [29]. During the early stages of osteoarthritis it has been shown that the 
number of synovial fluid MSCs increases [29] and continues to increase throughout the 
different stages of osteoarthritis [30]. But the role of synovial fluid MSCs in osteoarthritis 
is still uncertain.     
Osteoarthritis can be categorised into stages depending on the severity and progression 
of the disease, these stages are a guide and stages can overlap throughout the progression 
of the disease [31]. The first stage is the formation of micro-cracks known as fibrillation 
in the superficial zone of the articular cartilage. Chondrocyte aggregation can occur at 
this stage causing a lack of chondrocytes within the chondron. Stage two is defined as 
fibrillation of the superficial zone. Matrix can break off the articular cartilage surface and 
into the synovial fluid causing inflammation. As fibrillation in the articular cartilage 
reaches the middle zone, the third stage of osteoarthritis has been reached. Chondrocyte 
death is also a feature of stage three. Stage four is a crucial stage for matrix degradation, 
a build-up of excess water in the middle zone and further matrix erosion into the synovial 
fluid. Complete cartilage degradation to the subchondral bone is stage five of the disease. 
This is where an attempt at cartilage repair occurs by microfracture: the subchondral bone 
can release MSCs which differentiate to form fibrocartilage. Stage six is a further change 
in the articular cartilage structure with the formation of fibrocartilage. Osteophytes also 
develop during the progression of the disease but are not stage specific and can appear at 
any time [32]. Osteophytes may form due to remodelling of the joint caused by 
osteoarthritis, or as a result of the biochemical and biomechanical changes in the joint 
stimulating the growth. This means that osteophytes may be formed as a response to 
compensate for the injured articular cartilage.  
Fundamentally, the end result of osteoarthritis is the degradation of articular cartilage, 
with the formation of bony osteophytes and subchondral bone cysts [33]. This causes 
stiffness of the joint, painful articulation and inflammation. Currently, there is no cure for 
osteoarthritis and a full joint replacement is often required. There are treatments which 
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aim to extend the life of the joint to prolong the inevitable invasive joint replacement 
surgery. 
 
2.3 Current treatments for osteoarthritis 
The main symptom for osteoarthritis is chronic pain both when the joint is bearing 
weight and when the joint is at rest. Current treatments for osteoarthritis do not provide a 
cure, but provide valuable symptomatic relief by alleviating pain, helping them to 
maintain their mobility and independence. Nonsteroidal anti-inflammatories such as 
ibuprofen and pain relief medications, for example paracetamol, may be effective in the 
early stages of the disease as well as the use of assistive devices such as walking sticks to 
aid mobility [34]. To help relieve pain, patients are also advised to exercise to reduce the 
weight bearing on the joints and to build muscle strength around the joint to relieve 
pressure. These treatments are for patients with osteophytes and those progressing to 
damage, and thinning, of the cartilage [31], [35]. Even though these treatments do not 
provide a cure for osteoarthritis, they aid in pain reduction and prolonging the function of 
the joint before a joint prosthesis is required. Other treatments which are available on the 
National Health Service are arthroscopic debridement, hyaluronic acid injections, 
microfracture, and osteotomy, to realign the joint tissues if clinically indicated, and the 
cartilage transplantation technique, mosaicplasty. Eventually replacement of an arthritic 
joint with a joint prosthesis may be required.    
 
2.3.1 Intra-joint injections of hyaluronic acid 
Hyaluronic acid is a main component of synovial fluid and aids in; the lubrication of 
articular joints; the protection of cartilage; and provides the viscoelastic properties of 
synovial fluid [36]. When the concentration of hyaluronic acid in synovial fluid is 
decreased or the hyaluronic acid is degraded the viscosity is lowered. This has an effect 
on the biomechanics of the joint and leaves it susceptible to damage. Hyaluronic acid 
injections aims to replenish the hyaluronic acid in the synovial fluid to re-establish the 
lubrication of the joint and shock absorbance [37]. Joint homeostasis is only established 
for approximately three months after a hyaluronic acid injection due to the short half-life 
of the hyaluronic acid molecule. 
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2.3.2 Arthroscopic debridement and joint lavage 
Arthroscopic debridement of the joint is when areas of damaged cartilage or bone 
in the joint are surgically removed and the joint surface smoothed by abrasion. [38]. 
Debris found within the joint can be removed by joint lavage. However, the National 
Institute for Health and Care Excellence (NICE) guidelines indicate that this procedure is 
not an effective procedure for alleviating pain for sufferers of osteoarthritis [39]. 
 
2.3.3 Microfracture 
Microfracture involves drilling holes through subchondral bone causing a wound site 
in the area of the damaged cartilage [40]. The wound site stimulates healing by forming 
a blood clot and releasing MSCs from the bone marrow which migrate into the wound. 
The MSCs proliferate and differentiate to form fibrocartilage composed mainly of type I 
collagen. The disadvantage with this procedure is that fibrocartilage has inferior 
properties to hyaline articular cartilage due to the absence of appropriate viscoelastic and 
biochemical properties under compressive loading during joint movement. The success 
of the procedure is dependent on surgical technique and the rehabilitation after surgery.  
 
2.3.4 Osteotomy 
Osteotomy is a procedure where the bone is shortened in length and the joint realigned 
to relieve pressure on the joint [41]. This surgery is carried out when osteophytes have 
formed in the joint and this bone is removed to increase the space and reduce excess 
friction inside the joint. Removal of osteophytes alleviates pain and lengthens the life of 
the joint [42]. This procedure is only suitable for a small number of patients with 
osteoarthritis.  
 
2.3.5 Mosaicplasty 
Mosaicplasty is a procedure which involves transplanting an allograft or autograft of 
cartilage to the injured areas [26]. Osteochondral disks are removed from a non-weight-
bearing area and implanted into the injury site, until the site is covered. The graft tissue 
integrates into the joint and behaves as the natural tissue. This procedure has had very 
good results in a follow up study of up to seventeen years [43]. However, due to the nature 
of the treatment the potential donor site morbidity is a potential significant problem with 
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time. It is not known whether the donor sites for the osteochondral plugs develop in to 
osteoarthritis.      
 
2.3.6 Joint replacement 
As osteoarthritis progresses, the articular cartilage is eroded and the joint space 
between the bones of the joint become closer together reducing the space in the joint 
capsule, decreasing the volume of synovial fluid in the joint. This reduces joint mobility 
making articulation very difficult and painful for the patient. A total joint replacement is 
the final treatment option and the only treatment that provides a solution to the problem 
but is not ideal as a long-term solution for osteoarthritis. Between 2003 and 2014, 772,818 
artificial joint replacements of the knee and 708,311 replacements of the hip were carried 
out, of which 96 % and 93 %, respectively, of cases were due to osteoarthritis [44]. Joint 
replacements have been very successful for patients over the age of 65, increasing the 
patient’s quality of life. For younger, more active patients the joint replacements loosen 
over time due to increased pressure on the artificial joint [45]. Revision surgery is required 
to replace the joint which is an invasive procedure and approximately 5 % of those that 
have a joint replacement will require revision surgery within 10 years of surgery [46]. 
Between 2003 and 2014, 47,829 revision surgeries of the hip and 79,859 revision 
surgeries of the knee were carried out [44].  Research is being undertaken into new 
materials for artificial joints or techniques for repairing the cartilage particularly in 
younger patients [45]. Other concerns over total joint replacements is the invasive surgical 
procedure with a 20 cm – 30 cm incision required, however mini-incision surgery is now 
recommended decreasing the incision to 10 cm – 12 cm [47]. Concerns over a greater risk 
of revision surgery and infection for mini-incision surgery have been reduced as NICE 
have reported that less than 1 % of patients treated with mini-incision surgery or the 
conventional joint replacement surgery were treated for an infection. However, patients 
required revision surgery sooner in mini-incision surgery in comparison to the 
conventional joint replacement. Research is focusing on increasing the longevity of the 
artificial joint or finding new methods for repairing cartilage for patients who require the 
artificial joint to last longer than 20 years to reduce the economic burden on the National 
Health Service. 
The current treatments for osteoarthritis are currently far from ideal. They enable 
sufferers to maintain their independence and mobility but have a finite life-span. Younger 
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patients will require revision surgery which is an invasive procedure and not as effective 
as the first joint replacement surgery. This is why research in this area is crucial for 
osteoarthritis sufferers and the burden on the social and healthcare systems for example 
the National Health Service.  
Tissue engineers are currently researching techniques based on the theory that natural 
tissue is much better at doing its job compared to joint prostheses. Cartilage is made up 
of chondrocytes which are derived from MSCs. This is why it is thought that cell therapies 
such as autologous chondrocyte implantation (ACI), that deliver chondrocytes or MSCs 
to the site of injury, could enable the regeneration of the damaged area given the 
appropriate environment. ACI is a potential treatment for the repair of the initial cartilage 
injury to prolong the joint and reduce the development into osteoarthritis.     
    
2.4 Tissue engineering and regenerative medicine 
Tissue engineering and regenerative medicine focuses its research on repairing and 
regenerating damaged tissue in the body this is because there is a limited availability of 
organs and tissues for transplantation. Due to an increasingly aging population there has 
become a much higher demand for tissue grafts and organs for repair or replacement of 
damaged tissues [48]. Regenerative medicine is an emerging field which seeks to find 
alternative methods to repair damaged, diseased or missing tissue and organs using 
various technologies, such as tissue engineering. Tissue engineering uses the knowledge 
of both cellular and molecular biology combined with materials and mechanical 
engineering to fabricate tissue grafts formed in situ or in vitro [49]. This technique is 
currently being researched for the treatment of cartilage injuries. ACI is the delivery of 
chondrocytes to the cartilage defect to aid in the repair of the tissue. This has been 
discussed in more detail below, section 2.4.1.  
 
2.4.1 Autologous chondrocyte implantation 
ACI is under investigation because it is thought that the results will produce a more 
hyaline cartilage structure and function compared to other treatments such as 
microfracture which produces fibrous cartilage. The type of cartilage produced during 
repair is important for the function of the joint. Brittberg et al was the first to publish ACI 
in 1994 and involves the implantation of cells, specifically chondrocytes, to the cartilage 
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defect [50]. The cells are isolated from an autologous biopsy of cartilage taken from a 
non-weight bearing area of the joint, cultured in the laboratory and implanted back into 
the patient [51]. After isolation, chondrocytes are cultured in monolayer on tissue culture 
plastic in the laboratory. During this culture the cells take up a fibroblast like morphology 
and after four passages the morphology changes and the cells dedifferentiate and begin to 
lose their phenotype [52]. However, it is known that the early passages of chondrocytes 
can regain full mature chondrocyte phenotype once cultured on a 3-dimensional (3D) 
substrate such as a fibrous or gel scaffold. This is why ACI is feasible and has the potential 
to regenerate injured cartilage. By isolating chondrocytes from an autologous cartilage 
biopsy, the risk of rejection is very low. However, this does mean a donor morbidity site 
is established in a non-load bearing area of the joint. Not only is this an additional surgical 
procedure for the patient, the lesion created may increase the risk of osteoarthritis in the 
future [53].  
Research into this method has been conducted since the 1990’s and therefore there are 
studies with follow up times of up to twenty years [54], [55], [56], [57]. The studies 
involve delivery of chondrocytes to an injury in the cartilage. Comprehensive clinical 
trials into ACI for osteoarthritis have not yet been conducted. The first generation of ACI 
involves the use of a periosteal flap [58]. The surgical procedures in the studies are 
invasive using a parapatellar arthrotome approach of creating a lesion [59] this approach 
opens up the knee joint completely. The injured cartilage is trimmed and neatened during 
the surgical procedure and an autologous periosteal flap was sutured over the defect 
allowing the chondrocytes to be injected between the flap and the injured cartilage [54]. 
Thus keeping the cells localised in the damaged area. Using an autologous periosteal flap 
means a reduced chance of rejection and infection however, it also means a potential site 
of morbidity which can cause further complications and procedures. A periosteal flap has 
been shown to undergo hypertrophy in a number of patients and has required further 
surgical procedures [57] highlighting the need for further research into cell delivery and 
localisation of cells to the defect.  
 ACI for cartilage defects has given good results in clinical trials and has been 
compared to microfracture as a treatment method in random clinical studies. The studies 
are mostly based on pain, improvement and satisfaction outcomes from questionnaires 
filled in by the patient over the follow up period.  A five-year follow up study has shown 
no significant differences between ACI and microfracture treatment methods in terms of 
patient pain and procedure failures [60]. Both treatments significantly reduced the pain 
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for the patient compared to pain before treatments. Unfortunately, rehabilitation was not 
enforced or controlled on this study and therefore it is not possible to determine if these 
results are due to the success of the procedure and satisfactory or lack of rehabilitation. 
Other studies have found long-term benefits to ACI including reduced pain and increased 
mobility but these studies have not seen a complete regeneration of the cartilage [56]. It 
has also been shown that ACI can form hyaline-like cartilage [55] however some cartilage 
repairs did not achieve this [54] [61]. The periosteal flap was thought to encourage 
chondrocyte de-differentiation and benefit the ACI process. However, due to 
complications such as hypertrophy, other techniques are under investigation instead of 
the use of a periosteal flap such as matrix-induced autologous chondrocyte implantation 
(MACI). 
MACI is the second generation of ACI, and involves the use of a collagen scaffold to 
seed the patient’s chondrocytes after the cell numbers have been expanded in the 
laboratory as previously described. The chondrocyte-seeded scaffold is then adhered in 
the joint using fibrin glue [62]. The use of the collagen scaffolds to deliver the 
chondrocytes to the joint keep the chondrocytes in situ and do not require further surgical 
intervention due to hypertrophy [63]. Patients experienced a reduction in pain after 
surgical intervention with MACI and hyaline-like cartilage or hyaline-like with fibro-
cartilage was found to have formed over the defect [62]. These results suggest that a 
periosteal flap is not needed to encourage hyaline-like cartilage formation and other 
scaffolds have the benefit of less complications such as hypertrophy or sutures. Therefore, 
the surgical procedure can be quicker and the need for revision surgery for the removal 
of hypertrophy is not required. 
ACI can be affected by a number of factors for example the size of the defect and age 
of the patient. Patients were analysed with defect areas of less than or greater than 15 cm2 
meaning that if the defect was a perfect circle the diameter of the defect would be 4.37 cm 
[57]. The mean defect area was measured at 8.4 cm2. A larger defect area of greater than 
15 cm2 had significantly higher outcomes scores compared to those with defects with an 
area of less than 15 cm2 however, the failure rate for larger defects was significantly 
higher over the fifteen year follow up. The age of the patient is a major factor in the 
regeneration of the cartilage using ACI, patients aged between thirty and forty five at the 
time of surgery had a significantly lower rate of success compared to those under the age 
of thirty. These studies are only investigating ACI for cartilage defects and not for the 
repair of cartilage for osteoarthritic patients. Other factors include subchondral treatments 
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attempting to repair the cartilage prior to ACI which may affect the success rate of the 
treatment, for example microfracture. If microfracture has been carried out prior to ACI 
the treatment is less effective compared to that of just ACI [64] [65].  
Research is being undertaken in MSC delivery to regenerate cartilage, this is the 
natural next step to using chondrocytes because chondrocytes are formed from the 
differentiation of MSCs. Microfracture releases MSCs from the subchondral bone but the 
cartilage formed is inferior to articular cartilage, and a scaffold material is not used to 
retain the MSC’s in the cartilage lesion. MSCs have the ability to differentiate into many 
cell lineages including chondrogenic differentiation [66] and maintain their multipotency 
on tissue culture plastic [67]. Growth factors and the cellular environment determines 
MSC differentiation for example chondrogenic differentiation requires MSCs to be 
cultured in a 3D environment in the presence of transforming growth factor beta (TGF-β) 
[68]. MSCs are more readily available compared to chondrocytes and can be found from 
different sources for example bone marrow [69], synovial fluid [70], and adipose tissue 
[71]. Due to the variance in isolation of MSCs from different sources resulting in different 
characteristics, a broad set of criteria has been set in place to classify a cell as a MSC. 
The definition includes three criteria: adherence to tissue culture plastic; multipotent 
differentiation specifically osteogenic, chondrogenic and adipogenic differentiation; and 
the expression of specific surface antigens [72]. Human MSCs must adopt all three of 
these criteria however, when using animal models the expression of surface antigens may 
not be fully established and therefore this criteria may be removed. By introducing these 
criteria, MSC characteristics will become internationally standardised to ensure that all 
research and clinical practises are using MSCs. The differentiation capacities and 
versatility of MSCs makes them suitable for a wide range of applications. Currently 
research is focussing on how to utilise MSCs in tissue engineering. MSCs have been 
shown to migrate towards injury sites and undergo specific injury site differentiation [73]. 
The reason for migration to a site of injury is still unknown, however intracellular 
signalling pathways and chemoattractive factors have been shown to induce cell 
migration [74]. MSCs also have anti-inflammatory responses at injury sites making them 
attractive for delivery to wound sites or for tissue regeneration [73]. Cell migration and 
anti-inflammatory responses are also reasons why MSCs are being investigated for tissue 
regeneration.   
ACI is a promising treatment for cartilage defects due to the positive and successful 
results with reduction of pain and increased joint mobility. However, the cartilage does 
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not fully regenerate over the long term follow up periods, and therefore more research 
needs to be carried out to find out why full cartilage regeneration may not occur. Part of 
this may be down to the delivery method, the chondrocytes used for implantation, and the 
donor morbidity site caused by a cartilage biopsy. Results with collagen scaffolds have 
shown more promising results compared to that of the periosteal flap. Further 
disadvantages of the periosteal flap are: the invasive surgical procedure; another donor 
morbidity site; the potential of the flap to undergo hypertrophy; and a desirable 3D 
environment is not created due to the chondrocytes being injected under a periosteal flap. 
This is why the third generation ACI is being investigated [75]. 3D scaffolds are being 
used to provide a more natural tissue-like environment for cell delivery and localisation 
of cells in the injury site via a less invasive method. It has been shown that implanting 
cells to a site of injury can aid in the regeneration of tissue. It is essential that there is a 
method of delivering cells safely and keep them localised in the injured area to help repair 
the damaged tissue. 
 
2.4.2 Scaffolds 
One way of regenerating tissue is by supplying appropriate cells to the damaged area 
however, the main challenge associated with this is ensuring cells remain localised at the 
injury site. Therefore, there is a need to develop novel scaffolds. The function of scaffolds 
is to provide a supporting system for cell adhesion, growth and differentiation. For the 
majority of tissue engineering applications, the basic process remains the same; cells are 
seeded onto a supporting 3D scaffold in vitro and then implanted to the site of injury [76]. 
At this point, cell adhesion, proliferation and differentiation occur across the scaffold and 
the tissue regeneration process can begin. An objective for tissue engineers is to create 
suitable 3D scaffolds to provide temporary support and guidance for tissue growth and 
regeneration [77]. There are two main ways in which scaffolds can be seeded with cells 
to encourage tissue regeneration: one way is to create a scaffold from either natural or 
synthetic materials and introduce cells in vitro, the other way is to encapsulate cells within 
the materials during the formation of the scaffold in vitro [77]. The materials used and 
the final biological application will determine which scaffold fabrication route will 
provide the best support for the desired cell type. 
Scaffolds have a very important role in tissue engineering, and need the necessary 
chemical and physical properties to support cell adhesion, growth, migration, 
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differentiation [78], and vascularisation [79], all of which are essential for the 
regeneration of most body tissues. The chosen scaffold materials must be biocompatible, 
and degradable [80], with a controllable degradation rate [81], the material and 
degradation by-products must be non-toxic and non-immunogenic, [82]. The surface 
chemistry must promote cell adhesion [83], whilst the mechanical properties should 
ideally, mimic those of the ECM of the desired tissue [84]. Porosity and interconnected 
pores [85] are essential to ensure cell migration and the delivery of nutrients and oxygen 
to the cells as well as encouraging ECM production [86]. Scaffold materials need to be 
easily fabricated in 3D in a variety of different sizes and shapes [83]. Culturing cells on 
a 3D support is essential for promoting effective tissue formation. Research in two- 
dimensional (2D) cell culture has resulted in the addition of extensive scientific 
knowledge. However, 2D culture does not enable cells to fully function as they would in 
the human body [87]. Most tissue-derived cells rapidly de-differentiate in 2D culture 
systems. Cell-cell interaction, which is essential for cell function, is limited in 2D culture 
as communication can only occur between neighbouring cells. Cells naturally grow and 
exist as 3D cultures with ECM performing the supporting ‘scaffold’ function, within the 
human body. 3D culture allows cells to have virtually 100 % contact with each other or 
the developing ECM, and therefore increasing the cell-cell interactions and mimicking 
the natural environments for the cells [88]. 
Scaffolds are used for a variety of different applications including cartilage repair [89], 
nerve regeneration [90], skin tissue engineering [91], bone regeneration [92], wound 
healing [93], and drug [94], and growth factor delivery [95]. Each of these applications 
requires cell or drug delivery to encourage the tissue to regenerate and repair itself. 
Specifically cell encapsulation has been used to treat diabetes [96], growth factor 
deficiency [97] and Alzheimer’s disease [98]. 
Fibre and porous material scaffolds including collagen [99], polyglycolic acid [100] 
and polylactic acid [101] have been studied for use in tissue engineering applications. 
These scaffolds have been successful as a supporting system for cell proliferation and 
differentiation. However, the focus of this research is on gel based scaffolds known as 
hydrogels and this is because hydrogels have the potential for use as injectable, cell 
delivery systems.  
2.4.3 Gel based scaffolds  
Hydrogels are becoming increasingly popular as a scaffold for cell encapsulation and 
delivery. Their high water content, water insolubility and tissue-like-nature make them 
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ideal for tissue engineering applications [77]. Hydrogels can be formed from both natural 
and synthetic materials, examples of which are shown in Table 2.1. Naturally occurring 
materials used in cell encapsulation typically consist of proteins or ECM components and 
have been shown to encourage cell survival to a greater extent than synthetic biomaterials 
[87]. Cellular interactions with the ECM and cell – cell communication is essential for 
survival and growth of tissues [102]. Integrins within the ECM are available for cell 
adhesion which allows cells to communicate with the matrix and surrounding cells [103]. 
Natural materials have the advantage in that they contain ligands for cell binding, 
encouraging cell survival [104]. Synthetic biomaterials do not naturally contain ligands, 
however methods such as ultraviolet radiation-induced degradation of polymers can 
promote cell adhesion to a synthetic ECM [105]. Despite these surface modification 
techniques, cellular behaviour is often more comparable to the native tissue when cells 
are encapsulated in natural materials compared to synthetic materials [104]. A limitation 
of natural materials is that they are usually derived from animal sources and therefore, 
can pose a risk of infection, disease or prion transfer and a possibility of immunogenic 
reactions in patients because of the animal-protein components [106]. It is also difficult 
to control mechanical properties and degradation rates of naturally derived hydrogels. 
However, an advantage of natural hydrogels is that the human body can naturally degrade 
the gels and excrete any waste products [107]. An advantage of synthetic hydrogels is 
that the properties can be more readily modified. For example, the mechanical properties 
can be altered to suit different applications and synthetic gels are highly reproducible with 
very little batch to batch variation [108]. Synthetic hydrogels are becoming the focus of 
research for these reasons. The properties of hydrogels make them ideal for cell 
encapsulation and delivery but only certain materials can be used for this application. The 
process of cell encapsulation requires the cells to be re-suspended in one of the 
components and this must be non-toxic, cytocompatible and cell friendly in its liquid state 
[109]. However, an advantage to this system is the gelation process will occur in and fill 
the desired area without the need to manufacture in the required shape or dimension. 
Liquid precursors will disperse the cells evenly throughout the gel and create an injectable 
system ideal for cell delivery.  
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Table 2.1 A summary of different materials used as scaffolds/cell delivery applications 
in tissue engineering 
 
Gel Source 
Encapsulated cell 
types 
Reference 
Agarose Red algae 
Mesenchymal Stem 
Cells 
Human marrow 
stromal cells 
Chondrocytes 
Huang et al. 2004. [110] 
Karoubi et al. 2009. [111] 
Mauck et al. 2002. [112] 
Albumin 
Human blood 
plasma 
Islet cells 
Smooth muscle cells 
Shapiro et al. 2000. [113] 
Gonen-Wadmany et al. 
2007. [114] 
Alginate Brown algae 
Fibroblasts 
Chondrocytes 
 
 
Mesenchymal Stem 
Cells 
 
Osteoblasts 
Schwann cells 
Hunt et al. 2010. [115] 
Andrade et al. 2011. 
[116]. Jonitz et al. 2011. 
[117] 
Smith et al. 2007. 
[118].Yu et al. 2010. 
[119] 
Alsberg et al. 2001. [120] 
Pannunzio et al. 2005. 
[121] 
Collagen 
Animal/Human 
tissue 
Fibroblasts 
 
Chondrocytes 
Marenzana et al. 2006. 
[122] 
Galois et al. 2006. [123] 
Fibrin 
Animal/Human 
blood plasma 
Smooth Muscle Cells 
Keratinocytes 
Chondrocytes 
 
Urethral Cells 
Ahmann et al. 2010. [124] 
Voigt et al. 2006. [125] 
Park et al. 2005. [126] 
Bach et al. 2004. [127] 
Ho et al. 2006. [128] 
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Mesenchymal Stem 
Cells 
Gelatin 
Hydrolysation of 
Collagen 
Chondrocytes 
Hepatocytes 
Lien et al. 2009. [129] 
Wang et al. 2006. [130] 
Hyaluronic Acid 
Human/ Animal 
tissue including 
skin and cartilage 
Chondrocytes 
Dorsal Root Ganglia 
Yoo et al. 2005. [131] 
Horn et al. 2007. [132] 
Poly(caprolactone) Synthetic Chondrocytes Li et al. 2003. [133] 
Poly(ethylene 
glycol) 
Synthetic 
Mesenchymal stem 
cells 
Chondrocytes 
Fibroblasts 
Benoit et al. 2008. [134] 
 
Bryant et al. 2002. [135] 
Koh et al. 2002. [136] 
Poly(lactic-co-
glycolic acid) 
Synthetic Chondrocytes Shin et al. 2012. [137] 
 
2.5 Synthetic hydrogels 
A range of synthetic hydrogels are used in research for cell encapsulation and delivery. 
By using synthetic products the materials can offer greater versatility and control over the 
porosity, cross-linking density and the degradation rate of the gels. The sample of 
synthetic hydrogels as shown in Table 2.1, are discussed below in more detail. 
 
2.5.1 Poly (caprolactone) 
Poly (caprolactone) (PCL) is a polyester rarely used in forming hydrogels [133]. PCL 
has been shown to be compatible with a range of cell types but there are concerns over 
the slow degradation rate. This may hinder the growth of tissue in the hydrogel resulting 
in reduced regeneration but this property makes PCL suitable for long-term drug or factor 
delivery [138]. Vaccines are another application where PCL is used because the 
environment created is not acidic making it ideal for antigens. Co-polymerisation, for 
example with PEG, has been shown to improve the mechanical properties of PCL 
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including the degradation rate and biocompatibility making it a more desirable material 
[139].  
 
2.5.2 Poly (ethylene glycol) 
PEG is the most commonly used synthetic polymer in cell encapsulation [77] and 
many successful results have been reported with various cell types, including 
chondrocytes [140]. However, the use of PEG is limited to cells which do not require cell 
adhesion due to the absence of ligands. It is possible to overcome this limitation with 
cross-linking ‘arginine–glycine–aspartic acid’ (RGD) peptide sequences into the gel. This 
peptide sequence is known to permit cell adhesion and this has given successful results 
with MSCs [141]. There are a number of ways in which PEG can be fabricated into a 
hydrogel and then tailored to a specific application [142]. Photopolymerisation is the most 
common method using light to transform PEG from a liquid state to a solid hydrogel 
creating a biocompatible gel [143]. PEG consists of two functional groups which can be 
modified for cross-linking by introducing reactive vinyl groups [144]. The density of 
cross-linked vinyl groups also determines the mechanical properties and the porosity of 
the hydrogel both properties of which are important for cell encapsulation and delivery. 
Therefore, being able to tailor the mechanical properties and porosities of the PEG gels 
is a big advantage [77]. However, an increase in mechanical strength is achieved by 
increasing the cross-linking of the hydrogel which in turn leads to decreased pore size 
which can compromise the diffusion of nutrients into or release of drugs or cells from the 
gel. It is important to achieve a balance of porosity and mechanical strength for a desired 
application. PEG is not a naturally degradable polymer and therefore will not degrade as 
tissue is forming in the hydrogel. However, it is possible to change the degradation 
properties with the addition of co-polymers [145]. PEG co-polymerised with polylactic 
acid (PLA) [146] or PCL [147] has been shown to degrade naturally. PEG can also exist 
as a stable liquid precursor prior to gelation allowing for an in situ injectable gel 
application [143]. More recently, Kar et al researched PEG hydrogels containing disulfide 
moieties enabling molecules secreted by MSCs to degrade the hydrogel [148]. Versatility 
of the gel can be established by altering the cell seeding density, and cross-linking density. 
PEG is a desirable material for use in cell encapsulation because it is biocompatible and 
can easily be modified to suit different applications.  
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2.6 Natural hydrogels 
Cellular survival and differentiation has been demonstrated when encapsulated in 
natural hydrogels. Natural materials contain proteins and/or ECM components which 
allow for ECM – cell communication which is fundamental to cellular survival. Table 2.1 
demonstrates a range of hydrogels in research for cell encapsulation applications and a 
sample of the hydrogels have been discussed in greater depth below. 
 
2.6.1 Agarose 
Agarose is a polysaccharide derived from red algae which forms a porous, soft gel 
with mechanical properties similar to tissue [149]. It is a promising gel in tissue 
engineering due to its ability to encapsulate cells and factors required for regeneration of 
injured tissue. Agarose is a temperature dependant gel; between 40 °C and 90 °C agarose 
exists as a polymer solution and as cooling takes place to approximately 30 °C to 40 °C 
a solid gel forms [150]. This temperature induced gelation makes it very difficult to 
encapsulate cells below temperatures which would injure the cells (i.e. below 40 oC) as 
gelation occurs very rapidly below 40 oC [107]. To overcome this problem a liquid 
nitrogen cooling system has been fabricated which solidifies the agarose in thirty seconds 
[149]. A disadvantage of agarose is that it is non-biodegradable by mammalian tissues, 
meaning the gel could hinder tissue formation reducing the rate and effectiveness of the 
regeneration process [151].    
 
2.6.2 Albumin 
Albumin is the most abundant protein found in human blood, constituting up to 60 % 
of blood plasma [152]. It is composed of a polypeptide chain arranged in α-helices, bound 
together by di-sulphide bonds [153]. Albumin’s main roles include transport of various 
substrates and maintaining body fluid distribution [152]. Clinically, albumin is used as a 
blood substitute, in treating severe burns, diagnosing and treating breast cancer, diabetes 
and infectious diseases, and is also in clinical trials for further cancer treatments and drug 
delivery systems [154]. A desirable trait of albumin is its ability to bind to a number of 
different substrates including hormones, fatty acids, peptides, and drugs [155]. This 
property allows albumin to be used as a controlled release drug delivery system. Despite 
albumin having a high affinity for peptides and drugs, there is a lack of cell adhesion sites 
in the molecule which limits its potential in cell encapsulation and delivery [114]. To 
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overcome this problem, albumin could be cross-linked with other proteins such as 
fibrinogen which provides cell adhesion sites and supports cell migration, whilst the 
albumin moiety could control the release of bound drugs producing a potential cell and 
drug delivery system [155]. 
 
2.6.3 Alginate 
Alginate is a water soluble polysaccharide sourced from brown algae and is currently 
widely used in the food and drink industry [156]. It is composed of two polymers D-
mannuronic acid and L-guluronic acid, joined by 1, 4 – glycosidic linkages, alginate 
forms a gel in the presence of calcium ions [157]. Mechanical properties of the gel are 
dependent on the age, species and the location of the algae sourced [158]. However, it is 
possible to alter the mechanical properties by varying the concentrations of mannuronic 
acid and guluronic acid [108] or by using a co-polymer such as PEG [159]. An alginate 
gel is fabricated under mild conditions, is porous, and naturally degradable making it ideal 
for the release of proteins and cells [160]. A big advantage of this system is its pH 
sensitivity; protein release is inhibited at low pH enabling oral ingestion for 
pharmaceutical drug applications [161]. Retaining proteins [160] and cells [162] within 
the gel for a sustained release is the main challenge associated with this gel. The addition 
of the RGD sequence improved cell adhesion to the gel in long term cultures of up to 
forty-one days [163]. Alginate gels can be formed in situ [164] or in vitro by techniques 
such as 3D printing [165]. This versatility provides greater control over gelation and the 
structure of the gels making them ideal for tissue engineering applications.  
 
2.6.4 Collagen 
Collagen has received much attention for use in tissue engineering because it is the 
most abundant protein in ECM [166]. Over twenty different types of collagen are found 
in the body, however, type I collagen is the most common. Collagen hydrogels form at 
37 oC and therefore they can be used to form gels in situ on injecting into the body [167]. 
However, this process takes around ten minutes and for most surgical applications a much 
quicker gelation process is desirable.  
Collagen naturally binds to a variety of different cells making it an ideal scaffold to 
encourage cellular adhesion and growth [168]. Collagen hydrogels are degradable by 
proteolytic activity [169] and can be modified with the addition of fibronectin, 
chondroitin sulphate or hyaluronic acid to encourage the survival of different cell types 
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[170]. Collagen gels are mechanically weak despite being a native protein component of 
ECM. However, there are techniques which can improve the mechanical strength of 
collagen gels [171]. Cross-linking is one way to do this, which affects the covalent bonds 
between collagen molecules and the intramolecular bonds [172]. Another way is to 
‘reinforce’ the collagen gel with components such as organic or synthetic polymers. Poly 
(lactic-co-glycolic acid) (PLGA) [173], GAGs [174] and glycation with ribose [175] have 
been shown to improve the mechanical strength of collagen gels. Another limitation of 
collagen gels is that cells may cause contraction of the gel after encapsulation and so 
prevent the gel from filling the required area [176]. Also, batch to batch variation in 
collagen is problematic [177]. 
 
2.6.5 Hyaluronic acid 
Hyaluronic acid has been used in clinic for cosmetic applications [178] because of this 
hyaluronic acid has been investigated for use in tissue engineering and regenerative 
medicine. However, cross-linking is required to decrease its fast degradation rate [179]. 
Cross-linking with collagen decreases the degradation rate [180] and improves the 
mechanical properties of the gel [181]. Snyder et al. researched hyaluronic acid and fibrin 
gels but this resulted in a weak gel, the mechanical strength could be improved by 
modifying hyaluronic acid with methacrylic anhydride [182]. A modified hyaluronic acid 
gel was formed from photo-crosslinking with visible light, this creates a more feasible 
gelation system in clinic [183]. This hyaluronic acid gel was combined with plasma 
lysate, a known source growth factors, and cells to create a viscoelastic matrix that was 
successfully cryopreserved. This would enable an “off the shelf” product that could be 
used as an injectable system and gelled in situ with visible light. Hyaluronic acid is a 
versatile molecule in which the properties can be altered to suit different applications and 
therefore has promise in tissue engineering and regenerative medicine. 
 
2.6.6 Chondroitin Sulfate 
Chondroitin sulfate is a glycosaminoglycan and is present in ECM, as previously 
discussed. It has been shown that chondroitin sulfate has an anti-inflammatory effect and 
as a result could have a regenerative effect on delivery [184]. Chondroitin sulfate gels are 
mechanically weak [185] however, cross-linking with PEG increases the mechanical 
properties of the gel [186]. Lü et al researched a chondroitin sulfate – chitosan hydrogel 
that has the ability to self-repair in two hours [187]. Multiple aldehyde groups were 
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formed on chondroitin sulfate allowing imine bonds to form between the amine groups 
on N-succinyl-chitosan. Imine bonds continuously break and re-form when the gel 
remains in contact forming a strong, durable repair. This gel has a major advantage in 
tissue engineering for high load-bearing applications however, a lower repair rate would 
be desirable.    
     
2.6.7 Fibrin 
Fibrin is formed as the end product of the blood clotting cascade within the human 
body and it is the first natural scaffold cells adhere to during the wound healing cascade 
[188]. Fibrin formation requires two crucial components fibrinogen and the enzyme 
thrombin [189]. Fibrinogen monomers are 45 nm in length and are comprised of two D 
domains linked to a central E domain by a coiled-coil structure as shown in Figure 2.2 
[190]. A fibrinogen molecule is composed of two sets of three polypeptide chains, Aα, 
Bβ, and γ, in the E domain. Aα contains a fibrinopeptide A sequence while Bβ contains a 
fibrinopeptide B sequence [191]. Fibrin is formed from the cleavage of fibrinopeptides A 
and B by the enzyme thrombin releasing a polymerization site which binds to the D 
domain of the adjacent fibrinogen monomer. This process creates a dense network of 
fibrin fibres and is further stabilized by factor XIIIa, also activated by thrombin, which 
cross-links α and γ chains forming a stronger clot [192]. 
Clinically, fibrin is used as a haemostat to reduce bleeding in surgical applications, 
and can come in a variety of forms such as sprays, thin films and gels [193]. Fibrin gels 
have been successfully used to encapsulate different cell types and have many properties 
which make it ideal as a cell delivery system. A desirable advantage of fibrin gels is that 
the structural and mechanical properties can be modified by altering the concentration of 
fibrinogen, thrombin or calcium present during gelation [189]. Rowe et al found that 
higher thrombin concentrations of 1 unit of thrombin per milligram (mg) of fibrinogen, 
formed more compact gels with: an increase mechanical stiffness; an increase in fibre 
bundles; thinner fibres; lower porosity; and also faster gelation times, compared to that 
of gels formed with lower thrombin concentrations of 0.001 units of thrombin per mg of 
fibrinogen [194]. Herbet et al researched the effect of calcium concentration on the 
structure of fibrin [195]. A calcium ion concentration of 2 millimolar (mM) resulted in a 
decreased fibre bundle diameter, increased fibre bundles and higher mechanical stiffness 
in comparison to fibrin gels formed with higher calcium concentrations of 10 mM, [195]. 
Fibrin scaffolds degrade naturally by fibrinolysis, however, the degradation rate can be 
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rapid [189]. Cross-linking or use of protease inhibitors such as aprotinin can reduce the 
degradation rate allowing tissue to form before the fibrin fully degrades [196] [197].  
 
 
 
Figure 2.2 A fibrinogen monomer, with two outer D domains and a central E domain connected 
by a coiled-coil. The green circles represent the fibrinopeptides. B demonstrates the binding of 
the fibrinopeptides to the outer domains of adjacent fibrinogen molecules. C is a demonstration 
of a fibrin hydrogel forming fibres. 
 .  
Fibrinogen can be isolated from the patient’s own blood reducing the risk of 
transferring infection, making fibrin a highly desirable gel [198]. Fibrin is commercially 
available and has also been used widely in clinic and therefore is known to be 
biocompatible and non-toxic when used in the body. Fibrinogen and thrombin are 
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B 
C 
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commercially available as kits as a high quality and quality assured product. Fibrin gels 
can be fabricated in two ways: creating the gel and implanting it into the body or injecting 
the gel precursors into the desired area and forming a gel in situ [199]. The latter 
procedure allows fibrin to gel in any shape and to fill small cavities which might not have 
been previously noticeable [200]. Cells would be required to be re-suspended in the liquid 
precursor aseptically meaning this must be biocompatible before gelation but would allow 
for more uniform spreading of the cells within the gel [77]. The main disadvantage of 
fibrin gels is that they are mechanically weak and therefore may not be able to withstand 
physiological conditions [201]. Increasing the density of cross-linking and the addition 
of a synthetic or natural cross-linker such as methacrylated hyaluronic acid increases the 
mechanical strength of the gel making it more suitable for use in the human body [202] 
[182]. 
 
2.7 Natural-synthetic hydrogels 
Combinations of natural and synthetic hydrogels are one way to overcome the 
limitations of pure natural or synthetic gels. The main limitation of fibrin gels is the 
mechanical stiffness [201]. The mechanical stiffness of PEG–fibrinogen gels is increased 
as the PEG concentration is increased, because more functional groups are present from 
PEG creating a highly cross-linked structure [203]. Pure PEG hydrogels have a higher 
stiffness in comparison to PEG–fibrinogen gels because PEG carries five times more 
functional groups that are available for cross-linking. PEG–fibrinogen hydrogels should 
be able to withstand higher forces in the body compared to fibrin hydrogels. A limitation 
of synthetic hydrogels is the inability of cells to adhere however, the fibrinogen moiety 
provides the natural binding ligands for cell adhesion and to support cellular growth and 
differentiation [104]. An increase in PEG concentration increases the cross-linking in the 
network which results in an increase in mechanical strength of the gel but also a decrease 
in pore size limiting cell migration and also a decrease in the rate of degradation [204]. 
This means it is important to research the optimum functional groups present for cell 
survival. 
Interpenetrating networks are fabricated from two or more components which form a 
network by intertwining [205]. Dinescu et al formed gels based on interpenetrating 
polymer network with gelatin, alginate and polyacrylamide [206]. Cells were able to 
adhere to the natural gelatin and alginate whereas the material structure and properties 
were provided by polyacrylamide, providing a gel that supported chondrogenesis.  Wen 
et al investigated polymers such as PEG to reinforce thiolated chitosan to form a 
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biocompatible hydrogel for cell or drug delivery [207]. Also, an increased cross-linking 
density reduced the rate of drug release from the gel.  
Natural and synthetic gels enable greater versatility and control over the degradation 
rate, and mechanical strength. Synthetic polymers provide the structural and mechanical 
properties required to withstand forces within the body and the natural component 
provides biocompatibility and enables cell adhesion and encourages differentiation. 
These properties are essential for an optimal gel for cell delivery applications.    
 
2.8 Cross-linked hydrogels 
As discussed in natural and synthetic hydrogels one material cannot provide the 
material properties and biocompatibility required for optimum material degradation, 
strength, cell adhesion, proliferation and differentiation. Therefore, a popular method to 
increase the strength, durability and to decrease the degradation rate of hydrogels is to 
cross-link natural or synthetic materials.  
Pan et al. researched aldehyde dextran and amino gelatin as an in situ gel that formed 
within four minutes [208]. The importance of the concentrations of cross-linkers is 
highlighted in this study. The optimum concentrations had a quicker gelation rate and 
higher cross-linking density but a faster degradation rate. This is contradictory to other 
research where the higher the cross-linking density the slower the degradation rate [209] 
[210] [211]. Moghadam et al. cross-linked hydroxyethyl methacrylate with 
dimethacryloyl hydroxylamine to fabricate a gel with a long-term degradation rate and 
the ability to withstand load bearing applications [212]. 
Fibrin is another gel that suffers from rapid degradation rate and is mechanically weak, 
as previously discussed. The addition of aprotinin [213] or tranexamic acid [214] has been 
shown to reduce the degradation rate of the fibrin gels. Cross-linking is another way to 
overcome this problem. Genipin cross-linked with fibrin gels has been shown to reduce 
degradation rate and improve the mechanical properties of the gel [215]. The macroscopic 
structure of the cell encapsulated gel remained intact for up to 28 days in culture.  
 Self-assembling cross-linked gels are advantageous in tissue engineering applications. 
This will allow for gelation in situ which is highly desirable in a clinical setting, such as 
oxidised alginate and gelatin [216]. This gel formed in situ within twenty seconds without 
the need for external factors is highly advantageous in tissue engineering. Other self-
assembly gels that are being investigated for use in tissue engineering and regenerative 
medicine require external factors to aid in their gelation. For example, chitosan and 
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gelatin self-assembly gels were prepared via ice segregation that required temperatures 
of -196 ºC [217]. Gelation requiring external factors such as photoresponsive, 
temperature, or pH changes are not desirable for a clinical setting. One way to overcome 
these problems is by using nanoparticles that can be injected to the site of injury after 
gelation has occurred.  
Cross-linking can also be used to allow for a viscous or a weak gel cell delivery system 
that is thermo-responsive for gelation in situ. Cai et al have shown that a PEG based gel 
combined with a recombinant protein formed a weak, injectable network [218]. The 
cross-linking of the gel with poly(N-isopropylacrylamide) occurs in situ due to a thermal 
phase transition on injection into the body. This cross-linking improved cell retention and 
proliferation within the gels, creating an injectable, long-term delivery system. Kim et al 
also took advantage of a thermo-responsive gel formed from methylcellulose and ECM 
from adipose tissue, as the temperature was increased to 34 ºC a stronger gel formed 
making it ideal for gelation in situ [219]. These gels have many uses in tissue engineering 
and regenerative medicine by providing a non-toxic, easy delivery system and gelation 
ensures that cells remain localised at the injury site.  
Cross-linking can also be achieved by click chemistry. Click chemistry is commonly 
used to form gels because: the reaction cannot produce toxic by-products; is carried out 
under simple reaction conditions; and does not require the use of solvents [220]. Chitosan 
and hyaluronic acid can be modified to enable a click chemistry reaction forming a gel 
that supports in vitro cell viability [221]. However, other click reactions require external 
factors such as UV light [222]. A controlled degradation rate has been a limitation for 
popular materials used in cell delivery, click chemistry is one way to overcome this. By 
incorporating nitrobenzyl moiety into a PEG – gelatin based gel, the introduction of UV 
light causes the complete degradation of the gel in 2 – 3 minutes [223]. This would enable 
complete control over the degradation of the gel and is highly advantageous in cell 
delivery applications.   
The recent advances in hydrogel formation via cross-linking is a popular method to 
overcome the main limitations of materials used for cell delivery. As described 
throughout this section, a variety of different methods can be used to fabricate gels to 
allow for an injectable delivery system. Materials can be modified to provide gelation in 
situ without the need for external factors to ensure the hydrogels are suitable for and have 
potential use in clinic.   
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2.9 Commercial hydrogels 
According to GlobalData the market value for osteoarthritis therapies is $5 billion and 
set to continue rising. But the expense and lack of comprehensive clinical trial data of 
using cell therapies is inhibiting its progress. There are a range of commercially available 
hydrogels as shown in Table 2.2, which are available for research purposes or are used in 
current clinical trials. Each hydrogel is a cell free scaffold or delivers the patient’s own 
cells to the site of injury. The fabrication method and components of the 
scaffolds/hydrogels are not stated in Table 2.2 if they are unknown, this is because 
companies may not publish all aspects of their scaffolds for intellectual property reasons. 
All information displayed in Table 2.2 is publicly available.  
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Table 2.2 A table describing the current commercial hydrogels for use in research or clinic 
Company Product Material Application Cell type Comments 
Organogenesis Apligraf PLA 
Healing of 
venous leg 
ulcers and 
diabetic foot 
ulcers 
Human 
keratinocytes 
and 
fibroblasts 
The scaffold was made by solvent casting and sterilised with 
ethylene oxide 
Must be left in place for 5-7 days and then the dressing can be 
changed every 3 to 5 days. For 5-7 days the patient is unable to 
move and must remain in hospital until the wound has healed 
Cellon ArtiGEL N/A 
Research 
model 
Human 
adipose 
derived stem 
cells 
Available as two solutions: A - stored at room temperature B - 
stored at 4 ˚C. Different storage temperatures requires more set 
up time. 
Precursor solutions can be mixed with cell suspension in a 1:1 
ratio, then placed in a well, a 100 µl solution in a 96-well plate 
takes 8 minutes to gel. This is a long gelation period. 
ebers Go Matrix Gelatin 
Research 
model 
Fibroblasts 
Gelatin from porcine skin, this is an animal product therefore a 
risk of cross species contamination. 
Scaffolds are 9 mm diameter and 1 mm thick. Uniform pores 
with sizes of 60, 90 or 130 µm 
Cytograft TESA 
Cell extracellular 
matrix 
Regeneration 
of damaged 
tissue 
Dermal 
fibroblasts 
Cells are cultured and matrix synthesis is encouraged. This is 
used to form sheets, threads or sprays to repair damaged organs 
or deliver cells. 
The cells used are either allogenic which will give a risk of 
rejection or autologous cells isolated from a biopsy and 
cultured.  
 56 | P a g e  
 
C h a p t e r |  Literature review 
3D Biotek 3D Inserts 
PCL 
PLGA 
Polystyrene 
Hydroxyapatite 
discs 
Polystyrene and 
PCL 
Research 
model 
N/A 
Sterilised via gamma radiation. PCL comes ready to use as well 
plate inserts. This is a 100 % porous structure and has batch to 
batch reproducibility. Scaffolds are mechanically strong and 
easy to handle. 
Polystyrene and PCL combination has been used for cancer 
research and stem cell research 
PCL - is rarely used due to its slow degradation rate 
Histogenics NeoCart Collagen (type 1) 
Cartilage 
regeneration 
Patients own 
chondrocytes 
 
This company are in stage 3 of clinical trials. A biopsy of non-
load bearing cartilage is taken from the patient. The cartilage is 
digested into chondroctyes and are expanded in the laboratory 
and seeded onto the collagen scaffold. The scaffold is placed in 
a bioreactor under load bearing conditions for 1 week. The 
scaffold is then transferred to static culture for 1-2 weeks and is 
then re-implanted over the defect in the patient. 
Collagen - Gelation forms at 37 ˚C and therefore can form in 
situ in the body but this process takes about 10 minutes. It has 
the ability to bind to a variety of different cell types. There is 
batch to batch variation it is mechanically weak and as a gel 
contraction occurs after cell encapsulation. 
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ESI.BIO Stem 
Cell Solutions 
Sigma 
Biotime 
HyStem 
HyStem -C 
HyStem - HP 
Hyaluronic acid 
In vivo and in 
vitro research 
N/A 
Customisable hydrogels.  
HyStem - animal free 
HyStem - C contains thiol modified collagen to encourage cell 
adhesion. Contains animal products. 
HyStem - HP contains collagen for cell adhesion and heparin. 
Gives a slow more controlled release, suitable for growth factor 
delivery. Contains animal products 
Hyaluronic acid is a naturally occurring polysaccharide and is 
found in the extracellular matrix of connective tissue 
biotissue AmnioGraft 
Amniotic 
membrane 
Protect, repair 
and heal 
damaged eyes 
N/A 
 
Ready to use membrane that is removed from the packaging 
and placed directly on the patient’s eye to encourage healing. 
Usually used after surgery 
 
Corbion 
PURASORB 
poly DL-
lactide/glycolide 
(PDLG) 
poly DL - lactide 
(PDL) 
Controlled 
release 
systems 
N/A N/A 
PURASORB 
PLGA 
lactide/caprolactone 
copolymers 
Tissue 
regeneration 
scaffolds 
N/A N/A 
Organovo Bioprinting Human tissue Tissue repair N/A 
 
3D printing of human tissue for repair of damaged tissue 
DASILVA 
institue 
Stem cell 
therapy 
Adipose derived 
stem cells 
Tissue 
regeneration 
Adipose 
derived stem 
cells 
 
Stem cells are isolated from the patient’s naturally occurring 
adipose tissue. These are then re-implanted to the site of injury 
for regeneration 
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Advanced 
polymer 
materials INC. 
N/A 
PEG/PLA 
PEG/PCL 
PEG/PHB 
Drug delivery 
and tissue 
engineering 
N/A 
Supply companies with biocompatible and biodegradable 
polymers 
PEG - has no cell adhesion sites and doesn't degrade naturally, 
requiring cross-linking to make this happen. The mechanical 
properties and porosity can easily be tailored but increasing the 
strength results in a decrease in porosity interfering with 
nutrient transfer. 
 
DSM 
Drug 
delivery 
platform 
poly esteramide 
(PEA) 
Drug delivery N/A Short and long term drug delivery 
OPTRIX 
Porcine derived 
tissue 
Tissue repair 
and 
regeneration 
De-
cellularised 
 
Porcine tissue grafts that can be used for soft tissue repair. 
The graft is de-cellularised, disinfected and virus' inactivated. 
Contains collagen matrix and ECM components 
 
Regenexx 
Regenexx-
SD 
N/A 
Cartilage 
regeneration 
Bone marrow 
and blood 
samples from 
patient 
 
A bone marrow and blood sample are taken from the patient 
and sent to the lab for processing and re-injected into the 
injured area. The cells can be injected on the same day or if 
more cells are required, after culturing. MSCs are isolated from 
the bone marrow and growth factors are isolated from blood. 
 
Anika Orthovisc 
Highly purfied 
sodium hyaluronate 
Alleviate 
symptoms of 
osteoarthritis 
None 
 
An injection of hyaluronic acid into the joint to alleviate 
symptoms of osteoarthritis. 3 to 4 injections are given 1 week 
apart to reduce symptoms for up to 6 months. 
Non-animal product 
Reduction in joint pain and increased mobility 
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Anika Hyalofast Hyaluronic acid 
Scaffold for 
cartilage 
regeneration 
Mesenchymal 
stem cells 
 
The scaffold is a single 3D fibrous layer of a benzyl ester of 
hyaluronic acid. 
The scaffold can be cut to fit the injured area and implanted. 
MSCs can be entrapped on the scaffold, and the scaffold 
supports MSC adhesion, proliferation and differentiation. 
As the scaffold degrades hyaluronic acid is released into the 
joint providing a good environment for cells to grow. 
It is suggested that hyaline cartilage is formed from this method 
 
biotissue 
Bioseed 
A polymer fleece 
and biological glue 
Scaffold for 
cartilage 
regeneration 
Patients own 
chondrocytes 
 
The biological glue fixes the chondrocytes onto the fleece. 
Requires 28.8 million cells per scaffold 
The fleece and be implanted over the injury 4.5 weeks after the 
original biopsy. 
Fleece needs to be cut to fit injury 
 
Chondotissue 
Polymer fleece and 
hyluronic acid 
cartilage 
regeneration 
Cell free 
 
The fleece forms the network structure and the hyaluronic acid 
aids in regeneration of the cartilage. 
Fixation is with absorbable nails and involves an invasive 
surgery 
 
ISTO 
technologies 
RevaFlex scaffold free 
cell based 
cartilage 
Patients own 
cells 
 
A cell biopsy is taken from the patient and grown in the lab into 
a piece of cartilage and implanted over the site of injury 
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Haemostatix 
Ltd 
Peprostat 
Recombinant 
albumin coupled to 
fibrinogen binding 
peptides 
Wound 
healing 
N/A 
 
Recombinant albumin is an artificial product coupled to the 
fibrinogen binding peptide. This peptide can bind to fibrinogen 
rapidly without the need for the enzyme thrombin, like fibrin. 
Peprostat is being developed as a haemostat for surgical 
applications. 
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2.9.1 HyStem 
HyStem is a customisable hydrogel kit available from a variety of different companies. 
The basis of HyStem is hyaluronic acid which is thiolated making it highly versatile. 
Peptides can be linked onto thiolated hyaluronic acid by using simple chemistry for 
additional binding capabilities. As described previously, cross-linking has the additional 
advantages of increasing mechanical strength and providing cell adhesion sites. 
Hyaluronic acid is a component of synovial fluid and is known to encourage chondrogenic 
differentiation and therefore is a potential hydrogel for ACI. 
 
2.9.2 Regenexx 
The delivery of cells to a site of injury can be achieved without the use of a hydrogel 
or scaffold and has been done by Regenexx by obtaining bone marrow biopsies and blood 
samples and injecting these to the site of injury. The advantage of this is that the bone 
marrow can be injected to the site of injury on the day of isolation, reducing the patient’s 
procedures and the need to isolate and culture the cells from the biopsy. This deceases the 
costs of cell delivery dramatically. 
 
2.9.3 ISTO Technologies 
ISTO Technologies are taking a different approach and isolating chondrocytes from 
healthy cartilage biopsies from the patient. The cells are then used to produce a piece of 
healthy cartilage in the laboratory and re-implanted into the patient at the site of injury. 
The disadvantage to this method is that potential morbidity sites are formed which may 
develop into osteoarthritis in the future creating more complications from the procedure. 
The isolating and culturing of chondrocytes in the laboratory to enable cartilage formation 
will be expensive.  
 
2.9.4 Novel cross-linked fibrinogen gels 
Fibrin gels have been used in vitro for cell encapsulation and as a biological sealant 
and are formed from the cleavage of fibrinogen by the enzyme thrombin (section 2.6.7). 
However, thrombin is unstable and must be stored at -20 °C [224]. Haemostatix Ltd. have 
developed a novel haemostat, known as Peprostat, for surgical and wound healing 
applications. This novel haemostat consists of a carrier bound to the highly active 
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fibrinogen binding peptide (FBP) sequence (GPRP) [224]. The peptide sequence GPRP 
interacts with the distal ends of fibrinogen monomers resulting in a dense, branched 
fibrillar network without the need for the enzyme thrombin as shown in Figure 2.3 [225]. 
Peprostat is currently in clinical trials as a topical haemostat and consists of recombinant 
albumin coupled to FBP. Peprostat rapidly forms a durable clot which stems bleeding in 
surgical applications. Peprostat is stable in liquid form and is available in ready-to-use 
formulations and therefore is a much faster and more convenient haemostat for use in 
surgery, in comparison to the leading competitor fibrin. Further carriers for FBPs are 
being developed by Haemostatix Ltd. such as peptide sequences known as P15, P17 and 
the commercially available HyStem. The peptide sequence P15 contains the RGD 
sequence known to encourage cell adhesion [226]. P17 contains DGEA which binds to 
α2β1 integrin [227] present on collagen type I [228] and is known to interact with various 
cells via binding to α2β1 integrins on the cell surface. 
The research conducted for this thesis focused on the use of these novel cross-linked 
fibrinogen gels for cell encapsulation and delivery. In vitro, on introduction of the FBP 
carrier molecules to commercially available fibrinogen a novel fibrinogen cross-linked 
hydrogel is formed almost instantaneously. The stable, liquid precursor is a huge 
advantage in tissue engineering to allow cells to be re-suspended in the solution before 
gelation, adding to the ease of delivering cells to a site of injury. The liquid precursors 
also allow for an injectable system with gelation in situ, creating a less invasive procedure 
for patients. The fibrinogen – FBP carrier network is a cell friendly hydrogel and therefore 
has potential for tissue engineering applications. The structure and properties of the 
hydrogel are readily modified by altering the concentration of FBP available during 
gelation. In theory, the higher the concentration of FBP present during gelation, the 
greater the cross-linking density of the hydrogel producing a more compact and less 
porous gel. This allows the hydrogel to be tailored for specific cell types and applications. 
It is known that the environment in which the cells are in, can change cellular behaviour 
and therefore having a versatile hydrogel is important when a variety of different cell 
types can potentially be encapsulated [229]. The combination of natural and synthetic 
materials provides the benefits from the natural tissue-like environment for cell survival 
and the versatility of synthetic materials to ensure the porosity is optimal for cell survival 
and differentiation.  
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Figure 2.3 A schematic of the gelation process between FPA and fibrinogen molecules to create 
a cross-linked fibrous network A) shows the FPA molecule, the fibrinogen binding peptides are 
represented in red, B) shows the gelation process beginning with the active fibrinogen binding 
sequence binding the fibrinogen molecule, C) shows the highly cross-linked fibrous network. 
  
Soluble 
carrier 
Linker 
Fibrinogen 
binding 
peptide 
(GPRP) 
B 
C 
A 
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The FBPs are bound to different carrier molecules including Peprostat, P15, P17, and 
HyStem and when individually combined with fibrinogen form the novel cross-linked 
fibrinogen gels. As described above, recombinant albumin is one carrier for the FBP and 
is known as Peprostat. On introduction to commercially available fibrinogen in vitro a 
hydrogel is formed, this hydrogel will be known as FPA. Other carriers for the FBP that 
were researched as part of this thesis and when combined with fibrinogen to for a gel will 
be known as P15 and P17. As described above, P15 contains the sequence RGD which 
has been incorporated into gels to encourage cell adhesion and cell viability [230] [231].  
P17 contains the DGEA sequence which has been demonstrated to encourage cell 
differentiation [232]. Further information about these peptides are unavailable due to 
intellectual property sensitivity.   
HyStem is a commercially available research product and contains chemically 
synthesised hyaluronic acid and a thiol-reactive cross-linker, refer to Figure 2.4. This 
enables the incorporation of the active fibrinogen binding sequence to bind to the thiol-
reactive cross-linker. The FBP was linked to the hyaluronic acid molecule via the 12mer 
peptide sequence, refer to Figure 2.5. The thiol group binds to the 12mer peptide sequence 
using thiol-maleimide chemistry and the resulting molecule contains the FBP linked to 
the hyaluronic acid molecule, refer to Figure 2.6. On contact with fibrinogen the FBPs 
bind to the outer D domains of the fibrinogen molecules creating a hydrogel. HyStem is 
based on hyaluronic acid as a carrier for the fibrinogen binding peptide and was chosen 
because it has been shown to support chondrocyte differentiation and greater ECM 
deposition [233].  
 
 
A 
B 
Figure 2.4 The molecular structure of a hyaluronic acid molecule (A) and the thiolated 
hyaluronic acid molecule (B) 
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In summary, the cell encapsulation and delivery systems reported have limitations. 
Synthetic gels suffer from poor biocompatibility. Natural gels have the advantage of 
biocompatibility and provide a favourable environment for cell survival but have the 
added risk of disease transmission, and batch variability leading to challenges in quality 
assurance. Novel cross-linked fibrinogen gels based on the highly regulated and high 
quality commercial fibrinogen with synthetic cross-linkers, have the potential to 
overcome these issues to provide an innovative gel that is optimised for cell 
encapsulation. These novel cross-linked fibrinogen gels will not only provide the 
biocompatibility and tissue-like nature of natural materials but also the versatility of 
greater control over the cross-linking density. If developed further these novel fibrinogen 
gels should provide a superior cell delivery system that would improve the clinical 
outcomes of cell therapy and regenerative medicine approaches to hyaline cartilage 
repair. Therefore, this study will investigate the use for these novel fibrinogen gels for 
cell encapsulation and delivery focussing on cartilage repair. 
Figure 2.5 molecular structure of the 12mer peptide linked to the fibrinogen binding peptide 
(FBP) 
Figure 2.6 HyStem (R1) conjugated to the fibrinogen binding peptide (R2) via the 12mer 
peptide sequence 
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3.0 Aims and Objectives 
The literature review (chapter 2) outlines the need for cell therapies as a treatment for 
cartilage injury and the need for novel gels as a cell delivery system. Fibrin has been 
widely used for the encapsulation of cells in vitro with successful results but has 
limitations in that the enzyme thrombin is required for gelation, batch to batch variation 
of fibrin occurs and the cross-linking density of the gels cannot be readily modified. The 
novel cross-linked fibrinogen gels overcome the disadvantages of current gels used to 
encapsulate cells in vitro. Gelation occurs without the need for an enzyme and the porosity 
of the gels can readily be modified. The novel cross-linked fibrinogen gels have not been 
investigated for cell encapsulation, cell growth, and differentiation prior to this research. 
Therefore, this study focuses its research on the use of novel fibrinogen gels for cell 
encapsulation and delivery applications specifically for the regeneration of cartilage.  
The specific aims of this research are outlined below. 
1. To encapsulate bovine articular chondrocytes for the optimisation of the novel 
cross-linked fibrinogen gel fabrication technique and to create a cell friendly 
and reliable encapsulation system. Including the investigation of the role of 
calcium concentration on gelation and the effect this may have on chondrocyte 
survival.  
 
2. To investigate the viability and differentiation ability of chondrocytes within 
the novel cross-linked fibrinogen gels using the leading competitor fibrin and 
agarose gels as reference materials. The optimisation methods used in aim 1 
will be continued to investigate aim 2. Chondrocyte activity and differentiation 
will be analysed by PrestoBlue® assay, live/dead staining, glycosaminoglycan 
content and histological staining of Haematoxylin and Eosin to investigate cell 
morphology and distribution and Toluidine blue for visualisation of the 
proteoglycan content. Four concentrations of FPA used to form the FPA-
fibrinogen gels will be investigated: 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1 
and 0.7 mg.mL-1 of FPA.  
 
Hypothesis: chondrocytes encapsulated in FPA-fibrinogen gels formed from 
2.66 mg.mL-1 FPA will have greater survival, differentiation and formation of 
ECM in comparison to the lower concentrations of FPA.  
 67 | P a g e  
 
C h a p t e r |  Aims and Objectives 
3. To investigate the encapsulation of bovine bone marrow mesenchymal stem 
cells within the novel cross-linked fibrinogen gels using fibrin as a reference 
material, using the optimised techniques from aim 1. The mesenchymal stem 
cells will be cultured under chondrogenic conditions and the analysis will be 
carried out using the techniques in aim 2. The hypothesis is that the 
mesenchymal stem cells will exhibit greater survival, differentiation and ECM 
formation in FPA-fibrinogen gels formed from 2.66 mg.mL-1 FPA.  
 
Hypothesis: that both chondrocytes and mesenchymal stem cells will behave 
similarly when encapsulated in the FPA-fibrinogen and fibrin gels.   
 
4. To investigate the potential mechanisms responsible for bovine bone marrow 
mesenchymal stem cell migration and subsequent gel degradation when 
mesenchymal stem cells are encapsulated in FPA-fibrinogen and fibrin gels. 
Serum-free conditions and inhibitors for plasmin and matrix 
metalloproteinases will be investigated. Cell migration will be determined by 
crystal violet stain and gel degradation will be analysed by light microscopy.   
 
Hypothesis: Gel degradation and mesenchymal stem cell migration from the 
fibrinogen gels was caused by fibrinolysis.  
 
On completion of the research, the novel cross-linked fibrinogen gels will be optimised 
for chondrocyte and bone marrow mesenchymal stem cell encapsulation, survival and 
differentiation, under chondrogenic conditions. The optimisation process will be 
described in detail and will focus on biocompatibility and chondrocyte survival. The 
optimum method will be established and conducted for further in depth studies into 
chondrocyte and bone marrow mesenchymal stem cell survival and differentiation. This 
research will therefore determine if the novel cross-linked fibrinogen gels have potential 
for chondrocyte and bone marrow mesenchymal stem cell encapsulation and delivery for 
the repair of injured cartilage. This will add significant knowledge to the field of 
regenerative medicine by providing a versatile and innovative cell encapsulation and 
delivery system.      
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4.0 Materials and methods 
4.1 Materials 
A list of materials used throughout the research project. 
Cell Isolation and Culture Methods 
Tissue collection  
• 10 % Trigene – Scientific Laboratory Supplies, UK 
• 70 % Industrial methylated spirit – Genta Medical, York, UK 
• Post mortem blades and handles – Swann Morton, Sheffield, UK 
• Aluminium foil – Tesco 
• Dissection tray - Scientific Laboratory Supplies, UK 
• Scalpel handles - Scientific Laboratory Supplies, UK 
• Scalpel blades, size 22 and 11 - Scientific Laboratory Supplies, UK 
• Tweezers and Spatulas - Scientific Laboratory Supplies, UK 
• Electric saw –  Ryobi, B&Q, UK 
• Record Junior 51 vice 
• 50 mL Centrifuge tubes – BD Biosciences, Oxford, UK 
• Petri dishes – ThermoFisher Scientific, Loughborough, UK 
• Dulbecco’s phosphate buffered saline – Sigma-Aldrich, Poole, UK 
• Pasteur pipettes – Alpha Laboratories 
• Class 2 laminar flow cabinet – Walker Safety Cabinets Ltd, UK 
Chondrocyte isolation and expansion 
• Galaxy R Plus CO2 incubator – Eppendorf, UK 
• Class 2 laminar flow cabinet – Walker Safety Cabinets Ltd, UK 
• Trypsin – Sigma-Aldrich, Poole, UK 
• Stuart orbital shaker - Scientific Laboratory Supplies, UK 
• T75 flasks - Greiner Bio-One– Sigma Aldrich, Poole, UK 
• Bacterial collagenase  – Sigma Aldrich, Poole, UK 
Culture medium used 
• High glucose (4500 mg/l) Dulbecco's Modified Eagle Medium – Sigma 
Aldrich, Poole, UK 
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• Foetal calf serum, batch number F9665 – Sigma Aldrich, Poole, UK 
• Penicillin- Streptomycin solution – Sigma Aldrich, Poole, UK 
• 1 M HEPES buffer – Sigma Aldrich, Poole, UK 
• Non-essential amino acids– Sigma Aldrich, Poole, UK 
• L-alanyl-L-glutamine– Sigma Aldrich, Poole, UK 
• Human basic fibroblastic growth factor – PrepoTech, London, UK 
Bone marrow mesenchymal stem cell isolation and expansion 
• Galaxy R Plus CO2 incubator – Eppendorf, UK 
• Trypsin – Sigma-Aldrich, Poole, UK 
• Stuart orbital shaker - Scientific Laboratory Supplies, UK 
• Petri dishes – ThermoFisher Scientific, Loughborough, UK 
• Scalpel handles and size 22 blades - Scientific Laboratory Supplies, UK 
• Phosphate buffered saline - Sigma-Aldrich, Poole, UK 
• Tissue culture Cell+ growth surface treated T25 and T75 flasks for sensitive 
cells - Sarstedt, Germany 
Culture medium used 
• Low glucose (1000 mg/l) Dulbecco's Modified Eagle Medium – Sigma 
Aldrich, Poole, UK 
• MSC qualified serum, batch number 12664 – ThermoFisher Scienctific, 
Loughborough, UK 
• Penicillin- Streptomycin solution – Sigma Aldrich, Poole, UK 
• L-glutamate - Sigma Aldrich, Poole, UK 
• Human basic fibroblastic growth factor – PrepoTech, London, UK 
MG63 expansion 
• Human osteoblastic MG63 cell line - Sigma Aldrich, Poole, UK 
• Galaxy R Plus CO2 incubator – Eppendorf, UK 
• Tissue culture T75 flasks - Greiner Bio-One 
Culture medium used 
• Alpha modified minimum essential medium eagle - Sigma Aldrich, Poole, UK 
• Penicillin- Streptomycin solution – Sigma Aldrich, Poole, UK 
 70 | P a g e  
 
C h a p t e r |  Materials and methods 
• 1 M HEPES buffer – Sigma Aldrich, Poole, UK 
• L-alanyl-L-glutamine– Sigma Aldrich, Poole, UK 
• Human basic fibroblastic growth factor – PrepoTech, London, UK 
Articular cartilage isolation and injury 
• 6 mm and 3 mm disposable biopsy punches – Kai Medical 
• Scalpel handles and size 22 blades - Scientific Laboratory Supplies, UK 
Medium used 
• High glucose (4500 mg) Dulbecco's Modified Eagle Medium – Sigma Aldrich, 
Poole, UK 
• Foetal calf serum, batch number F9665 – Sigma Aldrich, Poole, UK 
• Penicillin- Streptomycin solution – Sigma Aldrich, Poole, UK 
• 1 M HEPES buffer – Sigma Aldrich, Poole, UK 
• Non-essential amino acids– Sigma Aldrich, Poole, UK 
• L-alanyl-L-glutamine– Sigma Aldrich, Poole, UK 
• Dexamethasone - Sigma Aldrich, Poole, UK 
Preparation of hydrogels 
Preparation of fibrinogen gels 
• Peprostat – Haemostatix Ltd, Nottingham, UK 
• Polyethylene glycol-bound fibrinogen binding peptides – Haemostatix Ltd, 
Nottingham, UK 
• Peptide sequences P15 and P17 – Haemostatix Ltd, Nottingham, UK 
• HyStem – Sigma-Aldrich, Poole, UK 
HEPES buffered saline solution containing calcium 
• HEPES – Sigma Aldrich, Poole, UK 
• Sodium Chloride - Sigma Aldrich, Poole, UK 
• Calcium Chloride - Sigma Aldrich, Poole, UK 
HyStem Preparation 
• HyStem – Sigma-Aldrich, Poole, UK 
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• 12mer peptide sequence – Haemostatix, Nottingham, UK 
• 5,5’-dithiobis-2 nitrobenzoic acid - Sigma-Aldrich, Poole, UK 
• Cysteine - Sigma-Aldrich, Poole, UK 
• N-ethylmaleimide- Sigma-Aldrich, Poole, UK 
• Stuart heat stirrer – N/A 
• Amicon® Ultra 0.5 mL Centrifugal Filters– Merck Millipore Ltd 
• 0.22 µm Millipore filter – Merck Millipore Ltd 
HEPES buffered saline solution 
• HEPES – Sigma Aldrich, Poole, UK 
• Sodium Chloride - Sigma Aldrich, Poole, UK 
Fibrinogen 
• TISSEEL ready to use tissue sealant solutions – Baxter Healthcare, UK 
HEPES buffered saline solution containing calcium 
• HEPES – Sigma Aldrich, Poole, UK 
• Sodium chloride - Sigma Aldrich, Poole, UK 
Agarose gels 
• Agarose - Sigma Aldrich, Poole, UK 
• Phosphate buffered saline - Sigma Aldrich, Poole, UK 
Cell encapsulation in gels 
Differentiation medium 
Additives 
• L-ascorbic acid – Sigma-Aldrich, Poole, UK 
• Bovine Pancreatic Insulin - Sigma-Aldrich, Poole, UK  
• Dexamethasone - Sigma-Aldrich, Poole, UK 
• Human transforming growth factor β-1 – PeproTech, USA 
• ITS liquid media supplement (100x) - Sigma-Aldrich, Poole, UK 
• Bovine serum albumin - Sigma-Aldrich, Poole, UK 
• β-glycerophosphate – Sigma-Aldrich, Poole, UK 
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Cell encapsulation in fibrinogen and fibrin gels 
• 96-well culture plates - Greiner Bio-One 
Cell encapsulation in 4 % agarose gels 
• Agarose - Sigma-Aldrich, Poole, UK 
• Phosphate buffered saline - Sigma-Aldrich, Poole, UK 
• 24-well culture plates - Greiner Bio-One 
Cell encapsulation and delivery to injured cartilage 
• 100 mm micro spatula – Scientific Laboratory Supplies, UK 
Fibrinogen based gels formed within well structures. 
Agarose wells for forming fibrinogen gels 
• Agarose - Sigma-Aldrich, Poole, UK 
• Phosphate buffered saline - Sigma-Aldrich, Poole, UK 
• 8 mm biopsy punch – Kai Medical  
• 4-well culture plates - Greiner Bio-One 
Polytetrafluoroethylene (PTFE) wells for forming fibrinogen gels 
• Polytetrafluroethylene 
• Bandsaw  
• Pillar drill  
• Elco plus saw handpiece – W&H, Hertfordshire, UK 
• Glossy polishing paste - Henry Schein Inc. USA 
• Grant ultrasonic bath XB2 
Gels formed in 96-well plates and transferred to 24 well plate 
• 96-well and 24-well culture plate - Greiner Bio-One 
• 100 mm micro spatula – Scientific Laboratory Supplies, UK 
Effect of calcium concentrations on fibrinogen gel formation 
• TISSEEL ready to use tissue sealant – Baxter Healthcare, UK 
• Peprostat – Haemostatix, Nottingham, UK 
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HEPES buffered saline solution containing calcium 
• HEPES – Sigma Aldrich, Poole, UK 
• Sodium Chloride - Sigma Aldrich, Poole, UK 
• Calcium Chloride - Sigma Aldrich, Poole, UK 
Gel degradation 
• Marimastat – R&D Systems 
• Aprotinin – R&D Systems 
• Dimethyl sulfoxide - Sigma Aldrich, Poole, UK 
• Plasminogen from bovine plasma - Sigma Aldrich, Poole, UK 
Plasmin detection 
• 96-well culture plates - Greiner Bio-One 
• L-Lysine - Sigma Aldrich, Poole, UK 
• Potassium Phosphate - Sigma Aldrich, Poole, UK 
• Sodium Phosphate - Sigma Aldrich, Poole, UK 
• D-Val-Leu-Lys p-nitroanilide dihydochloride plasmin substrate - Sigma 
Aldrich, Poole, UK 
• Monopotassium phosphate - Sigma Aldrich, Poole, UK 
• Sodium phosphate dibasic - Sigma Aldrich, Poole, UK 
• Tecan Spectrophotometer Infinite M200 – Tecan, Switzerland 
uPA and tPA detection 
• Amiloride - Sigma Aldrich, Poole, UK 
• Dimethyl sulfoxide (DMSO) - Sigma Aldrich, Poole, UK 
• BIOPHEN - Urokinase chromogenic substrate – Aniara Dianostica, USA 
• 96-well culture plates - Greiner Bio-One 
• Tecan Spectrophotometer Infinite M200 – Tecan, Switzerland 
Tris buffer 
• Tris base – Fisher Scientific, USA 
• Sodium Chloride - Sigma Aldrich, Poole, UK 
• Tween-20 - Fisher Scientific, USA 
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KC4 coagulation 
• KC4 coagulation analyser – N/A 
• TISSEEL ready to use fibrinogen – Baxter Healthcare, UK 
• Peprostat, P15 and P17 - Haemostatix, Nottingham, UK 
Scanning electron microscopy 
• Glutaraldehyde - Agar Scientific, Essex, UK 
• 0.1 M cacodylate buffer 
Cacodylate buffer 
• Sodium cacodylate - Sigma Aldrich, Poole, UK 
• Distilled water  
• Hydrochloric acid - Sigma Aldrich, Poole, UK 
Freeze dry dehydration 
• VirTis benchtop SLC freeze dryer – Biopharma Process Systems Ltd, UK 
• Scanning electron microscopy stubs – Agar Scientific, Essex, UK 
Ethanol dehydration 
• Ethanol - Fisher Scientific, USA 
• Osmium Tetroxide - Agar Scientific, Essex, UK 
• Scanning electron microscopy stubs – Agar Scientific, Essex, UK 
Cell viability assay 
• PrestoBlue® - Life Technologies, Paisley, UK 
• 96-well culture plates - Greiner Bio-One 
• Tecan Spectrophotometer Infinite M200 – Tecan, Switzerland 
Live/Dead Staining and Confocal Microscopy 
• 5-chloromethylfluorescein diacetate (CMFDA cell tracker Green) - Invitrogen 
Ltd 
• Propidium Iodide - Invitrogen Ltd 
• Formaldehyde - Fisher Scientific, USA 
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• Zeiss Axioskop LSM 510 meta confocal laser scanning microscope (Carl Zeiss 
Ltd, UK) 
• x10 (EC Plan – Neofluar 10x/0.3 dry objective lens 
Measurement of glycosaminoglycans using 1,9-dimethylmethylene blue dye 
• Tecan Spectrophotometer Infinite M200 – Tecan, Switzerland 
• Techne 60-well heat block – Scientific Laboratory Supplies, UK 
• 96-well culture plates - Greiner Bio-One 
• 1,9-dimethylmethylene blue - Sigma Aldrich, Poole, UK 
• Papain - Sigma Aldrich, Poole, UK 
• N-acetyl cysteine - Sigma Aldrich, Poole, UK 
• Chondroitin sulfate A - Sigma Aldrich, Poole, UK 
Phosphate buffer 
• Disodium phosphate - Sigma Aldrich, Poole, UK 
• Sodium dihydrogen phosphate - Sigma Aldrich, Poole, UK 
• Ethylenediaminetetraacetic acid - Sigma Aldrich, Poole, UK 
Histological examination 
• Aluminum foil – Tesco 
• Adhesive cork discs – Duratool 
• Liquid nitrogen – British Oxygen, UK 
• Optimal cutting temperature compound – ThermoFisher Scientific, 
Loughborough, UK 
• Microm HM560 cryostat  
• Microscope and camera  
• SuperFrost Plus glass slides - ThermoFisher Scientific, Loughborough, UK 
• Glass coverslips – VWR, USA 
• Paraformaldehyde - Sigma Aldrich, Poole, UK 
Haematoxylin and eosin stain 
• H&E Shandon staining line 
• Mayer’s Haematoxylin – ThermoFisher Scientific, Loughborough, UK 
• Eosin Y stain – ThermoFisher Scientific, Loughborough, UK 
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• Scott’s tap water – ThermoFisher Scientific, Loughborough, UK 
• Xylene - Fisher Scientific, USA 
Alcian Blue 
• Alcian blue – Merck Millipore Ltd  
• Neutral red – Merck Millipore Ltd 
• Distilled water 
• Xylene - Fisher Scientific, Loughborough, UK 
• DPX slide mounting medium - ThermoFisher Scientific, Loughborough, UK 
Toluidine blue 
• Toluidine blue – Merck Millipore Ltd 
• Distilled water 
• Xylene - Fisher Scientific, Loughborough, UK 
• DPX slide mounting medium- ThermoFisher Scientific, Loughborough, UK 
Crystal Violet 
• Crystal Violet – Merck Millipore Ltd 
• Distilled water 
TRIzol RNA Extraction 
• TRIzol – Life Technologies, Paisley, UK 
• Jencons Ultrasonic processor 
• Ethanol - Fisher Scientific, USA 
• Isopropanol - Fisher Scientific, USA 
• Distilled water 
• NanoDrop 1000 spectrophotometer – Thermo Scientific, USA 
• Water saturated 1-butanol - Fisher Scientific, USA 
• Water saturated diethylether – May & Baker Ltd, UK 
• Nuclease free water  
Extraction Isolate II RNA mini kit 
• Isolate II RNA mini kit – Bioline, London, UK 
• 2-Mercaptoethanol – Sigma-Aldrich, Poole, UK 
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Electrophoresis of RNA 
• Agarose – Sigma-Aldrich, Poole, UK 
• Distilled water 
• Formaldehyde – Sigma-Aldrich, Poole, UK 
• Ethidium bromide – Sigma-Aldrich, Poole, UK 
• SNCRWA electrophoresis machine – BioRad 
• Syngene INGENIUS 3 
MOPS buffer 
• MOPS - Fisher Scientific, USA 
• Sodium Acetate - Sigma Aldrich, Poole, UK 
• Ethylenediaminetetraacetic acid - Sigma Aldrich, Poole, UK 
 
4.2 Cell Isolation and Culture Methods 
4.2.1 Tissue collection 
Bovine metacarpophalangeal joints (from the 3rd metacarpal to the hoof) were obtained 
from a local abattoir from skeletally mature animals (18-24 months within six hours of 
slaughter for the meat industry). The joints were sprayed with 10 % Trigene and 70 % 
industrial methylated spirit (IMS) and the skin was removed from the joint using a post 
mortem blade, the ends were wrapped in aluminium foil leaving only the joint uncovered 
to reduce the risk of infection. The skinned joints were transferred to a class 2 laminar air 
cabinet and all subsequent procedures were carried out aseptically. 
The metacarpophalangeal joints were fully opened using a scalpel and the articular 
cartilage was removed from the joint surfaces using a scalpel and tweezers. The pieces of 
articular cartilage were transferred into Ca2+/Mg2+- free phosphate buffer saline (PBS) 
until the tissue collection was completed. The metacarpophalangeal joint was then 
removed from the laminar air cabinet and the 3rd metacarpal bone was removed from the 
lower bones using a post-mortem blade.  All the soft tissue was then removed and the 
bone was clamped in a vice. The end of the bone was removed using an electric saw to 
gain access to the bone marrow and the cut bone immediately transferred back to aseptic 
conditions. The surface of the bone marrow was discarded to reduce the risk of infection, 
and the underlying bone marrow was collected using a spatula into a 50 mL centrifuge 
tube.  
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4.2.2 Chondrocyte isolation and expansion 
The PBS was removed from the articular cartilage pieces and replaced with 2.5 % 
(w/v) trypsin followed by incubation of the tissue at 37 °C for 30 minutes. The trypsin 
was removed and the cartilage pieces washed thoroughly with PBS. High glucose 
Dulbecco's Modified Eagle Medium (DMEM) containing 1000 units.mL-1 penicillin, 
1000 µg.mL-1 streptomycin solution with 10 % foetal calf serum (FCS) and 2 mg.mL-1 of 
bacterial collagenase was added to the cartilage pieces. The container containing the 
cartilage was transferred to an orbital shaker and incubated with gentle shaking at 30 
rotations per minute (rpm) at 37 degrees (°C) for 24 hours to digest the tissue. The cell-
containing medium was removed and transferred to centrifuge tubes followed by 
centrifugation at 1,000 rpm, 192 g (g-force) for 10 minutes to pellet the chondrocytes. 
After centrifugation, the supernatant solution was removed and the cell pellet resuspended 
in PBS. The cells were pelleted by centrifugation at 1,000 rpm, 192 g for 10 minutes. This 
washing procedure and centrifugation was repeated again in the same manner. The final 
chondrocyte pellet was resuspended in high glucose DMEM and the cell number 
determined using a haemocytometer. The chondrocytes were then plated in tissue culture 
T75 flasks and cultured in monolayer culture in basic medium [high glucose DMEM 
containing 1000 units.mL-1 penicillin, 1000 µg.mL-1 streptomycin solution, non-essential 
amino acids, and 10 mM HEPES buffer pH 7.4. and 10 % v/v FCS]. The cell cultures 
were incubated at 37 oC in a humidified atmosphere of 95 % air/ 5 % CO2 until confluent. 
The cells were then passaged or used for experimentation as described in sections 4.4.2. 
 
4.2.3 Bone marrow mesenchymal stem cell isolation and expansion 
The bone marrow was transferred to a petri dish and minced using a scalpel blade. 
Low glucose basic medium [low glucose DMEM containing 1000 units.mL-1 penicillin, 
1000 µg.mL-1 streptomycin solution, and non-essential amino acids, buffer pH 7.4. and 
10 % v/v MSC-qualified FCS and 5 ng.mL-1 FGF2] and 2 mg.mL-1 of bacterial 
collagenase was added to the bone marrow. The petri dish was placed on an orbital shaker 
and incubated at 37 °C for 4 hours to digest the bone marrow. The digestion was collected 
in a 50 mL centrifuge tube and centrifuged at 1,000 rpm, 192 g for 10 minutes. The 
supernatant was removed and the pellet re-suspended in PBS and centrifuged at 1,000 
rpm, 192 g for 10 minutes, this was repeated twice. The cell pellet was then re-suspended 
with low glucose basic medium and plated in T25 flasks for sensitive cells. The cell 
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cultures were then incubated at 37 oC in a humidified atmosphere of 95 % air/ 5 % CO2 
until confluent. The cells were then passaged or used for experimentation as described in 
section 4.4.2. 
 
4.2.4 MG63 expansion 
The human osteoblastic MG63 cell line were cultured in alpha modified minimum 
essential eagle medium (αMEM) containing 1000 units.mL-1 penicillin, 1000 µg.mL-1 
streptomycin solution, non-essential amino acids, and 10 mM HEPES buffer pH 7.4 and 
10 % v/v FCS. The cell cultures were incubated at 37 oC in a humidified atmosphere of 
95 % air/ 5 % CO2 until confluent. The cells were then passaged or used for 
experimentation as described in section 4.4.2. 
 
4.2.5 Articular cartilage isolation and injury 
 
All procedures were carried out under aseptic conditions. The joint was opened as 
previously described in section 4.2.1. Articular cartilage was removed from the 
metacarpophalangeal joint (image A and C, Figure 4.1) by using a 6 mm disposable 
biopsy punch (image B, Figure 4.1) to create circular cartilage disc. The discs were 
removed from the underlying bone using a scalpel blade, image C, Figure 4.1 shows the 
result of the removed cartilage discs from the joint. Any pieces of cartilage that were 
removed with bone fragments attached were discarded. An example of this can be seen 
in image C, Figure 4.1, the white circle highlights the disruption of the bone during the 
removal of the cartilage discs by scalpel blades, the black circle shows that only the 
cartilage has been removed and therefore these cartilage discs were used for 
experimentation. This procedure created reproducible discs of cartilage, as seen in image 
D, Figure 4.1. The cartilage discs were incubated in basic medium containing 10 % FCS 
and 1 µM dexamethasone for 48 hours. The medium was then replaced with basic 
medium and 10 % FCS until required for experimentation. Injury to the cartilage was 
formed using a 3 mm sterile, disposable biopsy punch to create a 3 mm hole in the centre 
of the disc prior to experimentation. The black arrow in image E, Figure 4.1 shows the 
3 mm injury created in the circular cartilage disc, shown by the white arrow. Finally, the 
hydrogel (black arrow) was formed as described in 4.5.3 and transferred onto the cartilage 
injury (white arrow) using a sterile spatula, this can be seen image F, Figure 4.1.   
 80 | P a g e  
 
C h a p t e r |  Materials and methods 
 
 
Figure 4.1 Bovine articular cartilage injury model taken from the metacarpophalangeal joint (A). 
A 6 mm biopsy punch (B) was used to obtain reproducible circular discs of cartilage (D, white 
arrows) from the joint (C). Cartilage discs were discarded if bone fragments were attached (C, 
white circle) and used for experimentation if only cartilage was removed (C, black circle). A 
3 mm biopsy punch was used to create an injury (E, black arrow) in the cartilage disc (E, white 
Arrow), and the cell encapsulated fibrin or FPA-fibrinogen gels (F, black arrow) were placed over 
the injury (F, white arrow). 
 
  
A B 
D 
C 
E F 
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4.3 Preparation of hydrogels 
4.3.1 Preparation of novel cross-linked fibrinogen gels 
The FBP preparations used in this thesis (Peprostat, Polyethylene glycol, P15, and 
P17) were provided by Haemostatix Ltd. HyStem was purchased as a commercial kit and 
the FBP was linked to HyStem as described in section 4.3.2. The concentrations of FBPs 
were as follows: 
• Peprostat is based on the coupling of multiple FBPs to a soluble carrier of 
recombinant albumin. Preparation of FPA were used at concentrations of 
2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1 and 0.7 mg.mL-1 in 10 mM HEPES-buffered 
saline pH 7.4 containing 2 mM CaCl2  unless otherwise stated.
  
 
• Polyethylene glycol-bound fibrinogen binding peptides (PEG) were used at 
1 mg.mL-1, 0.75 mg.mL-1, 0.5 mg.mL-1 and 0.25 mg.mL-1 in 10 mM HEPES-buffered 
saline pH 7.4 containing 10 mM CaCl2 as indicated in individual experimental results. 
 
 
• P15 is a peptide containing the sequence RGD, the nature of this carrier is undisclosed 
due to intellectual property but it is coupled to the active FBP sequence. P15 was used 
at concentrations of 0.75 mg.mL-1, 0.5 mg.mL-1 and 0.25 mg.mL-1 in 10 mM HEPES-
buffered saline pH 7.4 containing 2 mM CaCl2 
 
 
• P17 is a peptide containing the sequence DGEA, the nature of this carrier is 
undisclosed due to intellectual property but is coupled to the active FBP sequence. 
P17 was used at concentrations of 0.75 mg.mL-1, 0.5 mg.mL-1 and 0.25 mg.mL-1 in 
10 mM HEPES-buffered saline pH 7.4 containing 2 mM CaCl2
 
 
• HyStem is a commercially available kit in which the FBP has been linked as described 
in section 4.3.2. This FBP was used at concentrations of 1 mg.mL-1 and 0.75 mg.mL-
1 in 10 mM HEPES buffered saline pH 7.4 containing 2 mM CaCl2 as indicated in 
individual experiments 
Each concentration of the above materials was chosen based on its ability to form a 
hydrogel with 34 mg.mL-1 fibrinogen. The concentrations used are summarised in table 
4.1 below.  
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Table 4.1 shows the ratio of fibrinogen binding peptides to fibrinogen molecules present during 
gelation for the concentrations used for each hydrogel. To form the fibrinogen gels, equal volumes 
of fibrinogen at 34 mg.mL-1 and the required concentration of the fibrinogen-binding peptides 
were mixed together. 
Carrier 
Fibrinogen: fibrinogen 
binding peptide 
Concentration of 
carrier (mg.mL-1) 
Peprostat 
1:8 2.66 
1:6 2 
1:4 1.33 
1:2 0.7 
PEG 
1:8 1 
1:6 0.75 
1:4 0.5 
1:2 0.25 
P15 
Unknown 0.75 
Unknown 0.5 
Unknown 0.25 
P17 
Unknown 0.75 
Unknown 0.5 
Unknown 0.25 
HyStem 
Unknown 0.75 
Unknown 0.5 
Unknown 0.25 
 
 
4.3.2 HyStem preparation 
A HyStem vial containing 10 mg of hyaluronic acid and 9.6 mg of phosphate buffer 
salts was thawed at room temperature and 1 mL of 20 mM phosphate buffer was added 
to the vial which left at 40 ˚C to dissolve the vial contents. Once dissolved, the thiol 
concentration was determined by Ellman’s assay. 4 mg.mL-1 of 5,5’-dithiobis-2 
nitrobenzoic acid (DTNB) was made up in Ellman’s buffer consisting of 0.1 M sodium 
phosphate buffer and 2 mM EDTA at pH 8. 3 mM cysteine was used as a standard. 980 
µL of Ellman’s buffer, 10 µL of sample and 10 µL of DTNB was pipetted into a cuvette 
and the absorbance was measured at 412 nm. The thiol number was estimated and the 12-
mer peptide was added at 1.5 times the mole concentration of the estimated thiols. This 
was left at 40 ˚C for fifteen minutes followed by incubation overnight on a gentle orbital 
shaker at ambient temperature. An Ellman’s assay was carried out to determine if there 
was any unreacted thiols in the solution. Filter centrifuge tubes were pre-washed in 
distilled water overnight. The filter centrifuge tubes were centrifuged for 14,000 rpm for 
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five minutes to remove the water. 500 µL of 0.9 % NaCl containing 10 mM HEPES-
NaOH pH 7.4 was added to the filter centrifuge tubes and the tubes centrifuged again at 
14, 000 rpm for five minutes. This washing procedure was repeated once more. 400 µL 
of HyStem – 12mer peptide was then added to three of the filter centrifuge tubes and 
centrifuged at 14, 000 rpm for three minutes. 150 µL of 0.9 % NaCl containing 10 mM 
HEPES pH 7.4 was added to each filter centrifuge tube and centrifuged at 14, 000 rpm 
for five minutes, this was repeated. The HyStem – 12mer peptide was collected and the 
concentration calculated. The solution was passed through a 0.22 µm Millipore filter to 
remove any gelled components and the gelation of the resultant Hystem-12mer peptide 
preparation was tested with 34 mg.mL-1 fibrinogen.  
 
4.3.3 Fibrinogen  
Human fibrinogen was purchased as “TISSEEL ready to use solutions” from Baxter 
Healthcare UK. The TISSEEL was supplied as in a dual syringe with a fibrinogen solution 
in one syringe and a solution of thrombin in the other syringe. The thrombin and 
fibrinogen solutions were removed individually and stored separately in aliquots at -20 oC 
for experimental use. The TISSEEL fibrinogen was supplied at 90 mg.mL-1 and diluted 
to 34 mg.mL-1 with 10 mM HEPES buffered saline solution pH 7.4  
 
4.3.4 Fibrin gels 
The fibrin-based tissue sealant preparation “TISSEEL ready to use solutions” was used 
to form the fibrin gels. The thrombin and fibrinogen solutions were supplied in separate 
sections of a dual syringe system. As described above in section 4.3.3, the fibrinogen and 
thrombin solutions were removed individually from the dual syringe system and stored 
separately in aliquots at - 20 oC for experimental use. The TISSEEL fibrinogen was 
supplied at 90 mg.mL-1 and diluted to 34 mg.mL-1 with 10 mM HEPES buffered saline 
pH 7.4. The fibrin hydrogels were formed using fibrinogen at a concentration 34 mg.mL-, 
which is the same concentration used for forming the fibrinogen gels. To form the 
hydrogels, thrombin at 192 IU.mL-1 was mixed with the fibrinogen solution in a 1:1 
volume ratio. 
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4.3.5 Agarose gels 
4 % agarose gel was made in non-sterile PBS by mixing 4 g of agarose powder with 
100 mL of non-sterile PBS. A 1 % agarose gel was also used to coat the well bottoms of 
the tissue culture multi-well plates to prevent cell adhesion to the tissue culture plastic, 
1 g of agarose powder was mixed with 100 mL of non-sterile PBS. The 1 % and 4 % 
agarose preparations were sterilised by autoclaving the gels at 115 °C for 15 minutes, and 
then leaving the gel solutions to cool overnight.  
 
4.4 Cell encapsulation in gels 
4.4.1 Differentiation medium 
• Chondrocyte medium consisted of basic medium as described in section 4.2.2 
with 10 % FCS, 50 µg.mL-1 L-ascorbic acid  and 1 µg.mL-1 insulin 
• bBM-MSC medium containing FCS consisted of low glucose basic medium as 
described in section 4.2.3 with 10 % MSC qualified FCS, 100 nM 
dexamethasone, 10 ng.mL-1 transforming growth factor (TGFβ-1), 10 µg.mL-1 
insulin, 5.5 µg.mL-1 transferrin, 5 ng.mL-1 selenium and 25 µg.mL-1 ascorbic 
acid.  
• bBM-MSC serum free medium consisted of low glucose basic medium as 
described section 4.2.3 containing 1 mg.mL-1 bovine serum albumin (BSA), 
100 nM dexamethasone, 10 ng.mL-1 transforming growth factor beta-1 (TGFβ-
1), 10 µg.mL-1 insulin, 5.5 µg.mL-1 transferrin, 5 ng.mL-1 selenium and 25 
µg.mL-1 ascorbic acid. 
• MG63 medium consisted of αMEM as described in section 4.2.4 containing 
2 % FCS, 1 mg.mL-1 BSA, 10 nM dexamethasone, 25 µg.mL-1 ascorbic acid, 
and 10 mM β-glycerophosphate.   
 
4.4.2 Cell encapsulation in fibrinogen and fibrin gels 
Cells were encapsulated in fibrinogen gels formed from either FPA, PEG, P15, P17, 
or HyStem coupled with fibrinogen. Cells were also encapsulated in fibrin gels and 4 % 
agarose gels.  
Chondrocytes and MG63s were detached from the tissue culture plastic by the 
following procedure. The culture medium was removed and the cell layer washed with 
PBS. The PBS was removed and replaced with a 0.05 % trypsin- 0.02 % EDTA solution 
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and the cultures incubated at 37 °C for 5 minutes. When the cells had detached, the 
cell/trypsin-EDTA solution was transferred into a centrifuge tube and FCS added to 1-
5 % vol/vol to inhibit the trypsin. The cells were pelleted by centrifugation at 1,000 rpm, 
192 g for 5 minutes. After centrifugation, the supernatant was removed and the cell pellet 
was resuspended in basic culture medium for chondrocytes and αMEM for MG63s ready 
for re-plating in monolayer culture or encapsulation into the gels. Chondrocytes at 
passage 2-3 were used for gel encapsulation experiments as it has been found in house 
that the chondrocytes at these passages will re-differentiate to gain a full mature 
chondrocyte phenotype during culture in 3D. MG63s at passage 30-40 were used for gel 
encapsulation experiments. 
Bovine bone marrow MSCs (bBM-MSCs) were removed from the tissue culture flask 
as follows: the culture medium was removed and the cell layer washed with PBS. The 
PBS was removed and replaced with 3 mL 0.025 % trypsin- 0.01 % EDTA solution in 1 
mL PBS to ensure the trypsin-EDTA does not cause cell death and the cultures were 
incubated at 37 °C for 3 minutes. When the cells had detached, the cell/trypsin-EDTA 
solution was transferred into a centrifuge tube and FCS added to 1-5 % vol/vol to inhibit 
the trypsin. The cells were pelleted by centrifugation at 1,000 rpm, 192 g for 5 minutes. 
After centrifugation, the supernatant was removed and the cell pellet was re-suspended in 
low glucose basic culture medium ready for re-plating in monolayer culture or 
encapsulation into the gels. bBM-MSCs at passage 2-4 were used for gel encapsulation 
experiments as it has been found in house that the bBM-MSCs at these passages will 
differentiate during culture in 3D 
 
Chondrocytes, bBM-MSCs, and MG63s were re-suspended in the fibrinogen at 6x106 
cells per 1 mL, unless otherwise stated. Individual hydrogels were formed by 
simultaneously pipetting 50 µL of the required carrier with 50 µL of the fibrinogen-cell 
suspension in a single well of a 96-well plate. As a control, cell-free hydrogels were also 
formed in wells of the 96-well plate. The 96-well plate was transferred to 37 ˚C for 5 
minutes to allow for complete gelation on an orbital shaker at 30 rpm and covered with 
200 µL of culture media appropriate to the cell type. Each of the experimental conditions 
were carried out in triplicate. 
 
 86 | P a g e  
 
C h a p t e r |  Materials and methods 
4.4.3 Cell encapsulation in 4 % agarose gels 
4 % agarose was slowly melted to form a solution in a microwave and cooled to 39 °C 
in a water bath. Once cooled, chondrocytes were re-suspended in the agarose solution at 
3x106 cells per 1 mL of 4 % agarose and an Eppendorf pipette was used to transfer 100 
µL of the 4 % agarose – cell suspension to a well in a 12-well plate. 1 % agarose was used 
to cover the tissue culture plastic, to inhibit cells from adhering to the bottom of the 12-
well culture plate. Cell-free 4 % agarose was used as a control and cell-containing 4 % 
agarose gels were produced in triplicate.  
 
4.4.4 Cell encapsulation and delivery to injured cartilage 
Cells were also delivered to the injured cartilage as previously described in section 
4.2.5. To do this 300,000 chondrocytes or bBM-MSCs were encapsulated in either 
fibrinogen gels formed from FPA 2.66 mg.mL-1 in 10 mM HEPES buffered saline 
solution pH 7.4 containing 2 mM CaCl2 or 34 mg.mL
-1 fibrin gels in 10 mM HEPES 
buffered saline solution pH 7.4 containing 2 mM CaCl2 in a well in a 96-well plate as 
described in section 4.4.2. When gelation was complete, the gels were then transferred to 
the cartilage injury site (image F, Figure 4.1), formed as described in section 4.2.5 by a 
sterile spatula. The cartilage and gels were then cultured in the appropriate medium for 
up to 14 days. 
 
4.5 Fibrinogen based gels formed within well structures 
Although gelation was almost instantaneous after mixing the Peprostat and fibrinogen, 
it was slow enough to allow spreading of the gel over the surface of the culture wells. The 
spreading of the gels was limited by using individual wells of a 96-well plate in which to 
cast the gels. However, the size of the well in relation to the number of cells (0.5 x 105 
cells per well) meant that the encapsulated cells had to have media changes every day. In 
addition, nutrient exchange may be compromised due the small volume of culture media 
that could be added to the culture wells. Gelation in larger wells meant that the cell/gel 
solution spread over the bottom of the culture wells before gelation was complete, hence, 
a thin gel film rather than a gel ‘ball-like’ structure was formed. Therefore, methods in 
which gelation can occur and the gels transferred to larger culture wells were investigated 
and two methods that were investigated are described below: 
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4.5.1 Agarose wells for forming fibrinogen gels  
A sterile 1 % agarose gel was formed as described in section 4.4.3. The agarose gel 
was melted by microwaving it at a low power for approximately 2 minutes. The agarose 
was quickly added at a volume of 1 mL to the bottom of the culture wells of a 24-well 
plate using an Eppendorf pipette and left to gel at room temperature for 30 minutes to 
form an agarose coating. A 6 mm diameter hole was created in the gel coating using a 
sterile biopsy punch and the agarose plug was removed. The FPA analogues were gelled 
with fibrinogen in the centre of the holes as seen in Figure 4.2, and as previously described 
in section 4.4.3. 1 mL of basic high glucose culture medium as described in section 4.2.2 
was then added per well. Using this methodology larger volumes of culture medium could 
then be provided for the encapsulated chondrocytes compared to chondrocytes 
encapsulated in a 96-well culture plate. The medium was then changed daily or every two 
days.  
 
 
Figure 4.2 A 24-well plate with 1% agarose lining the bottom of the plate. A 6 mm hole was 
removed from the agarose 1% and fibrinogen based gels were gelled inside the hole (these appear 
pink in colour). 
 
4.5.2 Polytetrafluoroethylene (PTFE) moulds for forming fibrinogen gels 
6 mm diameter holes with a depth of approximately 8 mm were drilled into a small 
blocks of PTFE, as seen in Figure 4.3. These blocks were cleaned in a Grant ultrasonic 
bath for 5 minutes and was then polished using a hand-held polisher and Henry Schein 
glossy polishing paste until the surface became smooth. The PTFE blocks were then 
carefully rinsed and cleaned in the ultrasonic bath again for 5 minutes, and then 
autoclaved at 115 °C for 15 minutes to sterilise them. The gels were produced as described 
in section Preparation of hydrogels but mixed with the co-polymer in the PTFE well. It 
was then possible to transfer the gel pellet from the PTFE blocks to a 12-well plate using 
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a sterile spatula. After transfer to the 12-well culture plates the gel encapsulated cells were 
cultured with 2 mL of basic high glucose culture medium as described in section 4.2.2.  
 
Figure 4.3 Blocks made from polytetrafluoroethylene, approximately 13 mm x 13 mm, the 
hole was drilled using a 6 mm drill piece to a depth of 8 mm and then polished. 
 
4.5.3 Gels formed in 96-well plates and transferred to 24 well plate 
Cells were suspended in the fibrinogen solution at 6x106 cells per 1 mL of fibrinogen 
and the cell encapsulated gels formed in a 96-well plate as described in section 4.4.2. 
After gelation was complete, the gels were transferred to a 24-well plate, to contain one 
gel per well using a sterile micro spatula. This allowed 2 mL of medium to be placed on 
the hydrogels providing more nutrients for the cells.  
 
4.6 Effect of calcium concentrations on fibrinogen gel formation 
High calcium concentrations can be detrimental to cellular survival but calcium ions 
are crucial for gelation of the fibrinogen based gels. Therefore, different calcium 
concentrations of: 20 mM, 10 mM, 5 mM, 2 mM and 0 mM were investigated to 
determine the lowest level of calcium which is required for gelation. The experiment was 
set up as previously described in section 4.5.2 initially without the inclusion of 
chondrocytes to check if a gels were formed at the Ca2+ concentrations investigated. The 
fibrinogen gels were then formed from the fibrinogen binding peptides and a fibrinogen 
solution in 10 mM HEPES-buffered saline solution (pH 7.4) containing and 3x106 
chondrocytes.mL-1. 
 
4.7 Gel degradation 
 Gel degradation by encapsulated bBM-MSC and MG63 in FPA gels at a concentration 
of 2.66 mg.mL-1 and fibrin gels was investigated by the addition of Marimastat (a 
metalloproteinase inhibitor) or aprotinin (a serine-proteinase inhibitor) into the culture 
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medium. Marimastat was used at a final concentration of 1 µg.mL-1 or 10 µg.mL-1 in 
culture medium to inhibit matrix metalloproteinase (MMP) activity. Aprotinin was used 
at a final concentration of 5 µM, 204.48 KIU, or 30 µM, 1226.48 KIU, in low glucose 
DMEM to inhibit plasmin. To investigate the activation of plasminogen to plasmin in the 
samples, cell free and cell encapsulated hydrogels were prepared as previously described 
in section 4.4.2. At day three 50 µM plasminogen in 20 mM Lysine buffer was added to 
the medium of each hydrogel for 24 hours.  
4.7.1 Plasmin detection 
The medium samples were collected and 100 µL samples were pipetted into a 96-well 
plate in triplicate. 90 µL of lysine/phosphate buffer containing 10 mM potassium 
phosphate, 70 mM sodium phosphate and 100 mM lysine was added. The plate was read 
at 402 nm wavelength using the TECAN infinite 200 series for a complete zero time point. 
10 µL of 6.5 mM D-Val-Leu-Lys p-nitroanilide dihydochloride plasmin substrate in 
10 mM sodium phosphate dibasic, 70 mM monobasic potassium phosphate and 100 mM 
lysine at pH 7.5. This was then added to each well at a final concentration of 0.3 mM and 
the maximum absorbance measured at 402 nm every 10 minutes for 2 hours using the 
TECAN infinite 200 series. The plates were incubated at 37 ºC for the duration of the 
measurements. 
4.7.2 uPA and tPA detection 
The medium was collected from the 24 hour plasminogen incubation and 100 µL 
samples were pipetted into two 96-well plates in triplicate. 5 µL of 500 µM amiloride in 
DMSO was added into the samples in one of the 96-well plates and 85 µL of Tris-buffer 
containing 50 mM Tris, 150 mM NaCl, 0.02 % Tween-20 was added to these samples. 
90 µL of Tris buffer was added to the plate which does not contain amiloride. The plates 
were read at an absorbance of 405 nm using the TECAN infinite 200 series to obtain an 
absolute 0 value. 10 µL of 0.1 mM urokinase substrate in Tris buffer was added to each 
sample. The plates were measured every 10 minutes for 1 hour at an absorbance of 405 
nm using the TECAN infinite 200 series. The plates were incubated at 37 ºC for the 
duration of the measurements. 
 
4.8 KC4 coagulation 
A cuvette was placed in the KC4 coagulation analyser and a ball bearing is inserted 
into the cuvette. 100 µL of 3 mg.mL-1 fibrinogen was pipetted into the cuvette, the timer 
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was started and at 10 seconds 30 µL of the fibrinogen binding peptide was pipetted into 
the cuvette. A magnet in the KC4 coagulation analyser held the ball bearing in place until 
a gel forms and releases the ball bearing. Once clotting had taken place, the timer 
automatically stopped to determine the clotting speed of the sample and is accurate to 0.1 
second. This was to ensure that the fibrinogen is biologically active with the clotting agent 
and was also a measure of gelation time. 
 
4.9 Scanning electron microscopy 
Cell free hydrogels were formed as previously described in section 4.4.2 and left in 
basic DMEM containing 10 % FCS for 48 hours. The DMEM was removed and the 
hydrogels fixed in 3 % glutaraldehyde for 1 hour. Two methods for hydrogel dehydration 
were investigated: freeze drying and ethanol dehydration as described below.  
Freeze dry dehydration 
Samples for freeze drying were left at -20 ˚C overnight. The plate was covered in 
parafilm and pierced over each hole with a needle. The plate was then placed in the VirTis 
benchtop SLC freeze dryer overnight. The samples were mounted on SEM stubs ready 
for imaging.  
Ethanol dehydration 
For ethanol dehydration fixed samples were stored at 4 ˚C overnight. 1 % osmium 
tetroxide was pipetted onto the hydrogels and left for 1 hour. Hydrogels were washed 3 
times in distilled water followed by a dehydration series of 30 %, 50 %, 70 %, 90 %, 95 % 
and 100 % ethanol for 15 minutes at each step. The plate was left overnight in the fume 
cupboard to dry. The samples were then mounted on SEM stubs ready for imaging.  
Before imaging on the SEM all samples regardless of dehydration protocol were gold 
coated using an emscope SC500 gold sputter coater for two minutes with a 15 mA current 
at 0.05 atm. Samples were imaged using Philips XL-20 SEM under vacuum. An electron 
beam was passed onto the sample and secondary electrons scattered in the chamber. These 
were detected and formed an image of the surface of the sample.  
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4.10 Cell viability 
4.10.1 Cell activity 
PrestoBlue® analysis was carried out to determine the cell viability of the chondrocytes 
encapsulated in the gel. PrestoBlue® is a commercially available preparation of the dye 
resazurin. Active cells take up the resazurin dye which is reduced within the mitochondria 
to resorufin which can freely diffuse chondrocyte out of the cells into the culture medium. 
The reduced resorufin dye is pink in colour can be detected fluorometrically. The cell 
viability assay was carried out according to the manufacturer’s instructions. PrestoBlue® 
was added to the culture media at a final concentration of 10 % (vol/vol) and incubated 
at 37 °C for time periods from 30 minutes to 4 hours. At the required time point, 200 µL 
samples were removed from each of the wells and the amount of resosrufin determined 
fluorometrically using a TECAN infinite 200 series plate reader with an excitation 
wavelength of 535 nm and an emission wavelength of 590 nm. 
Cell viability assays using PrestoBlue® were carried out on gel encapsulated cells after 
24 hours, 3 days, 7 days, 10 days, 14 days, and 20 days after encapsulation. When the 
assay was completed any remaining dye was removed from the well and washed with 
PBS before culture medium was added to the wells.  
 
4.10.2 Live Dead Staining and Confocal Microscopy 
Live/dead stain was carried out to determine cellular survival and death within the gels. 
The gels were kindly imaged by Saima Ahmed on the confocal microscope. 10 µM 5-
chloromethylfluorescein diacetate (CMFDA cell tracker Green) in DMSO and 10 µM 
propidium iodide (PI) was added to DMEM and incubated on the gels for 1 hour. The 
gels were then fixed in formaldehyde for 30 minutes. The fluorescently labelled samples 
were transferred to a glass microscope slide and imaged using an upright Zeiss Axioskop 
LSM 510 meta confocal laser scanning microscope. A x10 (EC Plan – Neofluar 10x/0.3 
dry objective lens was used to image the samples. CMFDA was imaged using an 
excitation wavelength of 488 nm and an emission wavelength of 517 nm, to detect green 
fluorescence to visualise live cells. PI was imaged using an excitation wavelength of 
543 nm and emission wavelength of 650 nm, to detect red fluorescence to visualise dead 
cells. The images were constructed using LSM image browser software to enable images 
of both live and dead cells.   
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4.10.3 Measurement of glycosaminoglycans using 1,9-dimethylmethylene blue dye 
One of the main components of the extracellular matrix of hyaline cartilage are the 
proteoglycans, and in particular aggrecan. These proteoglycans are heavily glycosylated 
(mainly with chondroitin and keratin sulphate) and quantification of proteoglycans is 
achieved through determining the concentration of the glycosaminoglycan (GAG) 
components. 1,9-Dimethylmethylene blue dye (DMB) can be used to determine the 
concentration of GAG’s present in a sample [234]. This is important to determine if the 
chondrocytes are undergoing differentiation or mesenchymal stem cells are undergoing 
chondrogenic differentiation in the gel and synthesising an extracellular matrix. After 21 
days the gels were removed from the media, placed in small conical tubes and incubated 
with 200 µL of papain solution consisting of 200 mM phosphate buffer containing 1 mM 
EDTA, 0.05 w/v % papain and 0.96 w/v % n-acetyl cysteine, and left at 60 °C for 24 
hours. Agarose gels were incubated with 0.2 µg.mL-1 agarase at 40 ºC for 24 hours before 
incubation with 200 µL of papain solution consisting of 200 mM phosphate buffer 
containing 1 mM EDTA, 0.05 w/v % papain and 0.96 w/v % n-acetyl cysteine at 60 ºC 
for 24 hours. A chondrotin sulphate standard curve was formed using chondroitin 
sulphate concentrations from 0-50 µg.mL-1. 20 μl of the chondroitin sulphate standards 
were added to a 96-well plate along with 20 μl of the samples. 250 μl DMB dye was 
added to each well using a multichannel pipette and the optical density measured at 525 
nm immediately using the TECAN infinite 200 series.  
 
4.11 Histological examination 
After experimental termination, samples were fixed with 4 % formaldehyde for 30 
minutes. Each hydrogel was fully submerged in OCT embedding matrix, surrounded by 
an aluminium foil structure formed by wrapping foil around a bijoux and folding the foil 
under the bottom leaving a small hole in the centre of the foil. The bijoux was removed 
leaving a cylinder of foil, the bottom was placed onto a piece of cork board enabling 
labelling of the sample. This was then placed in a glass beaker and lowered into liquid 
nitrogen at -196 ˚C and allowed to freeze to preserve the sample. These samples were 
then stored at -20 ˚ C ready for cryosectioning on the microtome HM560 cryostat. Sections 
of 8 μm thickness were taken and collected onto SuperFrost Plus glass slides. 
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4.11.1 Haematoxylin and eosin stain (H&E) 
Fixed sections were inserted in an automatic Shandon staining bath and emerged in 
baths of: running water, haematoxylin, running water twice, 0.1 % hydrochloric acid in 
70 % alcohol, running water twice, Scott’s tap water substitute, water, eosin twice, 
running water, 95 % alcohol, absolute alcohol, 1:1 absolute alcohol in xylene, and xylene 
twice. The sections were then mounted in DPX. Analysis of the images was carried out 
using imagej software to measure the pore diameter and number of pores per image. 
4.11.2 Toluidine blue 
Fixed sections were covered with 1 % toluidine blue in 0.5 % sodium borate made up 
in distilled water and stained for 5 seconds, immediately rinsed with distilled water, air 
dried, cleared in xylene and mounted in DPX. 
4.11.3 Crystal Violet 
Samples were fixed and left in the 24 well-plate for staining. The samples were 
covered with 0.1 % crystal violet in distilled water for 5 minutes, rinsed with distilled 
water, and immediately imaged.  
 
4.12 Molecular biology 
4.12.1 TRIzol RNA Extraction 
Ribonucleic acid (RNA) extraction by TRIzol was carried out according to the 
manufacturer’s instructions by adding 1 mL of TRIzol to the 300,000 chondrocytes 
encapsulated in 2.66 mg.mL-1 and fibrin gels in nuclease-free Eppendorf’s. The hydrogel 
was dissolved in the TRIzol by use of an ultrasonic processor. The samples were then 
stored at -80 ˚C until required. For RNA extraction 200 µL of chloroform was added to 
the TRIzol –gel solution and the Eppendorf was shaken vigorously for 15 seconds and 
left at room temperature for 3 minutes and then centrifuged at 12,000 g for 15 minutes at 
4 ˚C. The upper colourless phase of the solution was transferred to a new nuclease-free 
Eppendorf with a filter pipette tip without disturbing the lower, pink phase. The lower 
phase contains phenol and will cause contamination of the RNA. 500 µL of isopropanol 
was added to the RNA solution and incubated at room temperature for 10 minutes before 
centrifugation at 12,000 g for 10 minutes at 4 ˚C. The supernatant was removed and the 
RNA pellet was washed with 1 mL of 75 % ethanol diluted with distilled water, this was 
briefly vortexed and centrifuged at 7,500 g for 5 minutes at 4 ˚C. The ethanol supernatant 
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was removed until a thin layer remained at the bottom of the Eppendorf and these were 
left to air dry for 10 minutes. 20 µL of nuclease-free water was used to re-suspend the 
RNA pellet. RNA concentration was then determined on the NanoDrop 1000 
spectrophotometer. This was used to determine RNA concentration and if there are 
contaminants within the RNA solution. 1 µL of RNA solution was placed on the detector 
of the NanoDrop after using nuclease-free water as a blank. The programme then 
determined the concentration and purity of the RNA. 
Phenol contamination was detected during the NanoDrop analysis. Therefore, the 
RNA solution was washed by adding 500 µL of water-saturated 1-butanol, made from 
mixing equal volumes of distilled water and 1-butanol vigorously and left for 15 minutes, 
the upper layer formed is water-saturated 1-butanol. The RNA – water-saturated 1-
butanol solution was centrifuged for 30 seconds at 7,500 g. The upper layer was discarded 
leaving a thin layer on top of the RNA solution to minimise RNA loss. This was repeated 
three more times. The 1-butanol was removed from the samples by the addition of water-
saturated diethylether, 50 mL of distilled water was mixed with 500 mL of diethylether 
vigorously and left for 15 minutes, and the upper phase is the water-saturated diethylether. 
This was removed and 500 µL of water-saturated diethylether was added to the RNA 
solution and titurated 5 times with a filter pipette tip. This was centrifuged at 7,500 g for 
30 seconds and the upper phase removed leaving a thin layer to minimise RNA loss. This 
was repeated once more and the samples were then left to air dry in a fume cupboard for 
15 minutes to remove the final layer of water-saturated diethylether.    
4.12.2 RNA Extraction Isolate II RNA mini kit 
RNA was extracted by Isolate II RNA mini kit. The extraction was carried out in 
accordance with the manufacturer’s instructions and was as follows. The gels with 
300,000 cells per gel were transferred to one nuclease-free Eppendorf. 350 µL of Lysis 
Buffer and 3.5 µL of 2-Mercaptoethanol was added to the samples to lyse the cells and 
break down any protein. Guanidinium thiocyanate is present in the Lysis Buffer which 
deactivates endogenous RNA leaving only pure RNA for collection. An Isolate II filter 
was placed in a collection tube and the lysate solution was added to the filter via a filter 
pipette tip. This was centrifuged for 11,000 g for 1 minute. The Isolate II filter was 
discarded and 350 µL of 70 % ethanol in nuclease-free water was added to the lysate 
solution in the collection tube and titurated 5 times. This solution was loaded onto an 
Isolate II RNA mini column inserted in a 2 mL collection tube and centrifuged at 11,000 g 
for 30 seconds. The column contains a silica membrane in which the RNA binds. The 
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Isolate II RNA mini column was transferred to a new collection tube and 350 µL of 
membrane desalting buffer was added to the column using a filter pipette tip and 
centrifuged at 11,000 g for 1 minute. To remove any DNA contaminates DNase I reaction 
mixture was prepared by adding 10 µL of reconstituted DNase I to 90 µL of reaction 
buffer for DNase I per sample in a nuclease-free Eppendorf and was gently mixed by 
flicking the Eppendorf. 95 µL of DNase I reaction mixture was added to each Isolate II 
RNA mini column and incubated at room temperature for 15 minutes. The RNA was then 
washed to remove any salt contaminants with 200 µL of Wash Buffer 1 and centrifuged 
at 11,000 g for 30 seconds, 600 µL of Wash Buffer 2 was added to the column and 
centrifuged again at 11,000 g for 30 seconds, the solution collected in the collection tube 
was discarded and the column was placed back into the collection tube. The final RNA 
wash was 250 µL of Wash Buffer 2 centrifuged at 11,000 g for two minutes. The RNA 
was then eluted with 60 µL of nuclease-free water into a nuclease-free centrifuge tube by 
centrifugation at 11,000 g for 1 minute.    
4.12.3 Electrophoresis of RNA 
An agarose gel was made to determine if RNA is present in the samples. The gel was 
made by heating 0.5 g of agarose in 36 mL of distilled water in the microwave to dissolve 
the agarose. 5 mL of MOPS/EDTA x10 solution, made from 0.4 M mops at pH 7, 0.1 M 
sodium acetate, and 0.01 M EDTA, was added with 9 µL of formaldehyde. This mixture 
was poured into an RNA mould with a comb at one end to create holes in the gel, this was 
left to gel for 30 minutes in a fume cupboard. 2 µL of RNA solution was mixed with 4 
µL of ethidium bromide in a nuclease-free Eppendorf and placed in a heat block at 95 ˚C 
for 2 minutes. The comb was removed from the agarose gel and loaded into the tank of 
the SNCRWA electrophoresis machine (BioRad). The gel was covered in MOPS/EDTA 
x1 buffer and run for 45 minutes until the blue dye had travelled down the gel. The gel 
was then analysed using Syngene INGENIUS 3 to determine if any RNA bands were 
found.   
 
4.13 Statistical analysis 
All data was analysed by using GraphPad Prism 6. An unpaired t-test with Welch’s 
correction was used to compare the cell encapsulated fibrinogen gels with their cell free 
equivalent. One-way ANOVA with Tukey post-hoc test was used to compare the means 
of groups of cell encapsulated fibrinogen gels. Significance has been highlighted 
throughout.  
 96 | P a g e  
 
C h a p t e r |  Results: Structure of the hydrogels 
5.0 Results: Structure of the hydrogels 
The concentrations of all the fibrinogen hydrogels used throughout the thesis was 
based upon the ability to form gels with 34 mg.mL-1 fibrinogen. FPA gelled at 
concentrations of 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1 and 0.7 mg.mL-1 with 34 
mg.mL-1 fibrinogen. These concentrations of fibrinogen and FPA were determined by 
Haemostatix Ltd for forming the FPA-fibrinogen hydrogels, and therefore were used for 
all investigations into the structure and cell encapsulation. Visually, P15 and P17 gelled 
at concentrations of 0.75 mg.mL-1, 0.5 mg.mL-1 and 0.25 mg.mL-1 with 34 mg.mL-1 
fibrinogen, as recommended by Haemostatix Ltd. 
HyStem was investigated at 1 mg.mL-1, 0.75 mg.mL-1, 0.5 mg.mL-1, and 
0.25 mg.mL-1, which were concentrations recommended by Haemostatix Ltd. Visually, 
concentrations of 0.5 mg.mL-1 and below formed very small, weak gels with fibrinogen 
at 34 mg.mL-1 and therefore were not investigated further. However, HyStem 1 mg.mL-1 
and 0.75 mg.mL-1 formed a good gel with fibrinogen at 34 mg.mL-1 and were therefore 
investigated further and used throughout this project. 
 
5.1 Coagulation rate 
To measure the gelation capacity of the novel cross-linked fibrinogen gels a KC4 
coagulation analyser was used. The time of gelation was measured by a magnetic force 
breaking once a solid gel had formed, the KC4 coagulation analyser was accurate to 0.1 
seconds. It was observed that gelation occurred with all of the novel cross-linked 
fibrinogen gels. The gelation rate was analysed and Table 5.1 showed the mean gelation 
rate (expressed as coagulation rate) of each carrier of the FBP with fibrinogen. It was 
found that fibrin (formed using thrombin) formed more slowly in comparison to FPA-
fibrinogen, (4.7 seconds vs 3.4 seconds for FPA system) and 4-5 times slower compared 
to P15 and P17 carriers. P15 and P17 had a similar gelation rates which was over 3 times 
faster than FPA, refer to Table 5.1.  
A range of concentrations of FPA were tested to determine if the concentration of the 
FBPs had an effect on the ability to form a gel or the gelation time. The results are shown 
in Figure 5.1. It was observed that for the lowest concentration of FPA, 0.15 mg.mL-1, the 
gelation time was very slow (at 8.4 seconds). As the concentration of FPA was increased 
the gelation rate plateaued, between 0.23 mg.mL-1 and 2.55 mg.mL-1 concentrations of 
FPA which gave a gelation time of 2.9 seconds. At the higher concentrations of 
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7.3 mg.mL-1 started to increase again Figure 5.1. Therefore, at the concentrations of FPA 
used in this project the gelation rates were: 2.66 mg.mL-1 at 2.9 seconds, 2 mg.mL-1 at 2.2 
seconds, 1.33 mg.mL-1 at 2.1 seconds and 0.7 mg.mL-1 at 2.3 seconds, as calculated from 
Figure 5.1. The gelation rate of the novel cross-linked fibrinogen gels was similar.  
 
Table 5.1 Average coagulation time of 30 IU thrombin, 0.25 mg.mL-1 FPA, 0.25 mg.mL-1 P15 
and 0.25 mg.mL-1 P17 combined with 3 mg.mL-1 fibrinogen to determine the gelation speed. 
Fibrinogen binding peptide 
carrier 
Mean coagulation time 
(seconds) 
Thrombin 4.7 
FPA 3.4 
P15 1.0 
P17 1.2 
 
 
 
Figure 5.1 Mean coagulation rate of FPA at concentrations of 0.15 mg.mL-1, 0.23 mg.mL-1, 
0.3 mg.mL-1, 1.87 mg.mL-1, 2.55 mg.mL-1 and 7.23 mg.mL-1 with 3 mg.mL-1 fibrinogen. N=1. 
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5.2 Scanning electron microscopy images 
Fibrinogen gels formed using FPA at 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, 
0.7 mg.mL-1, and fibrin gels were imaged using the SEM to investigate the structure of 
the hydrogels. Two methods for dehydrating the gels for the SEM were investigated. 
These were dehydration using ethanol and freeze drying the sample overnight. From 
observations after the dehydration processes, freeze dried samples still retained their 3D 
structure and macroscopically appeared more like the hydrogel before dehydration. 
Ethanol dehydrated samples turned into a thin flake of material with no macroscopic 
resemblance of the hydrated hydrogels. The SEM images of the microscopic structure 
reflect these macroscopic observations of the effect of dehydration methods on the gel 
structure. The fibrinogen fibres appear much clearer and less fused together in the freeze 
drying samples (Figure 5.2 C and D) in comparison to the ethanol dehydrated 
counterparts. SEM images for FPA-fibrinogen 2 mg.mL-1 for ethanol dehydration at a 
magnification of 3,000 was unable to be obtained, due to the fused surfaces the structure 
was not able to be seen. Therefore, only the freeze dried samples will be looked at in more 
detail.  
The structures of fibrin and FPA-fibrinogen gels appear to be different. Fibrin gels 
have clear fibres which can be seen, Figure 5.2, whereas the FPA-fibrinogen gel structure 
is more foam-like in appearance, Figure 5.3 to 5.6. The structures of FPA-fibrinogen gels 
are very similar and the pore sizes of the gels do not appear to be very different, however 
it can be seen that gels formed with fibrinogen and FPA at 2.66 mg.mL-1, 2 mg.mL-1 
and 0.7 mg.mL-1 have larger pore sizes compared to FPA concentrations at 1.33 mg.mL-1. 
It can also be observed that the FPA-fibrinogen gels formed using 1.33 mg.mL-1 have 
more pores on the surface of the gel in comparison to gels formed from FPA at 
concentrations of 2.66 mg.mL-1, 2 mg.mL-1 and 0.7 mg.mL-1. Therefore, gels formed 
from concentrations of FPA 2.66 mg.mL-1, 2 mg.mL-1 and 0.7 mg.mL-1 seemed to create 
a more open porous structure in comparison to FPA at concentrations of 1.33 mg.mL-1.  
However, a range of pore sizes can be seen in the SEM images for all gel structures.  
Fibrinogen gels formed from P15-fibrinogen 0.75 mg.mL-1 ( 
Figure 5.7) and P17-fibrinogen 0.75 mg.mL-1 (Figure 5.8) gels had a much more open 
porous structure in comparison to FPA-fibrinogen gels and fibrin gels. There are areas of 
fibres and foam-like structures visible from both P15 and P17 – fibrinogen gels. Due to 
limitations in the amounts of available FBP materials, SEM could not be obtained with 
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gels formed from P15 and P17 – fibrinogen at concentrations of 0.5 mg.mL-1 or 
0.25 mg.mL-1.  
 
  
 
A B 
C D 
Figure 5.2 Scanning electron microscopy images of fibrin hydrogels dehydrated with ethanol (A 
and B) or freeze dried (C and D) taken at a magnification of A 1,500x, B 3,000x, C 811x and D 
3244x, scale bars are shown on the image. 
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Figure 5.3 Scanning electron microscopy images of FPA-fibrinogen 2.66 mg.mL-1 hydrogels 
dehydrated with ethanol (A and B) or freeze dried (C and D) taken at a magnification of A 800x, 
B 3,000x, C 1,500x and D 3141x, scale bars are shown on the image. 
  
A B 
C D 
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Figure 5.4 Scanning electron microscopy images of FPA-fibrinogen 2 mg.mL-1 hydrogels 
dehydrated with ethanol (A) or freeze dried (B and C) taken at a magnification of A 800x, B 
1,500x, and C 3,000x, scale bars are shown on the image. 
  
A 
B C 
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Figure 5.5 Scanning electron microscopy images of FPA-fibrinogen 1.33 mg.mL-1 hydrogels 
dehydrated with ethanol (A and B) or freeze dried (C and D) taken at a magnification of A 800x, 
B 3,000x, C 1,500x and D 3,000x, scale bars are shown on the image. 
A B 
C D 
 103 | P a g e  
 
C h a p t e r |  Results: Structure of the hydrogels 
 
Figure 5.6 Scanning electron microscopy images of FPA-fibrinogen 0.7 mg.mL-1 hydrogels 
dehydrated with ethanol (A and B) or freeze dried (C and D) taken at a magnification of A 1,383x, 
B 2,776x, C 1,530x and D 3,060x, scale bars are shown on the image. 
                                                              
Figure 5.7 Scanning electron microscopy images of P15-fibrinogen 0.75 mg.mL-1 
hydrogels freeze dried before imaging taken at a magnification of A 400x and B 800x, 
scale bars are shown on the image. 
A B 
C D 
A B 
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Figure 5.8 Scanning electron microscopy images of P17-fibrinogen 0.75 mg.mL-1 hydrogels 
freeze dried before imaging taken at a magnification of A 423x and B 1,694x, scale bars are shown 
on the image. 
 
Key summary 
• The gelation of fibrin gels was 1 second slower than the gelation of FPA-
fibrinogen gels, and 3 seconds slower than the P15-fibrinogen and P17 
fibrinogen gels. 
• Dehydration via ethanol did not maintain the macroscopic or microscopic 
structure of the fibrinogen gels, artefacts prevented observations of the 
microscopic structure. 
• Dehydration via freeze drying maintained the fibrinogen gels macroscopic 
structure and defined microscopic structure.  
• Structure of fibrin was clear, defined fibres. FPA-fibrinogen gels had a more 
foam-like structure. The difference in structure between the various 
concentrations of FPA was difficult to investigate through the captured SEM 
images and therefore has been analysed in section 6.3. 
 
  
A B 
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6.0 Results: Chondrocyte encapsulation 
As previously discussed in chapter 2, ACI is a technique being developed for the repair 
of injured cartilage. Successful results have been demonstrated within clinical trials. 
Therefore, the first investigation into cell encapsulation and delivery will be chondrocyte 
encapsulation. A range of novel fibrinogen gels will be used to encapsulate chondrocytes 
using fibrin and 4 % agarose gels as reference materials. 
6.1 Poly (ethylene glycol)-FBP/fibrinogen hydrogels (PEG) 
As previously described in section 4.4.2, chondrocytes were encapsulated in 
PEG - FBP - fibrinogen gels formed from concentrations of PEG at 1 mg.mL-1, 
0.75 mg.mL-1, 0.5 mg.mL-1, and 0.25 mg.mL-1 with 34 mg.mL-1 fibrinogen. Fibrin gels 
were formed from 34 mg.mL-1 with 192 IU/mL thrombin. 50,000 chondrocytes were 
encapsulated per gel. The gels were formed and cultured in 96-well culture plates.  
Cell viability 
Cell activity was assessed using PrestoBlue® as described in section 4.10.1. Cell 
activity results are displayed as the average fluorescence values from the incubation of 
one hour with PrestoBlue®. Cell free gels were also incubated with PrestoBlue® reagent 
to determine if the gel interfered with the assay. The cell free gels produced very low 
fluorescence results, see Figure 6.1, therefore the gels did not interfere with the assay. 
The culture medium was also taken from each gel and assayed to determine if the medium 
contained any active cells, see Figure 6.1. This experiment was to determine if the 
chondrocytes had migrated from the gel. The low fluorescent results suggested that there 
are no active cells within the culture medium, see Figure 6.1, indicating that the 
chondrocytes remained in encapsulation. High levels of cellular activity were detected in 
all the concentrations of bovine chondrocyte encapsulated PEG gels in comparison to 
classical fibrin gels throughout the 20 day culture period (Figure 6.2). The data in Figure 
6.2 also showed that over the 20 day culture period the rate of the reduced dye, resorufin, 
was increased with time in culture of the encapsulated cells in gels formed from all the 
PEG concentrations gelled with fibrinogen and fibrin gels. Therefore, all the gel 
formulations and the fibrin gels supported chondrocyte viability and proliferation for a 
20 day culture period. However, the rate of resorufin formation was significantly lower 
for the fibrin encapsulated chondrocytes compared to PEG encapsulated cells at all time 
points (days 1, 7, 14, 20) (Figure 6.2, Table 6.1). In comparing the chondrocyte 
encapsulated gels formed from the different PEG concentrations, all gave similar results. 
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However, by day 20, PEG gels formed with 1 mg.mL-1 concentration showed the highest 
level of cellular activity which was significantly greater (p<0.05) than 0.25 mg.mL-1 
(refer Figure 6.2 and Table 6.1). PEG 1 mg.mL-1 denotes there was a higher concentration 
of FBP groups present during gelation, which would create a more cross-linked, gel 
structure compared to the lower PEG concentrations.                                        
      
 
 
Figure 6.1 Effect of resazurin reduction (shown as relative fluorescence units per minute) over 
21 days by cell free (A) fibrin and fibrinogen-PEG gels and the culture medium samples (B) 
taken from the incubation with fibrin and fibrinogen-PEG gels. The error bars represent the 
standard error of the mean. N=3 
 
 
 
Figure 6.2 Cell activity of 50,000 chondrocytes per gel encapsulated for 20 days in fibrin gels 
and fibrinogen-PEG gels formed using concentrations of 1 mg.mL-1, 0.75 mg.mL-1, 
0.5 mg.mL-1, and 0.25 mg.mL-1. Readings were taken at day 1, day 7, day 14 and day 20 of 
culture. The error bars represent the standard error of the mean. Statistical analysis with using 
one-way ANOVA with Tukey post test was conducted shown in Table 6.1. N=3 
A B 
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Table 6.1 Comparative analysis between the cell activity of chondrocytes encapsulated in PEG-
fibrinogen gels and fibrin gels. The statistical analysis was carried out using one-way ANOVA 
with Tukey post hoc test comparing the group averages of gels formed from PEG 1 mg.mL-1, 
PEG 0.75 mg.mL-1, PEG 0.5 mg.mL-1, PEG 0.25 mg.mL-1, and fibrin, from the cell activity 
results taken at day 1, 7, 14, and 20 after encapsulation (refer to Figure 6.2). Significance: * 
P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. Results that are statistically not significant 
have not been shown in the table.   
 
  Tukey's multiple comparisons test 95% CI of diff. Summary 
Day 1 PEG 1 mg.mL-1 vs. Fibrin 1760 to 33937 * 
Day 7 PEG 1 mg.mL-1 vs. Fibrin 18725 to 29853 **** 
  PEG 0.75 mg.mL-1 vs. Fibrin 17838 to 28967 **** 
  PEG 0.5 mg.mL-1 vs. Fibrin 17321 to 28450 **** 
  PEG 0.25 mg.mL-1 vs. Fibrin 16645 to 27774 **** 
Day 14 PEG 1 mg.mL-1 vs. Fibrin 6964 to 24479 *** 
  PEG 0.75 mg.mL-1 vs. Fibrin 2198 to 19713 ** 
  PEG 0.5 mg.mL-1 vs. Fibrin 4424 to 21938 ** 
  PEG 0.25 mg.mL-1 vs. Fibrin 1178 to 18692 * 
Day 20 PEG 1 mg.mL-1 vs. PEG 0.25 mg.mL-1 307.3 to 12841 * 
  PEG 1 mg.mL-1 vs. Fibrin 5719 to 18253 **** 
  PEG 0.75 mg.mL-1 vs. Fibrin 2707 to 15241 ** 
  PEG 0.5 mg.mL-1 vs. Fibrin 4067 to 16601 *** 
 
Glycosaminoglycan content 
The GAG content of the gel-encapsulated cells was determined to investigate whether 
the encapsulated chondrocytes could form and accumulate ECM components. 
Measurement of GAG is an indicator of proteoglycan accumulation in a putative ECM. 
The GAG content of cell free gels and culture medium from the cell-encapsulated gels 
was also determined. The GAG content of cell free gels was very low and suggested that 
the gels did not interfere with the assay (Figure 6.3). Culture medium was taken and 
analysed from both cell free and cell encapsulated gels, very little GAG was detected in 
the medium and there were no significant differences between cell encapsulated and cell 
free gels from the media samples (Figure 6.3). The total GAG content for chondrocyte 
encapsulated PEG gels showed high levels of GAG per gel, however all gels gave similar 
results and are not significantly different between groups (Figure 6.4). The cell 
encapsulated gels are significantly different from their cell free equivalent for 1 mg.mL-1, 
0.75 mg.mL-1, and 0.5 mg.mL-1 concentrations of PEG. Showing that the chondrocytes 
are synthesising ECM within the PEG and fibrin hydrogels. 
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Figure 6.3 Effect of the cell-free (A) fibrin and PEG-fibrinogen gels on the DMB assay to 
measure GAG content. Total GAG content of the culture medium (B) taken at day 21 of culture 
from the incubation with cell free (CF) or chondrocyte encapsulated fibrin and PEG-fibrinogen 
gels. The error bars represent the standard error of the mean. Statistical analysis using one-way 
ANOVA with a Tukey post test showed no significant differences between the groups. N=3 
 
 
 
 
 
 
 
Figure 6.4 Total glycosaminoglycan content/gel  of chondrocytes encapsulated in the PEG-
fibrinogen gels formed with PEG 1 mg.mL-1, PEG 0.75 mg.mL-1, PEG 0.5 mg.mL-1, PEG 0.25 
mg.mL-1 or fibrin gels (shown as mean total GAG (µg/gel) indicating extracellular matrix 
deposition of 50,000 bovine chondrocytes per gel encapsulated for 21 days. The error bars 
represent the standard error of the mean. Statistical analysis using one-way ANOVA with a Tukey 
post test showed no significant differences between the groups. Refer to Table 6.2 for statistical 
analysis between the cell free counterparts.  N=3 
 
 
  
A B 
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Table 6.2 Comparative analysis between the total glycosaminoglycan content of chondrocytes 
encapsulated in PEG-fibrinogen gels or fibrin gels after 21 days of incubation vs cell-free gels. 
The statistical analysis was carried out using an unpaired t-test with Welch’s correction comparing 
fibrinogen gels formed with PEG 1 mg.mL-1, PEG 0.75 mg.mL-1, PEG 0.5 mg.mL-1, and PEG 
0.25 mg.mL-1, or  Fibrin, with their cell free equivalents from the total glycosaminoglycan content 
per gel measured at day 21 of culture. C denotes chondrocyte encapsulation, CF denotes the cell 
free gel. Significance: * P<0.05, ** P<0.01, **** P<0.0001. Non-significant results have not been 
shown in the table. 
 
Unpaired t-test with Welch’s correction Significance 
PEG 1 mg.mL-1 C vs. PEG 1 mg.mL-1 CF ** 
PEG 0.75 mg.mL-1 C vs. PEG 0.75 mg.mL-1 CF * 
PEG 0.5 mg.mL-1 C vs. PEG 0.5 mg.mL-1 CF * 
Fibrin C vs. Fibrin CF **** 
 
 
For strategic reasons, Haemostatix Ltd. decided that synthesis of the PEG-fibrinogen 
hydrogels would not be continued and therefore the investigation into the use of these 
gels was terminated. 
 
6.2 Peprostat hydrogels 
6.2.1 Initial biocompatibility 
Chondrocytes were encapsulated in FPA hydrogels and formed from fibrinogen and 
FPA at concentrations of 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1 and 0.7 mg.mL-1. 
Fibrin gels were formed from 34 mg.mL-1 fibrinogen with 192 IU/mL of thrombin. 
50,000 chondrocytes per gel were encapsulated in all gels to test biocompatibility of the 
hydrogels and their potential to support ECM formation by the chondrocytes. The gels 
were formed and cultured in 96-well culture plates.  
Cell viability 
Cell free gels were incubated alongside their chondrocyte encapsulated counterparts 
and were analysed to determine if the gels interfered with the assays used. Cell viability 
was determined by measuring the level of cell activity using PrestoBlue® as described in 
section 4.10.1. The cell free fibrin or FPA gels showed very low fluorescence indicating 
that the gels are not interfering with the assay by binding or reducing the resazurin  
(Figure 6.5). The medium from the chondrocyte encapsulated FPA gel cultures (refer to 
Figure 6.5) showed barely detectable fluorescence and therefore indicating that the 
chondrocytes remained encapsulated in the gel during the culture period. High levels of 
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cellular activity were detected in all FPA and fibrin gels encapsulated with bovine 
chondrocytes throughout the 21 day culture period (Figure 6.6). The rate of resorufin 
formation was significantly lower for the fibrin encapsulated chondrocytes compared to 
FPA encapsulated chondrocytes at day 7 and day 14 for FPA gels formed with 
2.66 mg.mL-1 and 2 mg.mL-1 (Figure 6.6, Table 6.3).  
           
Figure 6.5 The effect of resazurin reduction dye (shown as fluorescence per minute) by cell free 
FPA-fibrinogen and fibrin gels (A) and the culture medium samples (B) incubated with the 
chondrocyte encapsulated FPA-fibrinogen and fibrin gels. The error bars represent the standard 
error of the mean. N=3 
 
Figure 6.6 Rate of reduction of PrestoBlue® (shown as mean relative fluorescence units per 
minute) for chondrocytes encapsulated in fibrin gels and FPA gels formed using concentrations 
of  2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, 0.7 mg.mL-1 of FPA. Readings were taken on day 
1, day 7, day 14 and day 20 of culture. The error bars represent the standard error of the mean. 
Statistical analysis with use of a one-way ANOVA with Tukey post test was conducted see 
Table 6.3 for results. N=3 
A B 
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Table 6.3 Comparative analysis between the cell activity of chondrocytes encapsulated in PEG-
fibrinogen gels or fibrin gels vs cell-free gels during 21 days of incubation vs cell-free gels.  
The statistical analysis was by one-way ANOVA with Tukey post hoc test of the group 
averages. The cell viabilities were determined on days 1, 7, 14, 20 after encapsulation of 
chondrocytes (refer to Figure 6.6). 
 
  Tukey's multiple comparisons test 95% CI of diff. Summary 
day 7 FPA 2.66 mg.mL-1 vs. FPA 2 mg.mL-1 188.6 to 11317 * 
  FPA 2.66 mg.mL-1 vs. Fibrin 13243 to 24371 **** 
  FPA 2 mg.mL-1 vs. FPA 1.33 mg.mL-1 -11866 to -736.9 * 
  FPA 2 mg.mL-1 vs. FPA 0.7 mg.mL-1 -15114 to -3985 *** 
  FPA 2 mg.mL-1 vs. Fibrin 7490 to 18618 **** 
  FPA 1.33 mg.mL-1 vs. Fibrin 13791 to 24920 **** 
  FPA 0.7 mg.mL-1 vs. Fibrin 17039 to 28168 **** 
day 14 FPA 2.66 mg.mL-1 vs. FPA 1.33 mg.mL-1 1238 to 18752 * 
  FPA 2.66 mg.mL-1 vs. Fibrin 2309 to 19824 ** 
  FPA 2 mg.mL-1 vs. FPA 1.33 mg.mL-1 2859 to 20373 ** 
  FPA 2 mg.mL-1 vs. FPA 0.7 mg.mL-1 109.0 to 17624 * 
  FPA 2 mg.mL-1 vs. Fibrin 3930 to 21445 ** 
 
Glycosaminoglycan content 
The GAG content was measured and displayed as the total average content per gel. 
GAG content from cell free gels gave very low results (Figure 6.7) indicating that the gel 
is not interfering with the assay and that the chondrocytes in the cell encapsulated gels 
are synthesising ECM. The culture medium from day 21 of the culture of both cell free 
and chondrocyte encapsulated gels was also assessed for GAG content (Figure 6.7). The 
GAG content of culture medium from both cell free and chondrocyte encapsulated gels 
was very low and not significantly different from each other. The chondrocyte 
encapsulated FPA hydrogels (Figure 6.8) showed high levels of GAG content per gel and 
were significantly different from their cell free equivalents (Table 6.4) suggesting that the 
cells are synthesising ECM. The chondrocyte encapsulated gels in all FPA and fibrin gels 
gave similar results and were not statistically different from each other. 
 
 
 
 112 | P a g e  
 
C h a p t e r |  Results: Chondrocyte encapsulation 
 
 
 
Figure 6.7 The effect of DMB (shown as mean total GAG (µg/gel)) on cell free (A) FPA-
fibrinogen and fibrin gels. Total GAG content of the culture medium (B) taken at day 21 of 
incubation from the cell free (CF) and chondrocyte encapsulated FPA-fibrinogen and fibrin 
gels. The error bars represent the standard error of the mean. Statistical analysis by one-way 
ANOVA with Tukey post test was conducted. There was no significant differences between 
groups. Refer to Table 6.4 for statistical analysis comparison of cell free gels with cell 
encapsulated gels. N=3 
 
 
 
 
 
Figure 6.8 Total glycosaminoglycan content of 50,000 chondrocytes encapsulated in FPA and 
fibrin gels. Fibrinogen gels were formed with FPA at concentrations of 2.66 mg.mL-1, 2 mg.mL-
1, 1.33 mg.mL-1, and 0.7 mg.mL-1. Results are shown as the mean total GAG (µg/gel) after 21 
days in encapsulation. The error bars represent the standard error of the mean. N=3. 
 
 
  
A B 
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Table 6.4 Results of the statistical analysis of the data shown in Figure 6.7 and Figure 6.8. The 
data was analysed using one-way ANOVA with Tukey post hoc test to compare the group 
averages of FPA 2.66 mg.mL-1, FPA 2 mg.mL-1, FPA 1.33 mg.mL-1, FPA 0.7 mg.mL-1 or fibrin 
gels with their cell free equivalents. C denotes chondrocyte encapsulation, CF denotes the cell 
free gel. Significance: *** P<0.001, **** P<0.0001. Non-significant results have not been 
shown in the table. 
 
Tukey's multiple comparisons test 95% CI of diff. Significance 
FPA 2.66 mg.mL-1 C vs. FPA 2.66 mg.mL-1 CF 3.097 to 17.27 *** 
FPA 2 mg.mL-1 C vs. FPA 2 mg.mL-1 CF 5.819 to 19.99 **** 
FPA 1.33 mg.mL-1 C vs. FPA 1.33 mg.mL-1 CF 2.716 to 16.89 *** 
Fibrin C vs. Fibrin CF 5.866 to 15.89 **** 
 
 
6.2.2 Optimisation of gel fabrication 
Forming the cell-encapsulated hydrogels in wells of a 96-well culture plate and the 
culturing the resultant gels in the same wells only allowed for 200 µL of media to 
surround the gel. Therefore, there was a relatively high cell number comparative to the 
maximum volume of culture medium which could be added to the culture wells. This 
meant that had to be changed daily as the medium became very acidic if left for longer 
than 24-36 hours which meant that cell proliferation and differentiation became 
compromised. Also, changing the culture medium every day was not always practical and 
higher cell numbers could not be encapsulated in the gels. Therefore, a method of forming 
the hydrogels in a larger culture plate or transferring the cell-encapsulated hydrogels to a 
larger well plate was required. Therefore, a series of experiments were carried out to 
investigate ways of ensuring the cell encapsulated hydrogels could be formed in, or 
transferred to larger culture wells. 
 
Agarose wells 
An agarose well system was investigated for casting fibrin and FPA-fibrinogen gels. 
As previously described, the gels were cast in the centre of 1 % agarose wells, formed as 
described in section 4.5.1. The chondrocytes were cultured in this environment for 7 days 
and the cell viability was determined at day 1 and day 7 after cell encapsulation. These 
results showed that there was very little detectable cellular activity after 7 days post- 
encapsulation in the agarose moulds, (Figure 6.9) and therefore the experiment was 
terminated after this period of time. The use of the agarose well-system in which to cast 
the gels was abandoned.  
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Figure 6.9 Cell viability measured as the rate of reduction of PrestoBlue® (shown as relative 
fluorescence units per minute) of 50,000 bovine chondrocytes per gel encapsulated in fibrin and 
FPA-fibrinogen gels formed with FPA at concentrations of 2.66 mg.mL-1, 2 mg.mL-1, 1.33 
mg.mL-1, and 0.7 mg.mL-1. The gels were formed in a 1 % agarose well in a 24-well culture 
plate and cultured for 7 days. Readings were taken at day 1 and day 7 of culture. N=1. 
 
 
PTFE moulds 
The use of a PTFE mould in which to form the gels followed by transfer of the gels to 
a larger well in a culture plate was investigated. A custom-made PTFE mould was 
fabricated as described in section 4.5.2. The chondrocyte encapsulated gels were cast in 
PTFE moulds, after gelation was complete the gels were transferred to an individual well 
in a 24-well culture plate. It was observed that gelation was successful within the PTFE 
moulds and the gels were transferred with ease. However, the cellular activity was lower 
at days 1 and day 7 after chondrocyte encapsulation (Figure 6.10) compared to fabricating 
the gels in a well of a 96-well plate. Despite the lower cellular activity from the 
chondrocytes encapsulated in the PTFE moulds during preliminary experiments the PTFE 
moulds were used for further investigation into the concentration of calcium used during 
gelation, see section 6.2.4. This is because the FPA and fibrin gels formed within the 
PTFE wells were bigger and less visible solution was observed after gelation within the 
moulds. However, with successive usage, it became difficult to keep the PTFE wells clean 
and free from bacterial and fungal contaminants and therefore this method had to be 
abandoned.  
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Figure 6.10 Cell viability measured as the rate of reduction of PrestoBlue® (shown as mean 
fluorescence per minute) indicating the cell activity of 50,000 bovine chondrocytes encapsulated 
in fibrin gels and FPA gels using concentrations of 2.66 mg.mL-1, FPA 2 mg.mL-1, FPA 1.33 
mg.mL-1, FPA 0.7 mg.mL-1. The gels were formed in a PTFE well block, transferred to a well in 
a 24 well plate and cultures for 7 days. Readings were taken at day 1 and day 7 of culture. N=1. 
 
Fabrication in 96-well culture plates 
The final fabrication method of FPA and fibrin gels that was investigated was forming 
the FPA and fibrin gels in individual wells of a 96-well culture plate and transferring the 
gel to an individual well of a 24-well culture plate with a micro spatula (Figure 6.12). 
Chondrocyte encapsulated gels were fabricated and cultured in a well of a 96-well plate 
and used as a comparison, Figure 6.11. Gels formed from FPA at concentrations of 
2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-1 and fibrin gels were then 
fabricated using this method alongside fabrication and culture in a well in a 96-well 
culture plate. The cell activity data suggested that chondrocytes survived in all gels 
regardless of their method of fabrication or culture. There were no significant differences 
between the gels cultured in 96-well plates and those cultured in 24-well plates. 
Therefore, the transfer of the FPA and fibrin gels and culture in a larger well did not affect 
cellular survival. The method of fabrication in a well in a 96-well culture plate and 
transferring the gels to a well in a 24-well culture plate was used for the remaining 
experiments. 
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Figure 6.11 Cell viability of chondrocyte encapsulated fibrin gels and FPA gels measured as the 
rate of reduction of PrestoBlue®. 50,000 chondrocytes per gel were cultured in a well in a 96-
well culture plate for 21 days. Readings were taken at day 1, 7, 14 and 20 of culture. The error 
bars represent the standard error of the mean. Statistical analysis with use of a one-way 
ANOVA with Tukey post test was conducted. No statistically significant differences were found 
between groups. N=2 
 
 
Figure 6.12 Cell viability measured as rate of reduction of PrestoBlue (shown as mean relative 
fluorescence units per minute) of 50,000 chondrocytes per gel encapsulated in FPA-fibrinogen 
and fibrin gels. The gels were cultured in 24-well plates for 21 days. Cell viability was assessed 
on day 1, day 7, day 14 and day 20 of culture. The error bars represent the standard error of the 
mean. Statistical analysis using one-way ANOVA with Tukey post tests showed no statistically 
significant difference between the hydrogel groups. N=2 
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6.2.3 Cell seeding density 
To determine the optimum number of cells for encapsulating chondrocytes in the FPA 
and fibrin hydrogels cell seeding density experiments were carried out. 50,000, 150,000 
and 300,000 chondrocytes per gel were encapsulated in fibrin, and gels formed from FPA 
at concentrations of 2.66 mg.mL-1 and 0.7 mg.mL-1 and cultured for 21 days in 
chondrogenic conditions. The hydrogels were formed in 96-well plates and then 
transferred to a 24-well plate after gelation.  
 
Cell viability 
Cell activity analysis was carried out on the hydrogels at day 1, 7, 14 and 20 after 
encapsulation and is a measure of fluorescence per minute of incubation. It can be seen 
that for all hydrogels, fibrin (Figure 6.13), and gels formed from FPA at concentrations 
of 2.66 mg.mL-1 (Figure 6.14) and 0.7 mg.mL-1 (Figure 6.15) that the higher the cell 
number the greater level reduction of the resazurin to resorufin. For each measurement 
(day 1, 7, 14, 20) the rate of reduction of encapsulation of 300,000 chondrocytes 
encapsulated per gel were significantly higher than the counterparts with 50,000 
encapsulated cells per gel. It can also be seen from gels fabricated from FPA and fibrin 
that there is very little cellular activity in the gels containing 50,000 chondrocytes 
encapsulated, this suggested that the cell number needed to be increased. Interestingly, a 
drop in the cell activity between day 7 and day 14 is consistently observed which needs 
to be investigated further.  
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Figure 6.13 Effect of cell number on cell viability over 20 days of encapsulation in fibrin gels. 
Cell viability was determined by the rate of reduction of PrestoBlue® (shown as mean relative 
fluorescence units per minute). The error bars represent the standard error of the mean. 
Statistical analysis with use of a one-way ANOVA with Tukey post test was conducted. 
Significance: ** P<0.01, **** P<0.0001. Non-significant results have not been shown. 
Significance is displayed over the data plot and the colour corresponds to the condition in which 
the significance is compared to. N=2 
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Figure 6.14 Effect of cell number on cell viability over 20 days of encapsulation in FPA gels. 
Cell viability was determined by the rate of reduction of PrestoBlue® (shown as mean 
fluorescence per minute). FPA gels were formed using 2.66 mg.mL-1 FPA. Measurements were 
taken at day 1, day 7, day 14 and day 20 of culture. The error bars represent the standard error 
of the mean. Statistical analysis with use of a one-way ANOVA with Tukey post test was 
conducted. Significance: ** P<0.01, **** P<0.0001. Non-significant results have not been 
shown. Significance is displayed over the data plot and the colour corresponds to the condition 
in which the significance is compared to. N=2 
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Figure 6.15 Effect of cell number on cell viability over 20 days of encapsulation in fibrinogen-
FPA gels. FPA gels were formed using 0.7 mg.mL-1 FPA Cell viability was determined by the 
rate of reduction of PrestoBlue® (shown as mean fluorescence per minute). The error bars 
represent the standard error of the mean. Statistical analysis with use of a one-way ANOVA 
with Tukey post test was conducted. Significance: ** P<0.01, *** P<0.001, **** P<0.0001. 
Non-significant results have not been shown. Significance is displayed over the data plot and 
the colour corresponds to the condition in which the significance is compared to. N=2 
 
 
 
Glycosaminoglycan content 
 
For all fibrinogen based hydrogels, fibrin (Figure 6.16), and FPA at concentrations of 
2.66 mg.mL-1 (Figure 6.17) and 0.7 mg.mL-1 (Figure 6.18), the average GAG content 
increased with increasing cell number. Chondrocytes encapsulated at 50,000 cells per gel 
synthesized less ECM in comparison to the counterpart with 300,000 encapsulated 
chondrocytes per gel. However, the differences in the level of GAG production between 
gels containing 50,000 chondrocytes and gels containing 300,000 cells were not 
statistically different. These results showed that the 100 µL gels used were capable of 
supporting chondrocyte viability at 300,000 chondrocytes/gel and indicated that the 
chondrocytes could dedifferentiate in the gels to produce ECM components. Therefore, 
in all further experiments 300,000 cells were encapsulated per gel.        
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Figure 6.16 Effect of cell number of the GAG content of chondrocytes encapsulated in fibrin 
gels (shown as mean total GAG (µg/gel)) indicating ECM deposition after 21 days of culture in 
fibrin gels. The error bars represent the standard error of the mean. Statistical analysis with use 
of a one-way ANOVA with Tukey post-test was indicated that there was no statistical difference 
in the amount of GAGs produced by the higher number of chondrocytes encapsulated vs the 
lower number of chondrocytes. N=2 
 
 
 
 
 
Figure 6.17 Effect of cell number on the glycosaminoglycan content of chondrocytes 
encapsulated in fibrinogen-FPA gels formed from 2.66 mg.mL-1 FPA (shown as mean total 
GAG (µg/gel) and cultured for 21 days. The error bars represent the standard error of the mean. 
Statistical analysis with use of a one-way ANOVA with Tukey post test was conducted to 
determine statistical significance between results N=2 
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Figure 6.18 Effect of cell number on the glycosaminoglycan content of chondrocytes 
encapsulated in fibrinogen-FPA 0.7 mg.mL-1 gels (shown as mean total GAG (µg/gel) 50,000, 
150,000 or 300,000 chondrocytes were encapsulated per gel and cultured for 21 days. The error 
bars represent the standard error of the mean. Statistical analysis was performed using of a one-
way ANOVA with Tukey post test to determine statistical significance between results. N=2. 
 
6.2.4 Calcium concentration 
The initial gelation process for the fibrinogen gels took place in wells formed in PTFE 
blocks after which the gels were then transferred to individual wells of a 24-well plate 
(1 gel/well). Initial experiments used cell free gels to determine the minimum calcium 
concentration required for gelation. Gelation within the PTFE wells followed by transfer 
of the gels to 24-well plates was successful. Therefore, this method of casting fibrinogen 
gels was used to investigate the effect of calcium on the gelation process. The cell seeding 
density investigation determined that 300,000 chondrocytes encapsulated per gel was 
optimal for the culture conditions used and therefore was continued throughout the 
research. 
The effect of 20 mM, 10 mM, 5 mM, 2 mM and 0 mM CaCl2 on the gelation of 
fibrinogen by FPA was investigated. This experiment was undertaken to investigate 
whether the fibrinogen gelation could occur at low calcium ion concentrations which were 
more physiological and therefore less likely to cause toxic/adverse effects on the 
encapsulated cells. It was observed that all the concentrations of FPA (2.66 mg.mL-1, 
2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-1) and fibrin, gelled at 20 mM, 10 mM, 5 mM, 
and 2 mM CaCl2 concentrations. No gelation was observed in the absence of added 
calcium ions after 30 minutes under the conditions used. Therefore, bovine chondrocytes 
were encapsulated in fibrinogen-FPA gels and fibrin gels containing 2 mM CaCl2 
alongside gels made with 10 mM CaCl2 as a comparison.  
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Cell viability 
The results of the cell viability assay have shown that the chondrocytes have survived 
in all conditions for 21 days (Figure 6.20, Figure 6.19). Statistical analysis with a one-
way ANOVA and Tukey post-test shows there are no significant differences in cellular 
activity between 2 mM and 10 mM concentrations of CaCl2 present during gelation.  
 
 
 
Figure 6.19 Rate of reduction of PrestoBlue® (shown as mean fluorescence per minute) of gels 
containing 300,000 bovine chondrocytes encapsulated for 21 days in fibrin gels and FPA-
fibrinogen gels formed using FPA 2.66 mg.mL-1, FPA 2 mg.mL-1, FPA 1.33 mg.mL-1, FPA 0.7 
mg.mL-1 and fabricated with 2 mM CaCl2buffered saline.The error bars represent the standard 
error of the mean. Statistical analysis with use of a one-way ANOVA with Tukey post test was 
conducted to detect any significant differences between 10 mM CaCl2 and 2 mM CaCl2 results. 
N=4. 
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Figure 6.20 Rate of reduction of PrestoBlue® (shown as mean fluorescence per minute) of gels 
containing 300,000 bovine chondrocytes per gel and encapsulated for 21 days in fibrinogen gels 
formed using FPA 2.66 mg.mL-1, FPA 2 mg.mL-1, FPA 1.33 mg.mL-1, FPA 0.7 mg.mL-1 and 
fibrin gels fabricated with 10 mM CaCl2 buffered saline.. The error bars represent the standard 
error of the mean. Statistical analysis with use of a one-way ANOVA with Tukey post test was 
conducted between 10 mM CaCl2 and 2 mM CaCl2. N=4. 
 
 
Glycosaminoglycan content 
The GAG content suggested that the chondrocytes were synthesising ECM within all 
the FPA-fibrinogen and fibrin hydrogels (Figure 6.21, Figure 6.22). No statistical 
significant differences were found between the gels made from 2 mM and 10 mM CaCl2 
buffered saline. The results suggested that cellular viability was not affected by calcium 
concentration at 2 mM or 10 mM calcium ions. However, by lowering the concentration 
to physiological conditions the cells would be in a more physiological environment and 
are less likely to undergo apoptosis.    
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Figure 6.21 Total GAG content per gel from chondrocytes encapsulated in FPA-fibrinogen and 
fibrin gels fabricated with 2 mM CaCl2 buffered saline. The error bars represent the standard 
error of the mean. Statistical analysis using one-way ANOVA with a Tukey post test was 
conducted to detect any statistical differences between between 10 mM CaCl2 and 2 mM CaCl2 
results. N=4. 
 
 
 
 
 
 
 
Figure 6.22 Total GAG content per gel from chondrocytes encapsulated FPA-fibrinogen and 
fibrin gels fabricated with 10 mM CaCl2 buffered saline. The error bars represent the standard 
error of the mean. Statistical analysis using one-way ANOVA with a Tukey post test was 
conducted to detect any statistical differences between 10 mM CaCl2 and 2 mM CaCl2 results. 
N=4 
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Key Summary 
• FPA-fibrinogen gels were optimised for chondrocyte encapsulation, the following 
parameters were investigated and deemed optimum for the gelation of FPA-
fibrinogen gels and for cell survival and differentiation: 
o Gel fabrication in a well of a 96-well plate and transferred to a well in a 
24-well plate 
o 300,000 chondrocytes encapsulated per gel 
o 2 mM CaCl2 saline solution will be used to enable gelation – CaCl2 was 
required for gelation 
• These parameters were used to investigate chondrocyte survival and 
differentiation in greater depth (chapter 6.3) and to investigate the encapsulation 
bone marrow derived mesenchymal stems cells (chapter 7).  
  
6.3 Chondrocyte encapsulated Peprostat and fibrin gels after optimisation 
As seen previously in section 6.2.3 it was found that the optimum method for 
encapsulating the chondrocytes was to encapsulate 300,000 cells per gel with 2 mM CaCl2 
buffered saline. The formation of hydrogels was optimised in a 96-well culture plate and 
then transferred to a well in a 24-well plate (1 gel per well) using a sterile spatula. Transfer 
of the gels enabled 2 mL of medium to surround the chondrocyte encapsulated gels. Once 
the optimised method had been established the variability in chondrocyte survival was 
reduced.  
Phase contrast images 
Phase contrast images were taken at day 3 and day 21 after encapsulation with 
chondrocytes in fibrinogen gels formed from FPA 2.66 mg.mL-1 (Figure 6.24), FPA 
0.7 mg.mL-1 (Figure 6.25) and fibrin gels (Figure 6.23). It can be seen from the phase 
contrast images that the chondrocytes remain in encapsulation in all hydrogels and do not 
migrate out of the gels.  
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Figure 6.23 Phase contrast images of chondrocyte encapsulated fibrin gels, at day 3 after 
encapsulation (A and B) and day 21 after encapsulation (C and D) at x4 magnification (A and 
C) and x20 magnification (B and D). The blue arrows illustrate the edge of the hydrogel. Gel 
debris was observed by the black arrows in images B and D. Scale bars are shown on the image.  
                           
Figure 6.24 Phase contrast images of chondrocyte encapsulated FPA-fibrinogen gels at a 
concentration of 2.66 mg.mL-1 taken at day 3 after encapsulation (A and B) and day 21 after 
encapsulation (C and D) at x4 magnification (A and C) and x20 magnification (B and D). The 
edge of  the hydrogel is illustrated by the blue arrow. Gel debris was observed by the black arrows 
in images B and D. Scale bars are shown on the image.  
 
A B 
D C 
A B 
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Figure 6.25 Phase contrast images of chondrocyte encapsulated FPA-fibrinogen gels at a 
concentration of 0.7 mg.mL-1 taken at day 3 after encapsulation (A and B) and day 21 after 
encapsulation (C and D) at x4 magnification (A and C) and x20 magnification (B and D). The 
edge of the hydrogel is shown by the blue arrows. Gel debris was observed by the black arrows 
in images B and D. Scale bars are shown on the image. 
 
Chondrocyte viability 
Resazurin reduction was observed in all FPA-fibrinogen hydrogels: FPA 
2.66 mg.mL-1, FPA 2 mg.mL-1, FPA 1.33 mg.mL-1 and FPA 0.7 mg.mL-1 and fibrin 
(Figure 6.27). A peak in cell activity at day 10 was observed for chondrocyte encapsulated 
FPA-fibrinogen gels at all concentrations and fibrin gels after which the cellular activity 
decreased to day 21. Culturing chondrocytes in monolayer culture is well known to cause 
the cells to lose their chondrocyte phenotype which can be regained in 3D culture. Since 
differentiated chondrocytes tend to have a lower rate of metabolism it may be possible 
that the lower rate of resazurin reduction may be a reflection that the cells began 
synthesising ECM after this period of culture. There were no significant differences 
between the FPA-fibrinogen gels and fibrin gels which suggested that the FPA gels were 
comparable to fibrin in supporting cellular viability. Cell free gels exhibited very low 
results and therefore did not interfere with the assay, Figure 6.26. FPA 2.66 mg.mL-1, 
FPA 2 mg.mL-1, FPA 1.33 mg.mL-1 and FPA 0.7 mg.mL-1 and fibrin chondrocyte 
encapsulated gels were significantly different from their cell free counterparts at all time 
points, Table 6.5, this suggested chondrocyte survival. The medium was also analysed at 
A B 
D C 
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day 1, 3, 7, 10, 14, and 20 after encapsulation of chondrocytes, very little resazurin 
reduction was detected, see Figure 6.26, suggesting that the chondrocytes are not 
migrating from the FPA and fibrin gels and into the medium.   
 
 
Figure 6.26 The effect of the rate of reduction of PrestoBlue® (shown as mean relative 
fluorescence units per minute) on cell free FPA-fibrinogen and fibrin gels (A) and the rate of 
reduction of resazurin on the medium samples (B) incubated with the chondrocyte encapsulated 
FPA-fibrinogen and fibrin gels. Measurements were taken at day 1, day 3, day 7, day, 10, day 14 
and day 20 of culture. The error bars represent the standard error of the mean. Statistical analysis 
with use of a one-way ANOVA with Tukey post test was conducted. N=10 
 
Figure 6.27 Rate of reduction of PrestoBlue® (shown as mean fluorescence per minute) indicating 
the cell activity of 300,000 bovine chondrocytes per gel encapsulated for 21 days in FPA 2.66 
mg.mL-1, FPA 2 mg.mL-1, FPA 1.33 mg.mL-1, FPA 0.7 mg.mL-1 and fibrin gels fabricated with 2 
mM CaCl2 buffered saline. Readings were taken at day 1, day 3, day 7, day, 10, day 14 and day 
20 of culture. The error bars represent the standard error of the mean. Statistical analysis with use 
of a one-way ANOVA with Tukey post test was conducted. N=10 
 
A B 
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Table 6.5 Showing the statistical analysis of unpaired t-test with Welch’s correction comparing 
FPA 2.66 mg.mL-1, FPA 2 mg.mL-1, FPA 1.33 mg.mL-1, FPA 0.7 mg.mL-1, and Fibrin, with their 
cell free equivalents from the cell activity results taken at day 1, 7, 14, 20 after encapsulation of 
chondrocytes refer to Figure 6.27 and Figure 6.32. Significance: *** P<0.001, **** P<0.0001 
 Day of 
encapsulation 
Significance 
FPA 2.66 mg.mL-1 
chondrocyte encapsulated 
against cell free gels 
1 **** 
3 **** 
7 **** 
10 *** 
14 **** 
20 *** 
FPA 2 mg.mL-1 chondrocyte 
encapsulated against cell 
free gels 
1 **** 
3 **** 
7 **** 
10 *** 
14 **** 
20 **** 
FPA 1.33 mg.mL-1 
chondrocyte encapsulated 
against cell free gels 
1 **** 
3 **** 
7 **** 
10 *** 
14 **** 
20 **** 
FPA 0.7 mg.mL-1 
chondrocyte encapsulated 
against cell free gels 
1 **** 
3 **** 
7 **** 
10 *** 
14 **** 
20 **** 
Fibrin chondrocyte 
encapsulated against cell 
free gels 
1 **** 
3 **** 
7 **** 
10 **** 
14 **** 
20 *** 
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6.3.1 Live Dead stain 
Observations from the live/dead stain suggested the majority of chondrocytes were 
seen to be viable, green, on days 1 and day 21 of encapsulation in fibrin gels, see Figure 
6.28. Very few dead cells, red, are observed in the images. This has also been shown 
through the percentage of live cells in comparison to dead cells where as little as 2 % of 
chondrocytes were dead at day 21 of encapsulation in fibrin gels and 3 % in fibrinogen-
FPA gels formed from 2.66 mg.ml-1 FPA, refer to Figure 6.30. Similar cell viability 
results were observed for chondrocyte encapsulated FPA-fibrinogen gels at a 
concentration of 2.66 mg.mL-1, see Figure 6.29. The number of chondrocytes increased 
by greater than 2-fold in fibrin and almost 2-fold in FPA 2.66 mg.ml-1 gels from day 1 to 
day 21, see Figure 6.31. This result suggested cell proliferation, which is in accordance 
with the rise in apparent cell viability/cell activity by day 10. These results also suggested 
that the reduction in cell activity seen by day 21 is unlikely to be due to cell death. 
 
 
 
Figure 6.28 Live/Dead staining on chondrocyte encapsulated fibrin gels at day 1 (A) and day 21 
(B) of encapsulation. Images taken on the confocal microscope. Scale bars shown on the image 
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 132 | P a g e  
 
C h a p t e r |  Results: Chondrocyte encapsulation 
 
 
Figure 6.29 Live/Dead staining on chondrocyte encapsulated FPA-fibrinogen gels at a 
concentration of 2.66 mg.mL-1 FPA at day 1 (A) and day 21 (B) of encapsulation. Images taken 
on the confocal microscope. Scale bars shown on the image. 
 
 
Figure 6.30 Percentage of live and dead chondrocytes at day 1 and 21 of encapsulation in (A) 
fibrin and (B) FPA-fibrinogen gels formed from 2.66 mg.mL-1 FPA. Cell number was quantified 
from live/dead stained images taken on the confocal microscope. N=1 
 
A B 
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Figure 6.31 The number of live chondrocytes at day 1 and day 21 of encapsulation in (A) fibrin 
and (B) FPA-fibrinogen gel formed from 2.66 mg.mL-1 FPA. Cell number was quantified from 
live/dead stained images taken on the confocal microscope. N=1 
     
6.3.2 Glycosaminoglycan content 
All FPA-fibrinogen gels fabricated with FPA at concentrations of 2.66 mg.mL-1, 
2 mg.mL-1, 1.33 mg.mL-1, 0.7 mg.mL-1 and fibrin gels supported GAG deposition (Figure 
6.33). Gels formed from FPA 2.66 mg.mL-1 and FPA 1.33 mg.mL-1 had a significantly 
higher (P≤0.05) mean GAG content in comparison to FPA 0.7 mg.mL-1. Although gels 
formed from FPA 1.33 mg.mL-1  had a higher mean GAG content per gel in comparison 
to 2 mg.mL-1 and 0.7 mg.mL-1 the data is not significantly. The cell free counterparts of 
FPA 2.66 mg.mL-1, FPA 2 mg.mL-1, FPA 1.33 mg.mL-1, FPA 0.7 mg.mL-1 and fibrin 
exhibited high effects from the DMB which suggested interference with the assay, Figure 
6.32. No significant differences were observed between the chondrocyte encapsulated 
and the cell free counterparts from the FPA-fibrinogen and fibrin gels other than FPA 
1.33 mg.mL-1, refer to Table 6.6. Therefore, all the cell free data was subtracted from the 
counterparts of the chondrocyte encapsulated data. 
 
A B 
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Figure 6.32 The effect of DMB (shown as Total GAG (µg/gel) on cell free FPA-fibrinogen gels 
and fibrin gels. The error bars represent the standard error of the mean. Statistical analysis with 
use of a one-way ANOVA with Tukey post test was conducted. N=6 
 
 
Figure 6.33 Total glycosaminoglycan content per gel of chondrocyte encapsulated FPA-
fibrinogen and fibrin gels. Measurements were taken at day 21 of encapsulation. The error bars 
represent the standard error of the mean. Statistical analysis with use of a one-way ANOVA with 
Tukey post test was conducted. Significance: * P≤0.05. N=6 
 
Table 6.6 Showing the statistical analysis of an unpaired t-test with Welch’s correction 
comparing FPA 2.66 mg.mL-1, FPA 2 mg.mL-1, FPA 1.33 mg.mL-1, FPA 0.7 mg.mL-1, and 
Fibrin, with their cell free equivalents from the total GAG content measured at day 21 after 
encapsulation of chondrocytes refer to Figure 6.32 and Figure 6.33. Significance: ** P<0.01, ns 
is no significant differences 
  Significance 
FPA 2.66 mg.mL-1 ns 
FPA 2 mg.mL-1 ns 
FPA 1.33 mg.mL-1 ** 
FPA 0.7 mg.mL-1 ns 
Fibrin ns 
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6.3.3 Histological analysis 
H&E staining in cell free gels (Figure 6.35) showed that the hydrogel structure stained, 
but this staining was less than observed in chondrocyte encapsulated hydrogels (Figure 
6.36). Haematoxylin binds to chromatin and stains it purple whereas Eosin binds to ECM 
due to being an acidic dye and the stains ECM pink. It can be seen from the cell free 
images that the hydrogels stained pink due to the staining of fibrinogen and fibrin. From 
the H&E sections it is evident that the FPA-fibrinogen gels appeared more open-pored in 
comparison to the fibrin gels. Chondrocytes were seen evenly dispersed throughout the 
FPA-fibrinogen gels and fibrin gels (Figure 6.36). Due to the background staining from 
the hydrogel it is difficult to determine ECM formation. The cells appeared to be situated 
within the pores of the hydrogels individually and have maintained the spherical-like 
morphology, which is also observed in native articular cartilage Figure 6.34. It can also 
be observed that a dense cell layer had formed around the surface of the hydrogels 
surrounded by ECM synthesis, the chondrocytes have a flattened morphology similar to 
that of chondrocytes in the superficial zone of the articular cartilage.   
 
 
 
Figure 6.34 Histological H&E stained sections from native bovine articular cartilage from the 
metacarpophalangeal joint (A and B). Images taken at a magnification of x20 (A) and x40 (B). 
Scale bar shown on the image.       
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Figure 6.35 Histological H&E stained sections from cell free (A) fibrin, and FPA-fibrinogen gels 
formed from (B) 2.66 mg.ml-1 FPA, (C) 2 mg.ml-1 FPA, (D) 1.33 mg.ml-1 FPA and (E) 0.7 mg.ml-1 
FPA. Images were taken at a magnification of x20 and scale bars are displayed on the image. 
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Figure 6.36 Histological H&E stained sections from chondrocyte encapsulated for 21 days (A, B) 
fibrin and FPA-fibrinogen gels formed from (C, D) 2.66 mg.ml-1 FPA, (E, F) 2 mg.ml-1 FPA, (G, 
H) 1.33 mg.ml-1 FPA and (I, J) 0.7 mg.ml-1 FPA. Images taken at a magnification of x20 (A, C, 
E, G, and I) and x40 (B, D, F, H and J). Scale bars shown on the image. 
 
Toluidine blue stain was used for the detection of proteoglycans, in purple, and nucleic 
acids, in blue. Chondrocyte encapsulated FPA-fibrinogen and fibrin gels were stained at 
day 21 of culture as described in section 4.13. A high background due to the staining of 
the cell free hydrogels was observed (Figure 6.37). However, chondrocyte encapsulated 
FPA-fibrinogen and fibrin gels contain purple staining suggesting proteoglycans were 
deposited by the encapsulated chondrocytes. Proteoglycan formation suggests that the 
F E 
H G 
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chondrocytes are synthesising ECM over the 21 days in culture. A dense purple stained 
area is observed in sections of chondrocytes encapsulated in FPA-fibrinogen gels formed 
with 2.66 mg.mL-1 FPA (Figure 6.38, C, D) and 1.33 mg.mL-1 FPA (Figure 6.38, G, H) 
which is consistent with the higher total GAG content in comparison to fibrin, and FPA-
fibrinogen gels formed with 2 mg.mL-1 FPA and 0.7 mg.mL-1 FPA (refer to Figure 6.38). 
FPA-fibrinogen gels formed from 2.66 mg.mL-1 appeared to have areas of dense 
proteoglycan formation surrounding chondrocytes. The histological staining of the 
hydrogels was consistent with the GAG content (Figure 6.33) suggesting that the 
chondrocytes are synthesising ECM within the FPA-fibrinogen gels and fibrin gels. 
 
              
 
Figure 6.37 Histological Toluidine blue stained sections from cell free (A) fibrin and FPA-
fibrinogen gels formed from (B) 2.66 mg.ml-1 FPA, (C) 2 mg.ml-1 FPA, (D) 1.33 mg.ml-1 and (E) 
0.7 mg.ml-1 FPA. Images were taken at a magnification of x20 and scale bars are shown on the 
image. 
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Figure 6.38 Histological Toluidine blue stained sections from chondrocytes encapsulated for 21 
days in (A, B) fibrin and FPA-fibrinogen gels formed from (C, D) 2.66 mg.ml-1 FPA, (E, F) 2 
mg.ml-1 FPA, (G, H) 1.33 mg.ml-1 and (I, J) 0.7 mg.ml-1 FPA. Images were taken at a 
magnification of x20 (A, C, E, G, and I) and x40 (B, D, F, H, and J). Magnification windows are 
shown on in yellow Scale bars are shown on the image. 
 
 
The histological stained images were analysed for pore diameter and the average 
number of pores per image using imagej software. Pore diameter has been shown as a 
box plot with the minimum, maximum and median pore diameters and the interquartile 
range displayed. The analysis suggested that the chondrocyte encapsulated gels (Figure 
6.39, B, D)  had at least 5-fold more pores with a smaller pore diameter in comparison to 
the cell free counterparts (Figure 6.39, A, C). This suggested that the chondrocytes were 
occupying the pores and producing ECM within the pores. All chondrocyte encapsulated 
FPA-fibrinogen gels had virtually the same number and diameter of pores, however fibrin 
gels had larger pores but very few in comparison to the FPA-fibrinogen gels. This 
suggested that fibrin had a more compact and less porous structure in comparison to the 
FPA-fibrinogen gels.    
J I 
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Figure 6.39 Measurements of pore diameter (A, B) and number of pores (C, D) from analysed 
from the histological staining of cell free (A, C) and chondrocyte encapsulated (B, D) fibrin and 
FPA-fibrinogen gels formed from 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-1 
FPA. Pore diameter (A, B) is shown as a box plot indicating the minimum, median and 
maximum pore diameter and the interquartile range.  
 
 
The H&E and Toluidine blue stained chondrocyte encapsulated hydrogels have shown 
that the chondrocytes are evenly distributed throughout the gels and ECM formation can 
be observed in the centre and on the edges of the gels. Suggesting that the chondrocytes 
remained viable and were differentiating and forming ECM within the gels. Analysis of 
the stained images showed that the FPA-fibrinogen gels had a porous structure in 
comparison to fibrin and suggested that ECM formation had filled the pores of the gel.  
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In summary, the analysis of cell activity, GAG formation and proteoglycan staining it 
was observed that FPA-fibrinogen gels at a concentration of 2.66 mg.mL-1 was the 
optimal choice for chondrocyte encapsulation in comparison to FPA-fibrinogen gels at 
concentrations of 2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-1. The structure and porosity 
of the gels were very similar and therefore FPA 2.66 mg.mL-1 with fibrinogen was chosen 
as optimal due to the formation of a larger gel compared to those formed with lower 
concentrations of FPA. This meant that the FPA-fibrinogen gel using 2.66 mg.mL-1 FPA 
was easier to handle and to observe any changes in gel size throughout culture. Therefore, 
further investigations for chondrocyte encapsulation was continued with FPA-fibrinogen 
gels formed using 2.66 mg.mL-1 FPA.  
 
6.3.4 RNA extraction 
Investigations into chondrogenic gene expression and whether the peak in cell activity 
at day 10 of encapsulation is due to de-differentiation (see section 6.3.2), RNA was 
extracted from the chondrocyte encapsulated FPA-fibrinogen (2.66 mg.mL-1 FPA) and 
fibrin gels. Two methods for RNA extraction were investigated: TRIzol reagent and 
Isolate II RNA mini kit. The data on RNA extraction is preliminary.  
After extraction with TRIzol reagent, the RNA concentration at day 1 of chondrocyte 
encapsulation was very high for both FPA-fibrinogen gels formed from 2.66 mg.mL-1 
FPA and fibrin, 1272 ng.mL-1 and 305 ng.mL-1 respectively. However, the first peak in 
the RNA NanoDrop as shown by the black arrows in Figure 6.40 and Figure 6.41 
suggested contamination of the RNA pellet. Due to the phenol-based extraction method 
used, phenol contamination was suspected and this can cause a false high RNA 
concentration. Therefore, the RNA samples were passed through an RNA gel to 
determine if any RNA bands could be observed. Observations suggested that no RNA 
bands were found and therefore no RNA was present in the samples. TRIzol reagent 
extraction method was investigated again with a series of washes to remove the phenol 
contamination. A purer RNA sample was observed but the RNA concentration of the 
solution was very low at 2.1 ng.mL-1 at day 1 of chondrocyte encapsulation, (Table 6.7). 
Therefore, this method of extraction was abandoned and a different RNA extraction 
method was investigated. 
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Table 6.7 300,000 chondrocytes encapsulated for 1 or 7 days in FPA 2.66 mg.mL-1. RNA 
extraction was completed with TRIzol reagent and the RNA pellet washed. Showing the 
RNA concentration carried out on the NanoDrop and the 260/280 ratio reading. 
FPA 2.66 mg.mL-1 
hydrogel 
RNA concentration 
(ng.µL-1) 
260/280 
BAC day 1 2.1 2.44 
BAC day 7 1.4 1.68 
 
 
 
A B 
A B 
Figure 6.40 RNA extraction using TRIzol reagent of 300,000 bovine chondrocytes per gel 
encapsulated in 34 mg.mL-1 fibrin for (A) 1 day and (B) 7 days. The first peak in each graph, as 
shown by the arrow, is indicative of phenol contamination of the samples.  
Figure 6.41 RNA extraction using TRIzol reagent of 300,000 bovine chondrocytes per gel 
encapsulated in 2.66 mg.mL-1 FPA for (A) 1 day and (B) 7 days. The first peak on each graph, as 
shown on the figure by arrows, is indicative of phenol contamination. 
 144 | P a g e  
 
C h a p t e r |  Results: Chondrocyte encapsulation 
To obtain higher concentrations of RNA 3 gels per extraction was investigated 
with another isolation method. An Isolate II RNA mini extraction kit was used, this 
method does not contain phenol and therefore should reduce the contamination of the 
pellets. The method increased the purity of the RNA samples and RNA was obtained 
as observed on the NanoDrop (Table 6.8). Three gels were required per RNA 
extraction to obtain a concentration of 77.3 ng.mL-1 in comparison to one gel per 
extraction at 11.9 ng.mL-1. Therefore, three gels per RNA extraction was required to 
obtain enough RNA to carry out quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR). 
 
 
Table 6.8 RNA extraction using Isolate II RNA mini kit on 300,000 cells per gel encapsulated 
in FPA 2.66 mg.mL-1. Showing the RNA concentration (ng.µL-1) and the 260/280 ratio. 
FPA 2.66 mg.mL-1 hydrogel 
encapsulated with BAC 
RNA concentration 
(ng.µL-1) 
260/280 
1 gel per extraction 11.9 1.93 
3 gels per extraction 77.3 1.5 
 
 
  
 
After optimisation of the RNA extraction process from FPA 2.66 mg.mL-1 and 
fibrin gels, RNA was extracted at day 0, day 10 and day 21 after 300,000 
chondrocytes encapsulated per FPA-fibrinogen and fibrin gels. Three gels were used 
for one RNA extraction sample. RNA extraction at day 0 of encapsulation showed 
high RNA concentrations of 42.8 ng.mL-1 for FPA-fibrinogen gels and 38.2 ng.mL-1 
fibrin gels. The results also suggested no contamination was found in the RNA 
pellets. However, cell activity of day 10 and day 21 of chondrocyte encapsulation 
suggested that the chondrocytes had died. RNA was extracted and very low 
concentrations of below 4 ng.mL-1 was observed for both FPA-fibrinogen gels and 
fibrin gels (Table 6.9 and Table 6.10). There was also evidence of contamination 
suggested by the first peak of Figure 6.42.  
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Table 6.9 RNA extraction using Isolate II RNA mini kit on 300,000 chondrocytes encapsulated 
in FPA 2.66 mg.mL-1 gels, 3 gels per extraction. RNA concentration measured at day 0, day 10 
and day 21.  
FPA 
gel 
RNA 
concentration 
(ng.µL-1) 
260/ 
280 
RNA 
concentration 
(ng.µL-1) 
260/ 
280 
RNA 
concentration 
(ng.µL-1) 
260/ 
280 
Day 0 41.1 2.03 42.6 2.06 43.3 2.02 
Day 10 0.09 4.02 1.59 2.77 0.253 1.6 
Day 21 0.5 0.95 0.2 0.64 0.8 1.96 
 
 
Table 6.10 RNA extraction using Isolate II RNA mini kit on 300,000 chondrocytes encapsulated 
in fibrin gels, 3 gels per extraction. RNA concentration measured at day 0, day 10 and day 21. 
Fibrin 
gel 
RNA 
concentration 
(ng.µL-1) 
260/ 
280 
RNA 
concentration 
(ng.µL-1) 
260/ 
280 
RNA 
concentration 
(ng.µL-1) 
260/ 
280 
Day 0 36.7 2.05 40.6 1.99 37.2 1.97 
Day 10 3.89 1.89 0.3 2.15 7.93 2.44 
Day 21 0.4 1.32 0.1 0.16 0.4 0.48 
 
 
 
Figure 6.42 graphs showing the RNA extraction at day 21 of 300,000 chondrocytes encapsulated 
in fibrin (A) gels and FPA 2.66 mg.mL-1 (B) gels, 3 gels per extraction. The graphs show phenol 
contamination in the samples and no RNA. 
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The method to extract RNA was optimised by using the Isolate II mini kit with the 
chondrocyte encapsulated FPA-fibrinogen and fibrin gels. However, due to low RNA 
yields from day 10 and day 21, qRT-PCR could not be carried out in this investigation, 
therefore gene expression could not be determined. 
 
Key Summary 
• Chondrocytes remained in encapsulation throughout the 21 day culture 
period. The FPA-fibrinogen and fibrin gels did not visibly degrade during the 
culture period.  
• Chondrocytes encapsulated in FPA-fibrinogen and fibrin gels were 
metabolically active and proliferated within the gels. ECM deposition was 
observed through total GAG content per gel, Toluidine blue and H&E 
staining. 
• All concentrations of FPA and fibrin used to form gels performed similarly in 
terms of cell activity. FPA-fibrinogen gels formed from FPA 2.66 mg.mL-1 
and FPA 1.33 mg.mL-1 had statistically significant higher mean GAG content 
in comparison to FPA 0.7 mg.mL-1. All FPA concentrations total GAG 
content was comparable to fibrin. 
• RNA extraction from FPA-fibrinogen and fibrin gels required more 
optimisation before gene expression could be analysed. 
• FPA-fibrinogen and fibrin gels had similar average pore diameters. Fibrin had 
10-fold fewer pores in comparison to FPA-fibrinogen gels. Therefore, the 
FPA-fibrinogen gels had a more open porous structure in comparison to 
fibrin. 
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6.4 Agarose gels 
Agarose 4 % gels were used as a reference material to the fibrinogen-FPA gels. It is 
also known that chondrocytes survive and differentiate when encapsulated in 4 % agarose 
gels. Chondrocytes were encapsulated at 300,000 cells per gel in 100 µL gels.  
Cell activity 
Cell viability was measured by the reduction of resazurin to resarufin. Very little dye 
reduction was observed in cell free gels showing that 4 % agarose did not interfere with 
the assay, causing no binding or reduction of resazurin (Figure 6.43). Cell activity in 
chondrocyte encapsulated gels showed that the cells have survived over the 21 day period 
of encapsulation, (Figure 6.43). Interestingly, in common with chondrocytes encapsulated 
in fibrinogen-FPA and fibrin gels, a peak of cell activity was also seen at day 10 with the 
chondrocyte encapsulated 4 % agarose gels.  
 
 
Figure 6.43 The effect of the rate of reduction of PrestoBlue on cell free 4 % agarose gels and the 
cell viability of 300,000 chondrocytes encapsulated in 4 % agarose gels. This was measured by 
the rate of reduction of PrestoBlue® over 21 days. The error bars represent the standard error of 
the mean. N=6. 
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Glycosaminoglycan content 
Cell free gels did not interfere with the 1,9-dimethylmethylene blue assay to measure 
GAG (Figure 6.44). Figure 6.44 showed the GAG content of chondrocyte encapsulated 
in 4 % agarose gels. The results showed that the chondrocytes were synthesising ECM 
within the gels. Also, GAG levels in agarose were similar to those of the chondrocyte 
encapsulated fibrin and novel cross-linked fibrinogen gels, see section 6.3.  
 
Figure 6.44 The effect of cell free 4 % agarose gel on the DMB assay and the total GAG content 
(shown as Total GAG (µg/gel)) of chondrocyte encapsulated 4 % agarose gels, measurements 
were taken at day 21 of encapsulation. The error bars represent the standard error of the mean. 
N=6 
 
Histological staining 
Histological staining provided further evidence for ECM deposition in the agarose 
gels. The results of the staining sections, with H&E staining (Figure 6.45) and Toluidine 
blue staining (Figure 6.46). Very little staining was observed for cell free gels stained 
with H&E and Toluidine blue and therefore have not been shown. H&E staining of the 
agarose encapsulated chondrocytes showed a blue/black staining of the cell nuclei and 
light purple of ECM. This staining was observed due to the complete lack of background 
staining from the cell free gel. The chondrocytes have a spherical morphology and are 
more disorganised throughout the 4 % agarose gel. Figure 6.46 shows sections of the 21 
day chondrocyte encapsulated agarose gels showed a deep purple and blue colour. The 
metachromic shift in the dye colour is characteristic of the dye binding to proteoglycan 
components and was suggestive of proteoglycan formation in the gels.  
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Figure 6.45 Histological H&E staining of sections of chondrocyte-encapsulated agarose gels. 
(300,000 chondrocytes encapsulated per gel) (A and B) Images were taken at a magnification of 
x20 (A) and x40 (B). Scale bars are shown on the images 
 
 
Figure 6.46 Histological Toluidine Blue staining of sections of chondrocyte encapsulated agarose 
gels (300,000 chondrocytes/gel) (A and B). Images were taken at a magnification of x20 (A) and 
x40 (B). Scale bars are shown on the image. 
 
Key Summary 
• Confirmation of chondrocyte survival and differentiation in 4 % agarose gels. 
• Chondrocytes encapsulated in FPA-fibrinogen gels were comparable to fibrin 
and 4 % agarose gels for cell activity and total GAG content per gel.   
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6.5 P15, P17, and HyStem gels 
Gelation experiments were carried out with P15 and P17 - fibrinogen hydrogels at 
concentrations of 0.75 mg.mL-1, 0.5 mg.mL-1, and 0.25 mg.mL-1 of the FBP components 
of P15 and P17. All three concentrations of P15 and P17 formed gels however, it was 
observed that 0.25 mg.mL-1 of P15 or P17 formed smaller gels with fibrinogen in 
comparison to 0.75 mg.mL-1 of P15 and P17. HyStem formed considerably smaller and 
weaker gels below concentrations of 0.75 mg.mL-1. Gelation was observed at 1 mg.mL-1 
and 0.75 mg.mL-1 of HyStem which appeared to form larger and stronger gels compared 
to lower concentrations of HyStem. However, in comparison to P15, P17, fibrin and FPA 
the HyStem gels were much smaller. The concentrations of P15 and P17 that were 
investigated for chondrocyte encapsulation were 0.75 mg.mL-1, 0.5 mg.mL-1, and 
0.25 mg.mL-1 and the HyStem concentrations used were 1 mg.mL-1 and 0.75 mg.mL-1. 
FPA-fibrinogen gels formed using 2.66 mg.mL-1 FPA and fibrin gels were used as 
reference materials.  
Phase contrast, light microscopy images of the chondrocyte encapsulated P15, P17 and 
HyStem – fibrinogen gels (refer to Figure 6.47 to Figure 6.56, images A-D), showed that 
chondrocytes appeared to have adhered to the tissue culture plastic throughout the 21 day 
encapsulation period. This was not previously observed with chondrocyte encapsulated 
FPA-fibrinogen, PEG-fibrinogen or fibrin gels, see sections 6.1, 6.3, and 6.4. The 
hydrogels have shown very little apparent degradation throughout the culture period in 
terms of diminishing volume. At day 21, the gels were removed from the well and the 
tissue culture plastic was treated with crystal violet to stain any adherent chondrocytes to 
the surface of the tissue culture plastic. This allowed the observations of chondrocytes 
that migrated out of the fibrinogen gels (Figure 6.47 to Figure 6.56, images E-F). It can 
be seen that a ring-like distribution of chondrocytes was visible on the tissue culture 
plastic surrounding the areas occupied by the hydrogels. Therefore, the chondrocytes did 
not remain fully encapsulated during the 21 day incubation period. The ring-like 
distribution indicating that chondrocytes on the outer surface of the hydrogel may have 
been able to migrate out of the fibrinogen gels formed form P15, P17 or HyStem.  
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Figure 6.47 Phase contrast images chondrocyte encapsulated fibrin gels taken at day 1 (A and B) 
and day 21 (C and D) after encapsulation. Crystal violet on the tissue culture plastic after day 21 
of encapsulation (E and F). The blue arrows show a representation of the hydrogel and the black 
arrows show the migrating chondrocytes. Images taken at x4 magnification (A, C and E) and x20 
magnification (B, D and F). Scale bars are shown on the image. 
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Figure 6.48 Phase contrast images chondrocyte encapsulated FPA-fibrinogen gels using 
2.66 mg.mL-1 FPA. Images taken at day 1 (A and B) and day 21 (C and D) after encapsulation. 
Crystal violet on the tissue culture plastic after day 21 of encapsulation (E and F). The blue arrows 
show a representation of the hydrogel and the black arrows show the migrating chondrocytes. 
Images taken at x4 magnification (A, C and E) and x20 magnification (B, D and F). Scale bars 
are shown on the image. 
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Figure 6.49 Phase contrast images chondrocyte encapsulated P15-fibrinogen gels using 
0.75 mg.mL-1. Images taken at day 1 (A and B) and day 21 (C and D) after encapsulation. Crystal 
violet on the tissue culture plastic after day 21 of encapsulation (E and F). The blue arrows show 
a representation of the hydrogel and the black arrows show the migrating chondrocytes. Images 
taken at x4 magnification (A, C and E) and x20 magnification (B, D and F). Scale bars are shown 
on the image. 
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Figure 6.50 Phase contrast images chondrocyte encapsulated P15-fibrinogen gels using 
0.5 mg.mL-1. Images taken at day 1 (A and B) and day 21 (C and D) after encapsulation. Crystal 
violet on the tissue culture plastic after day 21 of encapsulation (E and F). The blue arrows show 
a representation of the hydrogel and the black arrows show the migrating chondrocytes. Images 
taken at x4 magnification (A, C and E) and x20 magnification (B, D and F). Scale bars are shown 
on the image. 
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Figure 6.51 Phase contrast images chondrocyte encapsulated P15-fibrinogen gels using 
0.25 mg.mL-1. Images taken at day 1 (A and B) and day 21 (C and D) after encapsulation. Crystal 
violet on the tissue culture plastic after day 21 of encapsulation (E and F). The blue arrows show 
a representation of the hydrogel and the black arrows show the migrating chondrocytes. Images 
taken at x4 magnification (A, C and E) and x20 magnification (B, D and F). Scale bars are shown 
on the image. 
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Figure 6.52 Phase contrast images chondrocyte encapsulated P17-fibrinogen gels using 
0.75 mg.mL-1. Images taken at day 1 (A and B) and day 21 (C and D) after encapsulation. Crystal 
violet on the tissue culture plastic after day 21 of encapsulation (E and F). The blue arrows show 
a representation of the hydrogel and the black arrows show the migrating chondrocytes. Images 
taken at x4 magnification (A, C and E) and x20 magnification (B, D and F). Scale bars are shown 
on the image. 
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Figure 6.53 Phase contrast images chondrocyte encapsulated P17-fibrinogen gels using 
0.5 mg.mL-1. Images taken at day 1 (A and B) and day 21 (C and D) after encapsulation. Crystal 
violet on the tissue culture plastic after day 21 of encapsulation (E and F). The blue arrows show 
a representation of the hydrogel and the black arrows show the migrating chondrocytes. Images 
taken at x4 magnification (A, C and E) and x20 magnification (B, D and F). Scale bars are shown 
on the image. 
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Figure 6.54 Phase contrast images chondrocyte encapsulated P17-fibrinogen gels using 
0.25 mg.mL-1. Images taken at day 1 (A and B) and day 21 (C and D) after encapsulation. Crystal 
violet on the tissue culture plastic after day 21 of encapsulation (E and F). The blue arrows show 
a representation of the hydrogel and the black arrows show the migrating chondrocytes. Images 
taken at x4 magnification (A, C and E) and x20 magnification (B, D and F). Scale bars are shown 
on the image.  
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Figure 6.55 Phase contrast images chondrocyte encapsulated HyStem-fibrinogen gels using 
1 mg.mL-1. Images taken at day 1 (A and B) and day 21 (C and D) after encapsulation. Crystal 
violet on the tissue culture plastic after day 21 of encapsulation (E and F). The blue arrows show 
a representation of the hydrogel and the black arrows show the migrating chondrocytes. Images 
taken at x4 magnification (A, C and E) and x20 magnification (B, D and F). Scale bars are shown 
on the image. 
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Figure 6.56 Phase contrast images chondrocyte encapsulated HyStem-fibrinogen gels using 
0.75 mg.mL-1. Images taken at day 1 (A and B) and day 21 (C and D) after encapsulation. Crystal 
violet on the tissue culture plastic after day 21 of encapsulation (E and F). The blue arrows show 
a representation of the hydrogel and the black arrows show the migrating chondrocytes. Images 
taken at x4 magnification (A, C and E) and x20 magnification (B, D and F). Scale bars are shown 
on the image. 
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Chondrocyte activity 
All cell free P15-fibrinogen, P17-fibrinogen, HyStem-fibrinogen, FPA-fibrinogen 
(2.66 mg.mL-1 FPA) and fibrin gels exhibited low resazurin reduction in the cell viability 
assay suggesting that the gels did not interfere by binding or reducing the dye chemically 
(Figure 6.57). The cell viability of the chondrocyte encapsulated gels was assessed. It was 
observed that all the fibrinogen gels supported chondrocyte survival over the 20 day 
culture period of encapsulation, a gradual increase in cellular activity was observed 
(Figure 6.58, Figure 6.59, Figure 6.60). It was observed that the HyStem gels in particular 
degraded throughout the culture period and chondrocytes had adhered to the tissue culture 
plastic. This may account for the higher cellular activity observed in the 0.75 mg.mL-1 
HyStem.  
 
 
Figure 6.57 The effect of the rate of reduction of PrestoBlue (shown as mean relative fluorescence 
units per minute) of cell free P15-fibrinogen gels (A), P17-fibrinogen gels (B) and HyStem-
fibrinogen gels (C). Measurements were taken at day 1, day 3, day 7, day, 10, day 14, day 17 and 
day 20 of culture. N=1 
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Figure 6.58 Rate of reduction of PrestoBlue (shown as mean fluorescence per minute) indicating 
the cell activity chondrocyte encapsulated fibrin, FPA-fibrinogen and P15-fibrinogen gels. The 
error bars represent the standard error of the mean. N=1 
 
 
Figure 6.59 Rate of reduction of PrestoBlue (shown as mean fluorescence per minute) indicating 
the cell activity chondrocyte encapsulated fibrin, FPA-fibrinogen and P17-fibrinogen gels. The 
error bars represent the standard error of the mean. N=1 
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Figure 6.60 Rate of reduction of PrestoBlue (shown as mean fluorescence per minute) indicating 
the cell activity chondrocyte encapsulated fibrin, FPA-fibrinogen and P15-fibrinogen gels. The 
error bars represent the standard error of the mean.. N=1 
 
Glycosaminoglycan content 
Cell free gels were tested for GAG content and P15, P17, HyStem, FPA 2.66 mg.mL-1 
and fibrin exhibited very little GAG in comparison to their chondrocyte encapsulated 
counterparts and therefore are not interfering with the assay (Figure 6.61). ECM synthesis 
was observed in P15, P17 and HyStem (Figure 6.63, Figure 6.64). The GAG content in 
P15, P17, HyStem, fibrin and FPA 2.66 mg.mL-1 under the conditions used showed very 
high values in comparison to those previously seen. However this could not be repeated 
due to insufficient material. 
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Figure 6.61 The effect of DMB on cell free P15-fibrinogen (A), P17-fibrinogen (B) and 
HyStem-fibrinogen (C) gels. N=1 
 
 
 
 
Figure 6.62 Total glycosaminoglycan content per gel of chondrocyte encapsulated in Fibrin, FPA-
fibrinogen, and P15-fibrinogen gels. The error bars represent the standard error of the mean. 
Statistical analysis with use of a one-way ANOVA with Tukey post test was conducted. N=1 
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Figure 6.63 Total glycosaminoglycan content per gel of chondrocyte encapsulated fibrin, FPA-
fibrinogen, and P17-fibrinogen gels. The error bars represent the standard error of the mean. 
Statistical analysis with use of a one-way ANOVA with Tukey post test was conducted. N=1 
 
 
Figure 6.64 Total glycosaminoglycan content per gel of chondrocyte encapsulated in fibrin, FPA-
fibrinogen, and HyStem-fibrinogen gels. The error bars represent the standard error of the mean. 
Statistical analysis with use of a one-way ANOVA with Tukey post test was conducted. N=1 
 
Haematoxylin and Eosin Stain 
Histological H&E stain was carried out after chondrocyte encapsulated P15, P17 and 
HyStem gels were cultured in chondrogenic conditions for 21 days. Unfortunately, cell 
free gels were unable to be stained due to samples being required for the DMB assay. 
Figure 6.65 illustrates the H&E staining. The chondrocytes appear to be disorganised 
when encapsulated in the P15, P17 and HyStem gels and had a spherical morphology. No 
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chondrocytes were stained from the H&E staining conducted on P17 0.75 mg.mL-1 and 
P17 0.25 mg.mL-1.  
 
 
Figure 6.65 Histological H&E stained sections of chondrocyte encapsulated P15-fibrinogen gels 
formed from (A) 0.75 mg.mL-1 P15, (B) 0.5 mg.mL-1 P15 and (C) 0.25 mg.mL-1 P15 and P17-
fibrinogen gels formed from (D) 0.75 mg.mL-1 P17, (E) 0.5 mg.mL-1 P17 and (F) 0.25 mg.mL-1 
P17. Images were taken at a magnification of x20 and scale bars are shown on the image. 
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Toluidine blue stain 
Toluidine blue staining was carried out on chondrocyte encapsulated P15, P17 and 
HyStem gels. Chondrocytes were not observed from the staining and very little 
proteoglycan staining was observed, Figure 6.66. This was inconsistent with the GAG 
content per gel, see Figure 6.61, Figure 6.63, and Figure 6.64. Unfortunately, cell free 
staining was unable to be obtained due to the samples being required for the GAG assay. 
There was limited materials available for the peptide work and therefore the histological 
staining could not be repeated.         
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Figure 6.66 Histological Toluidine blue stained sections of chondrocyte encapsulated P15-
fibrinogen gels formed from (A) 0.75 mg.mL-1 P15, (B) 0.5 mg.mL-1 P15 and (C) 0.25 mg.mL-1 
P15 and P17-fibrinogen gels formed from (D) 0.75 mg.mL-1 P17, (E) 0.5 mg.mL-1 P17 and (F) 
0.25 mg.mL-1 P17. Images were taken at a magnification of x20 and scale bars are shown on the 
image. 
 
Key Summary 
• Chondrocytes migrated from the P15, P17, and Hystem – fibrinogen gels. 
• HyStem – fibrinogen gels formed much smaller gels in comparison to P15, 
P17, FPA – fibrinogen and fibrin gels. Chondrocyte encapsulated HyStem – 
fibrinogen gels also degraded throughout the 21 day culture period. 
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• Chondrocytes encapsulated in P15, P17, and HyStem – fibrinogen gels 
survived and differentiated in the gels. 
• Proteoglycan staining by Toluidine blue did not reflect the high total GAG 
content by DMB assay.  
• Experimental repeats are required to confirm the accuracy of the results. 
 
6.6 Cell delivery to cartilage injury 
A cartilage injury model was developed in order to investigate events in a cartilage 
injury after the delivery of chondrocytes encapsulated within FPA-fibrinogen and fibrin 
gels. As described previously in section 4.2.5, and shown in Figure 4.1, a 6 mm biopsy 
punch was used to remove reproducible discs of articular cartilage from bovine 
metacarpophalangeal joints. The discs of cartilage were then injured by using a 3 mm 
biopsy punch to create a circular injury in the centre of the cartilage disc. Chondrocytes 
were delivered to the site of injury via encapsulation in fibrinogen-FPA gels at a 
concentration of 2.66 mg.mL-1 FPA and fibrin gels containing 300,000 chondrocytes per 
gel for 14 days. As shown in Figure 6.67, the cartilage disc can be seen in pink and the 
hydrogel, in blue, was formed prior to be placed over the cartilage injury.  
 
 
 
 
 
 
 
Cell viability 
The viability of the chondrocyte encapsulated fibrin or FPA-fibrinogen gels and 
cartilage was assessed over the time course of the incubation using PrestoBlue® (see 
section 4.10.1). The culture medium was collected and assayed for the capability to 
reduce the resazurin-based PrestoBlue®. Any apparent resazurin-reduction activity in the 
A B 
Figure 6.67 Schematic of the cartilage injury model. Top view (A) and side view (B) of the injured 
cartilage (pink) and chondrocytes delivered via the hydrogel (blue).  
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culture medium would be indicative of significant cell death in the model and release of 
cellular contents such as enzymes capable of the dye reduction or cells present in the 
medium. The culture medium showed very low level of resazurin reduction (Figure 6.68) 
which indicated no cell death or the release of cells into the medium had occurred during 
the culture of the injured cartilage and hydrogels. Figure 6.69 showed the viability of the 
cultured cartilage and chondrocyte-encapsulated fibrin and fibrinogen-FPA gels. The rate 
of PrestoBlue® reduction suggested that the cartilage and gel system remained viable 
throughout the incubation period with a trend for the rate of the dye reduction to increase 
over the 10 day incubation period.   
 
 
 
Figure 6.68 Rate of reduction of by culture medium removed during the time course of culture of 
fibrin and fibrinogen-FPA gels and injured articular cartilage. Readings were taken at day 1, day 
3, day 7, and day 10 of culture. N=1. 
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Figure 6.69 Viability of the injured articular cartilage and encapsulated chondrocytes. The data 
show the rate of reduction of PrestoBlue®. Readings were taken at day 1, day 3, day 7 and day 10 
of culture. N=1 
 
Phase contrast images  
Phase contrast images were taken of the model injury site on days 4 and 10 of culture. 
It was observed at day 4 that the chondrocytes had remained in encapsulation in the fibrin 
and FPA-fibrinogen gels, refer to Figure 6.70 (A, C). Figure 6.70, image A has a clear 
gap between the hydrogel (blue arrow) and the cartilage injury (purple arrow), where it 
can be observed that no chondrocytes had adhered to the tissue culture plastic. However, 
by day 10, refer to Figure 6.70 image B, chondrocytes are observed adhering to the tissue 
culture plastic (as demonstrated by the black arrow) between the FPA-fibrinogen gel (blue 
arrow) and the cartilage (purple arrow). This is an interesting observation as the 
chondrocytes did not migrate out of fibrin of fibrinogen-FPA gels incubated alone. The 
fibrin gel had formed a thin film over the tissue culture plastic and the cartilage injury, 
this can be seen in the gap between the fibrin gel (blue arrow) and cartilage (purple arrow), 
see Figure 6.70 image C. No chondrocytes could be seen between this gap at day 4, by 
day 10 the fibrin gel had completely obstructed the gap between the gel and the cartilage 
and therefore the light microscopy images have not been included. 
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Figure 6.70 Phase contrast light microscopy images showing the chondrocyte encapsulated 
fibrin and FPA-fibrinogen gels (blue arrow) in position in the cartilage injury site (purple 
arrow). The black arrow shows migratory cells. Images A and B show the injury site with 
chondrocytes encapsulated in fibrinogen-FPA gels, and image C shows the injury site with the 
fibrin-encapsulated chondrocytes. Images were taken at day 4 (A and C) and day 10 (B) of 
culture. Scale bars are shown on the image. 
 
Haematoxylin and Eosin staining 
H&E staining of histological sections taken from the encapsulated chondrocytes in the 
cartilage injury site was carried out to determine if ECM formation had occurred. Figure 
6.71 and Figure 6.72 shows stained sections from chondrocyte encapsulated fibrin and 
FPA-fibrinogen gels, respectively, for 14 days. Dense cell layers and ECM, green arrows 
Figure 6.71, can be seen from chondrocytes encapsulated in fibrin gels, blue arrow. Figure 
6.72 showed that large volumes of the fibrinogen-FPA gel, blue arrow, have been 
occupied with developing ECM deposition, green arrows, after just 2 weeks of culture. 
In addition, the chondrocytes appeared to show some alignment as seen in native articular 
cartilage. The ECM deposition had integrated with the cartilage, red arrow, suggesting 
that this is the early stages of cartilage repair.   
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Figure 6.71 Images showing H&E stained sections of chondrocytes encapsulated in fibrin gels, 
blue arrow, at the cartilage injury site, purple arrow, for 14 days. ECM deposition is shown by 
the green arrows. Images were taken at a magnification of x4 (A), x10 (B), x20 (C) and x40 (D) 
and the magnification window is yellow. Scale bars are shown on the image. 
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Figure 6.72 Histological H&E staining of 300,000 chondrocytes encapsulated in 2.66 mg.mL-1 
FPA-fibrinogen gels, blue arrow, and delivered to an articular cartilage injury, purple arrow, 
cultured for 14 days. ECM deposition was observed and shown by the green arrow. Images taken 
at a magnification of x4 (A), x10 (B), x20 (C) and x40 (D), the magnification window is in yellow. 
Scale bars are shown on the image.  
 
Key Summary 
• The injured cartilage appeared to dramatically increase ECM formation from 
the encapsulated chondrocytes in FPA-fibrinogen and fibrin gels, in 
comparison to the gels cultured without injured cartilage.  
• The integration of the hydrogel, chondrocytes and cartilage can easily be seen 
suggesting that cartilage repair is in progress.  
• The cartilage explant injury model is a viable model to investigate cartilage 
repair in vitro. 
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7.0 Results: Encapsulation of MSC’s and the osteoblastic cells 
MG63 
MSCs are currently in research for cartilage regeneration due to the ability to undergo 
chondrogenic differentiation. MSC’s are also released during the microfracture treatment 
for osteoarthritis. Therefore, bBM-MSCs were encapsulated in a range of novel 
fibrinogen gels to determine their potential for use in cell encapsulation and delivery to 
repair injured cartilage. 
   
7.1 MSC encapsulation in FPA gels 
Previous optimisation results from chondrocyte encapsulated FPA-fibrinogen and 
fibrin gels suggested that 300,000 cells per gel was optimal for encapsulation. Therefore, 
this cell number was used for the following experiments investigating the encapsulation 
of bovine bone marrow derived mesenchymal stem cells (bBM-MSCs) and human MG63 
osteoblastic cells in fibrin and FPA-fibrinogen gels. 
bBM-MSCs were encapsulated in fibrin, and fibrinogen–FPA gels formed from 
2.66 mg.mL-1, 2 mg.mL-1, 1.33 1, and 0.7 mg.mL-1 FPA. The gels were incubated in basic 
culture medium for 7 days to allow for cell proliferation. However, in contrast to 
experiments with encapsulated chondrocytes, during this 7 day incubation period the 
bBM-MSCs started to migrate out of the all the FPA-fibrinogen and fibrin gels at day 3 
of encapsulation, as shown by the black arrows on Figure 7.1 to Figure 7.5. All FPA-
fibrinogen and fibrin gels were observed to show initial stages of degradation at this time 
(i.e. the gels were visibly smaller).  The MSCs were observed to attach to the surface of 
the culture plates. By day 15 after MSC encapsulation all bBM-MSC encapsulated gels 
had almost completely degraded, this can be seen in the phase contrast, light microscopy 
images Figure 7.1 to Figure 7.5. These figures show the rapidly decreasing size of the 
gels during the incubation period. At day15 the cells attached to the culture surface were 
stained with crystal violet. In contrast, cell free gels, however, showed no signs of 
degradation in the culture condition used and therefore it must be the encapsulated bBM-
MSCs which must be causing the degradation of the fibrin and fibrinogen-FPA gels.  
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Figure 7.1 Light microscopy images of bBM-MSC encapsulated fibrin gels, blue arrow, taken at 
day 1 (A), day 3 (B), and day 15 (C). Cells were stained with crystal violet at day 15 of 
encapsulation (D), black arrows point to a representation of migratory cells. Images were taken 
at a magnification of x4. Scale bars are shown on the image. 
      
Figure 7.2 Light microscopy images of bBM-MSC encapsulated FPA-fibrinogen gels formed 
using 2.66 mg.mL-1 FPA, blue arrow. Images taken at day 1 (A), day 3 (B), and day 15 (C). Cells 
were stained with crystal violet at day 15 (D) black arrows point to a representation of migratory 
cells. Images were taken at a magnification of x4. Scale bars are shown on the image. 
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Figure 7.3 Light microscopy images of bBM-MSC encapsulated FPA-fibrinogen gels formed 
using 2 mg.mL-1 FPA, blue arrow. Images taken at day 1 (A), day 3 (B), and day 15 (C). Cells 
were stained with crystal violet at day 15 (D) black arrows point to a representation of migratory 
cells. Images were taken at a magnification of x4. Scale bars are shown on the image.       
          
Figure 7.4 Light microscopy images of bBM-MSC encapsulated FPA-fibrinogen gels formed 
using 1.33 mg.mL-1 FPA blue arrow. Images taken at day 1 (A), day 3 (B), and day 15 (C). Cells 
were stained with crystal violet at day 15 (D) black arrows point to a representation of migratory 
cells. Images were taken at a magnification of x4. Scale bars are shown on the image. 
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Figure 7.5 Light microscopy images of bBM-MSC encapsulated FPA-fibrinogen gels formed 
using 0.7 mg.mL-1 FPA, blue arrow taken at day 1 (A), day 3 (B), and day 15 (C). Cells were 
stained with crystal violet at day 15 (D) black arrows point to a representation of migratory cells. 
Images were taken at a magnification of x4. Scale bars are shown on the image. 
 
7.1.1 Encapsulation of osteoblastic cell MG63 
Osteoblastic MG63 cells were encapsulated in fibrin, and FPA-fibrinogen gels formed 
from 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-1 FPA and incubated in 
basic αMEM culture medium as described in section 4.2.5. In common with the bBM-
MSCs, the cells rapidly migrated from all the gels. By day 7 the gels had greatly 
diminished in size and the MG63 cells migrated outward on the surface of the culture 
wells, shown by the black arrows in image D, Figure 7.6 to Figure 7.10. In contrast, no 
apparent gel shrinkage/degradation was observed in the cell free gel controls. Figure 7.6 
to Figure 7.9 shows phase contrast microscopy images of the encapsulated MG63 and 
cell free controls. These figures clearly show the shrinkage of the encapsulated gels and 
the migration of the MG63 cells. Therefore, it was decided to investigate the mechanism 
of gel degradation that was occurring in the fibrin and FPA-fibrinogen gels encapsulated 
with MG63s and bBM-MSCs. The actual decrease in size of the cell encapsulated gels 
suggested a fibrinolysis mechanism 
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Figure 7.6 Light microscopy images of cell free (A and C) and MG63 encapsulated (C and D) 
fibrin gels, blue arrow, at day 1 (A and B) and day 7 (C and D) of encapsulation. Black arrows 
show MG63s adhering to the tissue culture plastic surrounding the gel. The images were taken at 
a magnification of x4. Scale bars are shown on the image 
           
Figure 7.7 Light microscopy images of cell free (A and C) and MG63 encapsulated (C and D) 
FPA-fibrinogen gels, blue arrows, formed using 2.66 mg.mL-1 FPA at day 1 (A and B) and day 7 
(C and D) of encapsulation. Black arrows show the cells adhering to the tissue culture plastic 
surrounding the gel. The images were taken at a magnification of x4. Scale bars are shown on the 
image. 
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Figure 7.8 Light microscopy images of cell free (A and C) and MG63 encapsulated (C and D) 
FPA-fibrinogen gels, blue arrows, formed using 2 mg.mL-1 FPA at day 1 (A and B) and day 7 
(C and D) of encapsulation. Cells escaping from the gel in image D, have been shown by the 
black arrow. The images were taken at a magnification of x4. Scale bars are shown on the 
image. 
        
Figure 7.9 Light microscopy images of cell free (A and C) and MG63 encapsulated (C and D) 
FPA-fibrinogen gels formed using 1.33 mg.mL-1 FPA, blue arrow, at day 1 (A and B) and day 7 
(C and D) of encapsulation. The black arrows show the MG63s that have escaped from the gel. 
The images were taken at a magnification of x4. Scale bars are shown on the image. 
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7.1.2 Investigation of the mechanism responsible for cell migration and gel 
degradation 
Investigations were carried out to determine the cause of FPA-fibrinogen and fibrin 
gel degradation and the migration of bBM-MSCs and MG63s from the FPA-fibrinogen 
and fibrin gels. In vivo, the fibrin structure of blood clots is broken down by fibrinolysis. 
The activation of plasminogen in the plasma is activated to a serine protease, plasmin 
which causes the breakdown of the fibrin clots. The in vitro incubations of the fibrin and 
FPA-fibrinogen gels was carried out in culture medium containing serum. The serum may 
have been a source of plasminogen which could have been activated by enzymes released 
by the MG63 cells and bBM-MSCs. Alternatively, the BM-MSCs and MG63 cells may 
have released ECM-degrading enzymes such as matrix metalloproteinases (MMP). 
Two mechanisms were therefore investigated: fibrinolysis and MMP activity. Plasmin 
was inhibited by incubated with gels with a serine protease inhibitor, aprotinin. MMP’s 
B A 
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Figure 7.10 Light microscopy images of cell free (A and C) and MG63 encapsulated (C and D) 
FPA-fibrinogen gels formed using 0.7 mg.mL-1 FPA, blue arrow, at day 1 (A and B) and day 7 
(C and D) of encapsulation. MG63s migrated out of the gel and this is shown by the black arrow. 
The images were taken at a magnification of x4. Scale bars are shown on the image. 
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were inhibited with Marimastat. Inhibition of plasmin and MMP’s were therefore used to 
determine the cause of the gel degradation.  
To determine if the activation of plasminogen was the cause of gel degradation FPA-
fibrinogen gels formed from the concentration of 2.66 mg.mL-1 FPA and fibrin gels were 
encapsulated with 300,000 bBM-MSCs per gel. As described in section 4.7, these gels 
were incubated for 3 days in basic culture medium. After 3 days of culture, the medium 
was removed and replaced with serum-free medium containing 50 µM plasminogen for 
24 hours. The inhibitors aprotinin and Marimastat were added to the culture medium to 
determine the mechanism of gel degradation.  
After the incubation, gels were examined by phase contrast microscopy. Preliminary 
data, Figure 7.11 and Figure 7.15, showed incubation of plasminogen with cell free fibrin 
and FPA-fibrinogen gels formed using 2.66 mg.mL-1 FPA, blue arrows, had no effect on 
the macroscopic structure. However, incubating the FPA-fibrinogen (Figure 7.16) and 
fibrin (Figure 7.12) encapsulated bBM-MSCs gels with plasminogen resulted in bBM-
MSC migration from the fibrinogen gels. This suggested that the bBM-MSCs produced 
an enzyme which either activated plasminogen to plasmin or directly degraded the 
fibrinogen-based gels. Gel degradation and bBM-MSC migration was investigated further 
by incubating the gels with aprotinin, a serine protease inhibitor, or Marimastat, a MMP 
inhibitor, in the serum-free culture conditions with plasminogen. 
Incubation with Marimastat did not inhibit the degradation of the fibrin gels and FPA-
fibrinogen gels 2.66 mg.mL-1 FPA as seen in Figure 7.13 and Figure 7.17, respectively. 
The addition of aprotinin inhibited gel degradation and reduced cell migration, shown 
from the crystal violet stain in fibrin and FPA-fibrinogen gels (2.66 mg.mL-1 FPA), shown 
by black arrows in Figure 7.14 and Figure 7.18, respectively. The inhibition of FPA-
fibrinogen and fibrin gel degradation by incubation with aprotinin was investigated 
further by analysing the medium for plasmin, urokinase plasminogen activator (uPA) and 
tissue plasminogen activator (tPA).  
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Figure 7.11 Phase contrast images of cell free fibrin gels, blue arrow, before (A and B) and after 
(C and D) incubation in serum free medium containing plasminogen for 24 hours. The fibrin gels 
did not degrade during the incubation period. Images were taken at a magnification of x4 (A and 
C) and x20 (B and D). Scale bars are shown on the image. 
 
B A 
D C 
 184 | P a g e  
 
C h a p t e r |  Results: Encapsulation of MSC’s and the osteoblastic cells MG63 
 
Figure 7.12 Phase contrast images of bBM-MSC encapsulated fibrin gels, blue arrows, before (A 
and B) and after (C and D) incubation in serum free medium containing plasminogen for 24 hours. 
C and D show that the fibrin gel degraded, and cell migration occurred, black arrows. Crystal 
violet stain on hydrogels after incubation with plasminogen (E and F) at a magnification of x4 (A, 
C and E) and x20 (B, D and F). Scale bars are shown on the image. 
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Figure 7.13 Light microscopy images of bBM-MSC encapsulated fibrin gels, blue arrows, before 
(A and B) and after (C and D) incubation in serum free medium containing plasminogen and 
Marimastat for 24 hours. C, D, E,F show that the fibrin gel degraded, and cell migration occurred, 
black arrows. Crystal violet stain on hydrogels after incubation with plasminogen containing 
Marimastat (E and F) at a magnification of x4 (A, C and E) and x20 (B, D and F). Scale bars are 
shown on the image. 
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Figure 7.14 Phase contrast images of bBM-MSC encapsulated fibrin gels, blue arrows, before (A 
and B) and after (C and D) incubation in serum free medium containing plasminogen and 30 µM 
aprotinin for 24 hoursCrystal violet stain on hydrogels after incubation with plasminogen 
containing 30 µM aprotinin (E and F) at a magnification of x4 (A, C and E) and x20 (B, D and 
F). . Little cell migration was observed, black arrows. Scale bars are shown on the image.  
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Figure 7.15 Phase contrast images of cell free FPA-fibrinogen 2.66 mg.mL-1 gels, blue arrows, 
before (A and B) and after (C and D) incubation in serum free medium containing plasminogen 
for 24 hours. Showing that the gels did not degrade. Images were taken at a magnification of x4 
(A and C) and x20 (B and D). Scale bars are shown on the image. 
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Figure 7.16 Phase contrast images of bBM-MSC encapsulated FPA-fibrinogen 2.66 mg.mL-1 gels, 
blue arrows, before (A and B) and after (C and D) incubation in serum free medium containing 
plasminogen for 24 hours. Crystal violet stain on hydrogels after incubation with plasminogen (E 
and F). Demonstrating that cell migration, black arrows, and gel degradation occurred. Images 
taken at a magnification of x4 (A, C and E) and x20 (B, D and F). Scale bars are shown on the 
image. 
 
B A 
D C 
F E 
 189 | P a g e  
 
C h a p t e r |  Results: Encapsulation of MSC’s and the osteoblastic cells MG63 
 
Figure 7.17 Phase contrast images of bBM-MSC encapsulated FPA-fibrinogen 2.66 mg.mL-1 gels, 
blue arrows, before (A and B) and after (C and D) incubation in serum free medium containing 
plasminogen and Marimastat for 24 hours. Crystal violet stain on hydrogels after incubation with 
plasminogen containing Marimastat (E and F) at a magnification of x4 (A, C and E) and x20 (B, 
D and F). Demonstrating that cell migration, black arrows, and gel degradation occurred 
(C,D,E,F). Scale bars are shown on the image. 
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Figure 7.18 Phase contrast images of bBM-MSC encapsulated FPA-fibrinogen 2.66 mg.mL-1 gels, 
blue arrows, before (A and B) and after (C and D) incubation in serum free medium containing 
plasminogen and 30 µM aprotinin for 24 hours. Crystal violet stain on hydrogels after incubation 
with plasminogen containing 30 µM aprotinin (E and F) at a magnification of x4 (A, C and E) 
and x20 (B, D and F). Demonstrating that the gel did not degrade but some cell migration 
occurred, back arrows (C, D, E, F). Scale bars are shown on the image. 
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7.1.3 Plasmin, uPA and tPA detection 
A serine protease inhibitor, aprotinin, inhibited FPA-fibrinogen and fibrin gel 
degradation and bBM-MSC migration from the gels. The gels were incubated with 
plasminogen for 24 hours in serum-free conditions. The medium was collected and 
analysed for plasmin, the presence of plasmin would suggest that bBM-MSCs are 
activating plasminogen to plasmin. The presence of plasmin would cause FPA-fibrinogen 
and fibrin gel degradation by fibrinolysis, as described previously. The medium collected 
from bBM-MSC encapsulated FPA-fibrinogen and fibrin gels incubated without 
inhibitors and with the inhibitors aprotinin and Marimastat were analysed. Figure 7.19 
shows the plasmin levels of culture medium with and without plasminogen incubation, 
cell free FPA-fibrinogen and fibrin gels, bBM-MSC encapsulated gels with and without 
Marimastat or aprotinin.  
Culture medium, incubated with and without plasminogen was analysed for plasmin 
within the samples and no plasmin was detected, see Figure 7.19 (A). This suggested that 
plasmin is not present in the culture medium used and therefore was not causing the 
fibrinogen gel degradation. The medium collected from cell free FPA-fibrinogen 
(2.66 mg.mL-1 FPA) and fibrin gels incubated with plasminogen, revealed no plasmin 
within the samples, Figure 7.19 (A). Significantly higher levels of plasmin was detected 
in the medium from samples collected from the incubation of bBM-MSC encapsulated 
FPA-fibrinogen and fibrin gels with and without the incubation with Marimastat, Figure 
7.19, (B). The bBM-MSC encapsulated FPA-fibrinogen and fibrin gels incubated with 
aprotinin resulted in no plasmin detection, Figure 7.19 (C). The data was significantly 
lower compared to bBM-MSC encapsulated FPA-fibrinogen gels (2.66 mg.mL-1 FPA) 
and fibrin gels incubated without inhibitors or with Marimastat.  
Due to the inhibition of gel degradation with aprotinin, there was evidence to suggest 
that the activation of plasminogen to plasmin was causing gel degradation. The 
mechanism for plasminogen activation was investigated by analysing uPA and tPA levels 
in the previously collected medium. uPA and tPA are serine proteases known to be 
secreted by some cell types and are activators of plasminogen to plasmin. tPA and uPA 
levels in the medium for FPA-fibrinogen (2.66 mg.mL-1 FPA) and fibrin encapsulated 
with bBM-MSCs and incubated without inhibitors and in the presence of aprotinin or 
Marimastat. All medium collected, from all conditions was barely detectable, therefore 
preliminary data suggested that uPA and tPA were not activating the plasminogen, results 
are shown in Figure 7.20 and Figure 7.21.  
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Figure 7.19 Plasmin activity in serum-free medium (DMEM) incubated with (A) cell free fibrin 
and FPA-fibrinogen 2.66 mg.mL-1 gels, and bBM-MSC encapsulated fibrin and FPA-fibrinogen 
2.66 mg.mL-1 gels incubated with and without (B) Marimastat and (C) aprotinin, for 24 hours 
containing plasminogen, and serum free culture medium with and without plasminogen. N=2 
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Table 7.1 One way ANOVA with Tukey post-test comparing the group means statistical analysis 
of the plasmin detection assay. Significance **** P>0.0001.  
Tukey's multiple comparisons test 95% CI of diff. Summary 
DMEM vs. Fibrin no inhibitors -0.6453 to -0.5414 **** 
DMEM vs. Fibrin + Marimastat -0.6556 to -0.5517 **** 
DMEM + plasminogen vs. Fibrin + Marimastat -0.6367 to -0.5328 **** 
DMEM + plasminogen vs. Fibrin + Marimastat -0.6470 to -0.5431 **** 
Fibrin cell free vs. Fibrin no inhibitors -0.6376 to -0.5337 **** 
Fibrin cell free vs. Fibrin + Marimastat -0.6478 to -0.5440 **** 
Fibrin no inhibitors vs. Fibrin + aprotinin 0.5491 to 0.6530 **** 
Fibrin Marimastat vs. Fibrin aprotinin 0.5594 to 0.6632 **** 
DMEM + plasminogen vs. FPA + aprotinin -0.6571 to -0.5533 **** 
DMEM + plasminogen vs. FPA + Marimastat -0.6893 to -0.5855 **** 
DMEM vs. FPA no inhibitors -0.6657 to -0.5619 **** 
DMEM vs. FPA + Marimastat -0.6979 to -0.5941 **** 
FPA cell free vs. FPA no inhibitors -0.6610 to -0.5572 **** 
FPA cell free vs. FPA + Marimastat -0.6932 to -0.5894 **** 
FPA no inhibitors vs. FPA + aprotinin 0.5631 to 0.6670 **** 
FPA + Marimastat . FPA + aprotinin 0.5953 to 0.6992 **** 
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Figure 7.20 uPA activity (shown as absorbance) measured from the medium taken from the 
incubation of (A) cell free 2.66 mg.mL-1 FPA-fibrinogen and fibrin gels in serum-free medium 
(DMEM) and culture medium containing plasminogen, and 2.66 mg.mL-1 FPA-fibrinogen and 
Fibrin gels encapsulated with bBM-MSCs in serum-free medium containing plasminogen with 
and without (B) Marimastat, and (C) aprotinin. N=1 
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Figure 7.21 tPA activity (shown as absorbance) measured from the medium taken from the 
incubation of (A) cell free 2.66 mg.mL-1 FPA-fibrinogen and fibrin gels in serum-free medium 
(DMEM) and culture medium containing plasminogen, and 2.66 mg.mL-1 FPA-fibrinogen and 
Fibrin gels encapsulated with bBM-MSCs in serum-free medium containing plasminogen with 
and without (B) Marimastat, and (C) aprotinin. N=1 
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7.1.4 Detection of plasmin, uPA and tPA in chondrocyte encapsulated gels 
It has been previously established (see section 6.2) that the chondrocytes remained in 
encapsulation of the FPA-fibrinogen and fibrin gels. Therefore, the activity of plasmin, 
uPA and tPA was investigated in chondrocyte encapsulated fibrinogen gels. This is 
because if plasmin was present with chondrocyte encapsulated gels, then the mechanism 
for gel degradation could not be due to plasmin. Therefore, cell free and chondrocyte 
encapsulated FPA-fibrinogen gels formed from 2.66 mg.mL-1 FPA and fibrin gels were 
incubated in serum free conditions with plasminogen for 24 hours. The medium was 
analysed for plasmin, uPA and tPA. Figure 7.23 and Figure 7.24 suggested that uPA and 
tPA was barely detectable in the medium incubated with fibrin and FPA-fibrinogen 
2.66 mg.mL-1 gels encapsulated with or without chondrocytes. Plasmin levels were also 
investigated in the medium incubated in serum-free conditions containing plasminogen 
for 24 hours. Figure 7.22 shows the plasmin levels contained in the control samples: 
serum-free medium and serum-free medium with plasminogen, very low plasmin was 
detected within these samples. Figure 7.22 shows that virtually no plasmin was detected 
in the chondrocyte encapsulated FPA-fibrinogen 2.66 mg.mL-1 and fibrin gels and 
therefore plasminogen is not being activated to plasmin, under the conditions used. This 
suggested that the mechanism of gel degradation is plasmin. 
 
 
Figure 7.22 Plasmin activity (shown as absorbance) measured from serum-free medium 
(DMEM), serum-free medium incubated with plasminogen, the medium taken from the 
incubation of chondrocyte encapsulated 2.66 mg.mL-1 FPA-fibrinogen and fibrin gels in serum-
free medium containing plasminogen. N=2 
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Figure 7.23 uPA levels (shown as absorbance) measured from the medium taken from the 
incubation of (A) cell free 2.66 mg.mL-1 FPA-fibrinogen and fibrin gels in serum-free medium 
(DMEM) and culture medium containing plasminogen, and chondrocyte encapsulated 2.66 
mg.mL-1 FPA-fibrinogen and fibrin gels in serum-free medium containing plasminogen with and 
without (B) Marimastat, and (C) aprotinin N=1 
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Figure 7.24 tPA activity (shown as absorbance) measured from the medium taken from the 
incubation of (A) cell free 2.66 mg.mL-1 FPA-fibrinogen and fibrin gels in serum-free medium 
(DMEM) and culture medium containing plasminogen, and chondrocyte encapsulated 2.66 
mg.mL-1 FPA-fibrinogen and fibrin gels in serum-free medium containing plasminogen with and 
without (B) Marimastat, and (C) aprotinin N=1 
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Key Summary 
• bBM-MSCs exhibited different behaviour in comparison to chondrocyte 
encapsulation in FPA-fibrinogen and fibrin gels.  
• bBM-MSCs and MG63s migrated from the FPA-fibrinogen and fibrin gels and 
rapid gel degradation occurred.  
• The mechanisms responsible were investigated and incubation with aprotinin 
reduced bBM-MSC migration and inhibited gel degradation. Inhibition of 
MMPs had no effect on cell migration or gel degradation.  
• Plasmin was detected in all conditions that resulted in gel degradation and not 
in the presence of aprotinin in which no gel degradation occurred.  
• Preliminary data suggested that the activation of plasminogen to plasmin is the 
cause for FPA – fibrinogen and fibrin gel degradation. 
 
7.2 MSC encapsulation with serum free medium 
Previous results suggested that incubation with a serine protease inhibitor, aprotinin, 
inhibited FPA-fibrinogen and fibrin gel degradation and reduced bBM-MSC migration 
from the gels, see section 7.3. This suggested that plasminogen activation to plasmin may 
be causing the degradation of the FPA and fibrin gels. Plasminogen is present in culture 
serum and is essential for cellular survival. Removing the source of plasminogen i.e. 
culture serum, was investigated to determine if the FPA-fibrinogen and fibrin gels would 
undergo degradation.  
The FPA-fibrinogen 2.66 mg.mL-1 and fibrin gels were encapsulated with 300,000 
bBM-MSCs and incubated with and without aprotinin in serum-free conditions for 21 
days. Cell free fibrin and FPA-fibrinogen 2.66 mg.mL-1 did not degrade over the 21 day 
culture period, Figure 7.25 and Figure 7.28. The fibrin and FPA 2.66 mg.mL-1 gels 
encapsulated with bBM-MSCs exhibited evidence for cell migration, illustrated by the 
black arrows, from the gels and FPA-fibrinogen and fibrin gel degradation over the 21 
day period, Figure 7.26 and Figure 7.29. However, FPA-fibrinogen 2.66 mg.mL-1 and 
fibrin gels encapsulated with bBM-MSCs and incubated with aprotinin maintained the 
gel structure throughout the 21 day culture period and less bBM-MSC migration was 
observed, Figure 7.27 and Figure 7.30.  
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Figure 7.25 Phase contrast images of cell free fibrin gels indicated by the blue arrows. Images 
were taken at day 1 (A and B) and day 21 (C and D) at a magnification of x4 (A and C) and x20 
(B and D). Scale bars are shown on the image.    
 
         
Figure 7.26 Phase contrast images of bBM-MSC encapsulated fibrin gels indicated by the blue 
arrows. Images were taken at day 1 (A and B) and day 21 (C and D) showing the migration of the 
cells from the gels, black arrows. Images were taken at a magnification of x4 (A and C) and x20 
(B and D). Scale bars are shown on the images. 
 
B A 
D C 
B A 
D C 
 201 | P a g e  
 
C h a p t e r |  Results: Encapsulation of MSC’s and the osteoblastic cells MG63 
                  
Figure 7.27 Phase contrast images of bBM-MSC encapsulated fibrin gels, blue arrows, incubated 
with aprotinin. Images were taken at day 1 (A and B) and day 21 (C and D) showing some cell 
migration from the gels, black arrow. Images were taken at a magnification of x4 (A and C) and 
x20 (B and D). Scale bars are shown on the image. 
 
              
Figure 7.28 Phase contrast images of cell free FPA-fibrinogen 2.66 mg.mL-1 gels, blue arrows. 
Images taken at day 1 (A and B) and day 21 (C and D) at a magnification of x4 (A and C) and 
x20 (B and D). Scale bars are shown on the image. 
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Figure 7.29 Phase contrast images of bBM-MSCs encapsulated in FPA-fibrinogen 2.66 mg.mL-1 
gels, blue arrows. Images were taken at day 1 (A and B) and day 21 (C and D) showing gel 
degradation and cell migration from the gels, blue arrows. Images were taken at a magnification 
of x4 (A and C) and x20 (B and D). Scale bars are shown on the image. 
 
                         
Figure 7.30 Phase contrast images of bBM-MSCs encapsulated in FPA-fibrinogen 2.66 mg.mL-1 
gels incubated with aprotinin, blue arrows. Images were taken at day 1 (A and B) and day 21 (C 
and D) showing little gel degradation and gel debris in C and D, yellow arrows. Images were 
taken at a magnification of x4 (A and C) and x20 (B and D). Scale bars are shown on the image. 
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Key Summary 
• It was previously established that the activation of plasminogen was causing 
the degradation of the FPA-fibrinogen and fibrin gels when encapsulated with 
bBM-MSCs. Plasmin was inhibited with aprotinin reducing bBM-MSC 
migration and FPA-fibrinogen and fibrin gel degradation.  
• Removing the source of the plasminogen from the culture medium resulted in 
FPA-fibrinogen and fibrin degradation over a 21 day culture period.  
• The gel degradation was slower in comparison to plasminogen present in the 
medium but still occurred.  
• This suggested that the bBM-MSCs are producing a serine proteinase that is 
directly causing the degradation of the fibrin and FPA gels. The serine 
proteinase was inhibited with aprotinin enabling control over the degradation 
rate. 
 
7.3 MSC encapsulation and culture with aprotinin  
As previously shown in section 7.1, aprotinin inhibited gel degradation and reduced 
bBM-MSC migration from the FPA-fibrinogen and fibrin gels. Therefore, bBM-MSCs 
were encapsulated in FPA-fibrinogen and fibrin gels for a 21 day culture period and 
incubated with aprotinin. Cell viability and ECM synthesis was able to be analysed. 
300,000 bBM-MSCs were encapsulated in FPA-fibrinogen gels formed from 
concentrations of 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-1 FPA, and 
fibrin gels, aprotinin was added to the medium to inhibit FPA-fibrinogen and fibrin gel 
degradation and minimise bBM-MSC migration from the gels.  
  
Cell viability results 
Figure 7.31 (B) shows the resazurin reduction from the culture medium removed from 
the FPA-fibrinogen and fibrin gels. Very little dye reduction was observed, however a 
slight peak in reduced dye was observed at day 3, and interestingly this is the time point 
at which the bBM-MSCs exhibited migration from the gels in the absence of aprotinin. 
Therefore, this may be very small numbers of cells migrating from the gel. This peak of 
dye reduction is very small in comparison to the rate of reduction observed from the cell 
encapsulated FPA-fibrinogen and fibrin gels. The cell free gels also showed very little 
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reduction is resazurin (Figure 7.31, (A)) suggesting that the gels or the addition of 
aprotinin interfered with the assay. Figure 7.32 displays the cell viability throughout the 
21 days of bBM-MSC encapsulation and showed that the bBM-MSCs were metabolically 
active and survived in encapsulation of FPA and fibrin gels throughout the 21 day culture 
period. Although the results are not significantly different, it is interesting to note that 
there is a trend suggesting that the FPA-fibrinogen gels appeared to support cell survival 
to a greater extent than fibrin.  
 
 
 
 
Figure 7.31 The effect of the rate of reduction from PrestoBlue® (shown as mean relative 
fluorescence units per minute) from cell free FPA-fibrinogen gels (A) and the culture medium 
(B) taken from the incubation bBM-MSC encapsulated FPA-fibrinogen and fibrin gels. The error 
bars represent the standard error of the mean. Statistical analysis with use of a one-way ANOVA 
with Tukey post test was conducted. N=3 
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Figure 7.32 Rate of reduction of PrestoBlue (shown as mean fluorescence per minute) of bBM-
MSC fibrin, and FPA-fibrinogen gels formed from 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, and 
0.7 mg.mL-1 FPA. The error bars represent the standard error of the mean. Statistical analysis with 
use of a one-way ANOVA with Tukey post test was conducted. N=3 
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Table 7.2 Statistical analysis of unpaired t-test with Welch’s correction comparing fibrin and 
FPA-fibrinogen gels formed from 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-1, 
with their cell free equivalents from the cell viability results taken at day 1, 7, 14, 20 after 
encapsulation of chondrocytes refer to Figure 7.31 and Figure 7.32. Significance: * P<0.1, ** 
P<0.01, *** P<0.001, **** P<0.0001 
  Days in encapsulation Significance 
FPA 2.66 mg.mL-1 
1 **** 
3 *** 
7 *** 
10 ** 
14 *** 
17 * 
20 *** 
FPA 2 mg.mL-1 
1 **** 
3 **** 
7 **** 
10 *** 
14 **** 
17 **** 
20 *** 
FPA 1.33 mg.mL-1 
1 **** 
3 **** 
7 **** 
10 ** 
14 **** 
17 *** 
20 *** 
FPA 0.7 mg.mL-1 
1 **** 
3 **** 
7 **** 
10 ** 
14 ** 
17 *** 
20 ** 
Fibrin 
1 *** 
3 *** 
7 **** 
10 * 
14 ** 
17 ** 
20 * 
 
 
  
 207 | P a g e  
 
C h a p t e r |  Results: Encapsulation of MSC’s and the osteoblastic cells MG63 
Live/Dead staining 
Live/dead staining and observing the surface of the gels with a confocal microscope 
showed live bBM-MSCs, green cells, at day 1 and day 21 of encapsulation for both fibrin 
Figure 7.33 and FPA-fibrinogen 2.66 mg.mL-1 Figure 7.34 gels. Less than 10 % of the 
bBM-MSCs encapsulated in fibrin and FPA-fibrinogen gels were dead, red on the images, 
at day 1 and day 21 of encapsulation, see Figure 7.35. This suggested that the majority of 
cells were viable at day 21 of encapsulation. From the images and quantification of cell 
number, Figure 7.36, it was observed that the bBM-MSC number increased from day 1 
to day 21, and therefore there is evidence to suggest cell proliferation. Cell free FPA and 
fibrin gels were stained and imaged. No staining was detected and therefore all staining 
observed was from live or dead cells on the gels. 
 
 
 
 
Figure 7.33 Live/Dead staining of bBM-MSC encapsulated fibrin gels at day 1 (A) and day 21 
(B) of encapsulation. Images were taken using a confocal microscope 
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Figure 7.34 Live/Dead staining of bBM-MSCs encapsulated in FPA-fibrinogen 2.66 mg.mL-1 
gels at day 1 (A) and day 21 (B) of encapsulation. Images were taken using a confocal microscope 
 
 
 
 
Figure 7.35 Percentage of live and dead bBM-MSCs at day 1 and 21 of encapsulation in (A) fibrin 
and (B) FPA-fibrinogen gels formed from 2.66 mg.mL-1 FPA. Cell number was quantified from 
live/dead stained images taken on the confocal microscope. N=1 
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Figure 7.36 The number of live bBM-MSCs at day 1 and day 21 of encapsulation in (A) fibrin 
and (B) FPA-fibrinogen gel formed from 2.66 mg.mL-1 FPA. Cell number was quantified from 
live/dead stained images taken on the confocal microscope. N=1 
         
 
Glycosaminoglycan content 
ECM deposition was investigated by measuring GAG content of the encapsulated 
bBM-MSC gels. All gels contained some GAG deposition suggesting that all gels 
supported chondrogenic differentiation of the encapsulated bBM-MSC, shown in Figure 
7.38. However, analysis of the cell free gels showed relatively high background readings 
for GAG, and especially for cell free fibrin gels. The data was not significantly different 
between bBM-MSC encapsulated FPA-fibrinogen gels 2.66 mg.mL-1, and fibrin and their 
cell free counterparts but FPA-fibrinogen gels 2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-
1 were significantly higher in comparison to their cell free counterparts, Table 7.3. These 
results were subtracted from the bBM-MSC encapsulated GAG content to ensure that the 
results were from ECM deposition alone.  
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Figure 7.37 The effect of DMB (shown as Total GAG (µg/gel)) on cell free FPA-fibrinogen and 
fibrin gels. Measurements were taken at day 21 of culture. The error bars represent the standard 
error of the mean. Statistical analysis with use of a one-way ANOVA with Tukey post test was 
conducted. N=3 
 
 
Figure 7.38 Total GAG content per from bBM-MSC encapsulated FPA-fibrinogen and fibrin gels 
incubated with aprotinin. Measurements were taken at day 21 of culture. The error bars represent 
the standard error of the mean. Statistical analysis using one-way ANOVA with Tukey post test 
was conducted. N=3 
 
Table 7.3 Showing the statistical analysis of an unpaired t-test with Welch’s correction comparing 
the GAG content of fibrin and FPA-fibrinogen gels formed from 2.66 mg.mL-1, 2 mg.mL-1, 1.33 
mg.mL-1, and 0.7 mg.mL-1 FPA, with their cell free equivalents. Significance: ** P<0.01, ns is no 
significant differences 
 Significance 
FPA 2.66 mg.mL ns 
FPA 2 mg.mL * 
FPA 1.33 mg.mL ** 
FPA 0.7 mg.mL ** 
Fibrin ns 
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Haematoxylin and Eosin staining 
H&E staining was carried sections taken from bBM-MSC encapsulated FPA-
fibrinogen and fibrin gels. H&E staining showed dispersed cells throughout the FPA and 
fibrin gels, however the bBM-MSCs appear to behave differently in comparison to 
chondrocytes in which the bBM-MSCs congregate in pores of the gels rather than 
individually as the chondrocytes appeared, and this can be seen clearly on Figure 7.41 
images J and H. The cell free FPA-fibrinogen and fibrin gels stained pink (Figure 7.40) 
and therefore ECM deposition cannot be observed. The bBM-MSC have a spherical 
morphology within the FPA and fibrin gels similar to that of native articular cartilage 
(Figure 7.39). Cell layers with ECM deposition can be seen at the edges of all fibrin and 
FPA gel conditions.  
 
 
 
 
Figure 7.39 H&E staining on native articular cartilage (A and B). Images taken at a magnification 
of x20 (A) and x40 (B). Scale bars shown on the image. 
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Figure 7.40 Histological H&E stained sections from cell free (A) fibrin, and FPA-fibrinogen gels 
formed from (B) 2.66 mg.ml-1 FPA, (C) 2 mg.ml-1 FPA, (D) 1.33 mg.ml-1 FPA and (E) 0.7 mg.ml-1 
FPA. Images were taken at a magnification of x20 and scale bars are displayed on the image. 
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Figure 7.41 Histological H&E stained sections from bBM-MSC encapsulated (A, B) fibrin and 
FPA-fibrinogen gels formed from (C, D) 2.66 mg.ml-1 FPA, (E, F) 2 mg.ml-1 FPA, (G, H) 1.33 
mg.ml-1 FPA and (I, J) 0.7 mg.ml-1 FPA. Images taken at a magnification of x20 (A, C, E, G, and 
I) and x40 (B, D, F, H and J). Scale bars shown on the image.  
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Toluidine blue staining 
Toluidine blue staining suggested proteoglycan deposition occurred in all gels due to 
the purple stained areas observed throughout the stained bBM-MSC encapsulated gel 
sections (Figure 7.43). A cell layer at the outer gel shows higher proteoglycan formation 
in comparison to the centre of the gels. This was observed in histological sections from 
all bBM-MSC encapsulated FPA and fibrin conditions. Cell free FPA-fibrinogen and 
fibrin gels (Figure 7.42) did stain a dark blue colour rather than the blue-purple that is 
indicative of proteoglycan deposition and therefore proteoglycan deposition was 
observed.  
 
 
 
Figure 7.42 Histological Toluidine blue stained sections from cell free (A) fibrin and FPA-
fibrinogen gels formed from (B) 2.66 mg.ml-1 FPA, (C) 2 mg.ml-1 FPA, (D) 1.33 mg.ml-1 and (E) 
0.7 mg.ml-1 FPA. Images were taken at a magnification of x20 and scale bars are shown on the 
image. 
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Figure 7.43 Histological Toluidine blue stained sections from bBM-MSCs encapsulated for 21 
days in (A, B) fibrin and FPA-fibrinogen gels formed from (C, D) 2.66 mg.mL-1 FPA, (E, F) 2 
mg.mL-1 FPA, (G, H) 1.33 mg.mL-1 and (I, J) 0.7 mg.mL-1 FPA. Images were taken at a 
magnification of x20 (A, C, E, G, and I) and x40 (B, D, F, H, and J). Scale bars are shown on the 
image. 
 
 
The histological stained images were analysed for pore diameter and the average 
number of pores per image. Pore diameter has been shown as a box plot illustrating the 
minimum, maximum and median pore diameters and the interquartile range. The analysis 
suggested that the bBM-MSC encapsulated gels had a very similar number of pores in 
comparison to their cell free counterpart other than FPA-fibrinogen gel formed from 2.66 
mg.mL-1 and fibrin (Figure 7.44, C and D).  FPA-fibrinogen formed from 2.66 mg.mL-1 
had a 4-fold increase and fibrin had a 5-fold increase in pore number with bBM-MSC 
encapsulated gels. From the analysis there was very little difference between cell 
encapsulated and cell free gels for pore diameter (Figure 7.44, A and B). Cell free fibrin 
had a much more closed structure with fewer pores in comparison to the FPA-fibrinogen 
gels.    
I J 
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Figure 7.44 Measurements of pore diameter (A, B) and number of pores (C, D) from analysed 
from the histological staining of cell free (A, C) and bBM-MSC encapsulated (B, D) fibrin and 
FPA-fibrinogen gels formed from 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-1 
FPA. Pore diameter (A, B) is shown as a box plot indicating the minimum, median and 
maximum pore diameter and the interquartile range.  
 
 
The H&E and Toluidine blue stained bBM-MSC encapsulated hydrogels have shown 
that the bBM-MSCs appear to congregate within pores. ECM formation can be observed 
in the centre and on the edges of the gels, suggesting that the bBM-MSCs remained viable 
and were differentiating and forming ECM within the gels. Analysis of the stained images 
showed that the FPA-fibrinogen gels had a porous structure in comparison to fibrin.  
 
Key Summary 
• In the presence of aprotinin, bBM-MSC migration and FPA-fibrinogen and 
fibrin gel degradation was reduced.  
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• bBM-MSCs survived, proliferated, and differentiated in the FPA-fibrinogen 
and fibrin gels. 
• All FPA-fibrinogen gels were comparable to fibrin for cell activity and total 
GAG content per gel. 
• Pore diameter and number of pores per image were similar for all FPA-
fibrinogen and fibrin gels suggesting the structures of the gels were 
comparable. 
 
7.4   MSC encapsulation in P15, P17 and HyStem 
The volumes of the P15, P17 and HyStem fibrinogen binding peptide materials were 
limited in supply from Haemostatix Ltd. and therefore multiple repeats of all experiments 
was not possible. However, the data shown provides interesting preliminary results on 
how these gels functioned for MSC encapsulation. bBM-MSCs were encapsulated in 
fibrinogen gels formed from P15 0.75 mg.mL-1, P15 0.5 mg.mL-1, and P15 0.25 mg.mL-1, 
P17 0.75 mg.mL-1, P17 0.5 mg.mL-1, and P17 0.25 mg.mL-1, and HyStem 1 mg.mL-1, and 
HyStem 0.75 mg.mL-1, fibrin was used as a reference material. These concentrations were 
chosen based on previous gelation experiments with cell free gels. bBM-MSCs were 
encapsulated in the P15, P17, and HyStem – fibrinogen and fibrin gels at 300,000 cell per 
gel. All cell encapsulated gels were cultured for 9 days. Light microscopy images show 
that cell free P15, P17, HyStem and fibrin gels maintained their structure and exhibited 
no degradation, (images A and B, Figure 7.45 to Figure 7.53). However, bBM-MSC 
migration and gel degradation was observed in P15 0.5 mg.mL-1 (Figure 7.47), P15 0.25 
mg.mL-1 (Figure 7.48), P17 0.5 mg.mL-1 (Figure 7.50), P17 0.25 mg.mL-1 (Figure 7.51), 
HyStem 1 mg.mL-1 (Figure 7.52), and HyStem 0.75 mg.mL-1 (Figure 7.53) encapsulated 
with 300,000 bBM-MSCs. Less degradation was observed in the fibrinogen gels formed 
with higher concentrations of P15 0.75 mg.mL-1 (Figure 7.46), and P17 0.75 mg.mL-1 
(Figure 7.49). It was observed that fibrin showed the initial stages of gel degradation by 
day 9 of encapsulation, (Figure 7.45). Crystal violet staining showed cell migration from 
the gels was observed and the staining carried out at day 9 of encapsulation. It can be 
observed that bBM-MSC migration occurred in all P15, P17, HyStem and fibrin gels 
conditions, but visually, less cells appear to have migrated from the 0.75 mg.mL-1 
concentrations of P15 (image F, Figure 7.46) and P17 (image F, Figure 7.49). 
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Figure 7.45 Phase contrast images of cell free (A, B) and bBM-MSC encapsulated (C, D, 
E,  F) fibrin gels, blue arrows, images were taken at day 1 (A, C, D) and day 9 (B, E, F) 
and at a magnification of x4 (A, B, C, E and F) and x20 (D). Cells, black arrows, were 
stained with crystal violet at day 9 of encapsulation (F). Scale bars are shown on the 
image. 
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Figure 7.46 Phase contrast images of cell free (A, B) and bBM-MSC encapsulated (C, D, E,  F)  
P15-fibrinogen 0.75 mg.mL-1 gels, blue arrows, images were taken at day 1 (A, C, D) and day 9 
(B, E, F) at a magnification of x4 (A, B, C, E, F) and x20 (D). Cells, black arrows, were stained 
with crystal violet at day 9 of encapsulation (F). Scale bars are shown on the image. 
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Figure 7.47 Phase contrast images of cell free (A, B) and bBM-MSC encapsulated (C, D, E,  F)  
P15-fibrinogen 0.5 mg.mL-1 gels, blue arrows. Images were taken at day 1 (A, C, D) and day 9 
(B, E, F) at a magnification of x4 (A, B, C, E, F) and x20 (D). Cells, black arrows, were stained 
with crystal violet at day 9 of encapsulation (F). Scale bars are shown on the image. 
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Figure 7.48 Light microscopy images of cell free (A, B) and bBM-MSC encapsulated (C, D, E,  
F)  P15-fibrinogen 0.25 mg.mL-1 gels, blue arrows. Images were taken at day 1 (A, C, D) and day 
9 (B, E, F) at a magnification of x4 (A, B, C, E, F) and x20 (D). Cells, black arrows, were stained 
with crystal violet at day 9 of encapsulation (F). Scale bars are shown on the image. 
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Figure 7.49 Phase contrast images of cell free (A, B) and bBM-MSC encapsulated (C, D, E,  F) 
P17-fibrinogen 0.75 mg.mL-1 gels. Images were taken at day 1 (A, C, D) and day 9 (B, E, F) at a 
magnification of x4 (A, B, C, E, F) and x20 (D). Cells were stained with crystal violet at day 9 of 
encapsulation (F). Scale bars are shown on the image.  
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Figure 7.50 Phase contrast images of cell free (A, B) and bBM-MSC encapsulated (C, D, E,  F)  
P17-fibrinogen 0.5 mg.mL-1 gels, blue arrows, images were taken at day 1 (A, C, D) and day 9 
(B, E, F) at a magnification of x4 (A, B, C, E, F) and x20 (D). Cells, black arrows, were stained 
with crystal violet at day 9 of encapsulation (F). Scale bars are shown on the image. 
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Figure 7.51 Phase contrast images of cell free (A, B) and bBM-MSC encapsulated (C, D, E, F) 
P17-fibrinogen 0.25 mg.mL-1 gels, blue arrows. Images were taken at day 1 (A, C, D) and day 9 
(B, E, F) at a magnification of x4 (A, B, C, E, F) and x20 (D). Cells, black arrows, were stained 
with crystal violet at day 9 of encapsulation (F). Scale bars are shown on the image. 
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Figure 7.52 Phase contrast images of cell free (A, B) and bBM-MSC encapsulated (C, D, E, F)  
HyStem-fibrinogen 1 mg.mL-1 gels, blue arrows. Images were taken at day 1 (A, C, D) and day 9 
(B, E, F) at a magnification of x4 (A, B, C, E, F) and x20 (D). Cells, black arrows, were stained 
with crystal violet at day 9 of encapsulation (F). Scale bars are shown on the image. 
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Figure 7.53 Phase contrast images of cell free (A, B) and bBM-MSC encapsulated (C, D, E, F) 
HyStem-fibrinogen 0.75 mg.mL-1 gels, blue arrows. Images were taken at day 1 (A, C, D) and 
day 9 (B, E, F) at a magnification of x4 (A, B, C, E, F) and x20 (D). Cells, black arrows, were 
stained with crystal violet at day 9 of encapsulation (F). Scale bars are shown on the image. 
 
 
Key Summary 
• bBM-MSC migration and gel degradation occurred in P15, P17, and HyStem 
– fibrinogen gels. 
• P15 and P17 – fibrinogen gels formed from 0.75 mg.mL-1 P15 or P17, had a 
slower degradation rate and less cell migration in comparison to the lower 
concentrations of P15 and P17.   
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7.5 P15, P17 and HyStem gels incubated with aprotinin 
Due to the degradation of the P15, P17 and HyStem gels observed in the MSC-
encapsulated gels, aprotinin was added to the culture medium to inhibit gel degradation 
during the incubation period after the first 3 days of cell encapsulation. Previously, 
aprotinin inhibited FPA-fibrinogen and fibrin degradation when encapsulated with bBM-
MSCs. Therefore, it was probable that the addition of aprotinin would also inhibit gel 
degradation and cell migration from MSC encapsulated P15, P17 and HyStem – 
fibrinogen gels. 300,000 bBM-MSCs were encapsulated in P15 0.75 mg.mL-1, P15 0.5 
mg.mL-1, P15 0.25 mg.mL-1, P17 0.75 mg.mL-1, P17 0.5 mg.mL-1, P17 0.25 mg.mL-1, 
HyStem 1 mg.mL-1, HyStem 0.75 mg.mL-1, and fibrin gels. Due to experimental overlap 
and being unaware about the degradation of the P15, P17 and HyStem gels. Aprotinin 
was added on day 3 of encapsulation. The gels were then incubated in chondrogenic 
media with aprotinin for 21 days and ECM deposition analysis was conducted at day 24.  
 
Cell activity 
Resazrin reduction was measured from the medium incubated with the P15, P17, 
HyStem and fibrin gels throughout the culture period and very little reduction was 
observed in cell free P15, P17, HyStem and fibrin gel conditions (Figure 7.54 to Figure 
7.56, A). However, a small peak of resazurin reduction was observed in culture medium 
that had been incubated with MSC encapsulated fibrin gels may reflect the beginning of 
some MSC migration from the gels, as aprotinin was only added at day 3. The cell free 
gels showed very little resazurin dye reduction (Figure 7.54 to Figure 7.56, B). This data 
suggested the gels are not interfering with the assay and therefore this data was subtracted 
from the cell encapsulated gels (Figure 7.57 to Figure 7.59). Preliminary data of bBM-
MSC encapsulated gels showed that the cells survived in all gels throughout the 24 day 
culture period (Figure 7.57 to Figure 7.59). A peak of cell activity is observed at day 14 
of culture, when the metabolic rate of the cells reduces in activity. This is consistent with 
each hydrogel condition, P15, P17, HyStem and including fibrin.  
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Figure 7.54 The effect of the rate of reduction of resazurin from cell free (A) fibrin and 
P15-fibrinogen gels and the culture medium (B) incubated with bBM-MSC 
encapsulated fibrin, and P15-fibrinogen gels. N=1. 
 
Figure 7.55 The effect of the rate of reduction of resazurin from cell free (A) fibrin and 
P17-fibrinogen gels and the culture medium (B) incubated with bBM-MSC 
encapsulated fibrin, and P17-fibrinogen gels. N=1. 
  
Figure 7.56 The effect of the rate of reduction of resazurin from cell free (A) fibrin and HyStem-
fibrinogen gels and the culture medium (B) incubated with bBM-MSC encapsulated fibrin, and 
HyStem-fibrinogen gels. N=1. 
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Figure 7.57 Rate of reduction of resazruin of bBM-MSCs encapsulated in fibrin, P15-fibrinogen 
gels. Measurements were taken at day 1, 3, 8, 14, 19, and 24 of encapsulation. N=1. 
 
 
Figure 7.58 Rate of reduction of resazruin of bBM-MSCs encapsulated in fibrin, P17-fibrinogen 
gels. Measurements were taken at day 1, 3, 8, 14, 19, and 24 of encapsulation. N=1. 
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Figure 7.59 Rate of reduction of resazruin of bBM-MSCs encapsulated in fibrin, HyStem-
fibrinogen gels. Measurements were taken at day 1, 3, 8, 14, 19, and 24 of encapsulation. N=1. 
 
Glycosaminoglycan content 
The effect of the cell free P15, P17, HyStem – fibrinogen and fibrin gels on DMB 
assay which was used to measure the total GAG content of the cell encapsulated gels was 
assessed. It was observed that the cell free fibrin gels gave a high reading which suggested 
that the fibrin gel had non-specifically affected the assay during this experiment, however 
all values were subtracted from the cell encapsulated data to ensure that the data shown 
is only from the extracellular matrix deposition from the cells, (Figure 7.60). Total GAG 
content per gel suggested high levels of ECM deposition in all P15, P17, HyStem and 
fibrin gel conditions. However the cell encapsulated fibrin gels showed a spread of values 
for the GAG content which is reflected in the size of the standard error of the mean bars, 
(Figure 7.61 to Figure 7.63). It was observed that the P15, P17, HyStem – fibrinogen and 
fibrin gels did undergo some gel degradation and bBM-MSC migration was observed in 
the culture conditions used particularly with fibrinogen gels formed from HyStem 
1 mg.mL-1 and HyStem 0.75 mg.mL-1. To inhibit gel degradation the gels were then 
incubated in serum-free conditions with aprotinin. 
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Figure 7.60 The effect of cell free fibrin, P15 (A), P17 (B), and HyStem (C) – fibrinogen gels on 
DMB assay. Measurements were taken at day 25 of encapsulation. N=1. 
 
 
 
Figure 7.61 Total GAG content (µg per gel) of bBM-MSC encapsulated in fibrin, P15-fibrinogen 
gels. Measurements were taken at day 25 of encapsulation. N=1. 
 
A 
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Figure 7.62 Total GAG content (µg per gel) of bBM-MSC encapsulated in fibrin, P17-fibrinogen 
gels. Measurements were taken at day 25 of encapsulation. N=1. 
 
 
Figure 7.63 Total GAG content (µg per gel) of bBM-MSC encapsulated in fibrin, HyStem –
fibrinogen gels. Measurements were taken at day 25 of encapsulation. N=1. 
 
Key Summary 
• In the presence of aprotinin, bBM-MSC encapsulated P15, P17 and HyStem – 
fibrinogen gels exhibited good cell survival and differentiation within the gels. 
• HyStem – fibrinogen gels degraded throughout the 21 day culture period.  
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7.6 P15, P17 and HyStem incubation with serum-free medium and aprotinin 
Previously, it had been observed that HyStem degradation occurred in the presence of 
serum-containing differentiation medium (section 4.4.1) and aprotinin. From previous 
experiments conducted with bBM-MSC encapsulation in FPA-fibrinogen and fibrin gels, 
serum-free conditions prolonged the time period before degradation of the gels and MSC 
migration was observed. Therefore, 300,000 bBM-MSCs were encapsulated in fibrinogen 
gels formed from P15 at concentrations of 0.75 mg.mL-1, 0.5 mg.mL-1, and 0.25 mg.mL-1, 
P17 at concentrations of 0.75 mg.mL-1, 0.5 mg.mL-1, and 0.25 mg.mL-1, and HyStem at 
concentrations of 1 mg.mL-1 and 0.75 mg.mL-1, and fibrin gels. These gels were incubated 
in serum-free differentiation media (section 4.4.1) with aprotinin for 21 days. However, 
even under these serum-free conditions it was observed that MSC encapsulated HyStem-
fibrinogen gels formed using 1 mg.mL-1 and 0.75 mg.mL-1 HyStem had degraded during 
the 21 day culture period and cell migration had occurred onto the tissue culture plastic 
surface. In addition, cell migration was observed in all the other hydrogels but no apparent 
gel degradation (i.e. no decreases in cell volumes) was observed. These results are 
interesting, since, they show that the MSC migration from the fibrinogen gels formed 
with FPA, P15 or P17 could not have been due to chemical degradation as the cell-free 
gels remained intact and also the migration must have been independent of any influence 
of plasmin or other aprotinin-insensitive proteinase as there was no source of plasminogen 
in the serum-free culture medium and it contained the serine proteinase inhibitor, 
aprotinin. 
 
Cell activity  
Resazurin reduction by culture medium taken from the incubation of the cell 
encapsulated gels suggested very little cell activity, indicative of cells or cellular debris, 
within the medium, (Figure 7.64 image B to Figure 7.66 image B). Cell free gels exhibited 
little resarufin formation (the reduced form of resazurin) (Figure 7.64 image A to Figure 
7.66 image A). Preliminary data for bBM-MSC encapsulated gels suggests that all cells 
survived in all P15, P17, HyStem and fibrin hydrogel conditions for the 21 day period of 
encapsulation (Figure 7.67 to Figure 7.69). The reduction in resazurin plateaued at day 7 
of encapsulation which suggested that the cells became less metabolically active. It is 
possible that this lower level of cell activity is reflective of chondrogenic differentiation 
and that the cells were synthesising ECM.  
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Figure 7.64 The effect of the rate of reduction of resazruin from cell free fibrin and P15-fibrinogen 
gels (A) and the culture medium incubated with bBM-MSC encapsulated fibrin and P15-
fibrinogen gels (B).  N=1. 
 
Figure 7.65 The effect of the rate of reduction of resazruin from cell free fibrin and P17-fibrinogen 
gels (A) and the culture medium incubated with bBM-MSC encapsulated fibrin and P17-
fibrinogen gels (B).  N=1.  
 
Figure 7.66 The effect of the rate of reduction of resazruin from cell free fibrin and HyStem-
fibrinogen gels (A) and the culture medium incubated with bBM-MSC encapsulated fibrin and 
HyStem-fibrinogen gels (B).  N=1. 
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Figure 7.67 Rate of reduction of resazruin of bBM-MSCs encapsulated in P15-fibrinogen and 
fibrin gels. Measurements were taken at day 1, 3, 7, 14, 17, and 20 of encapsulation.  N=1. 
 
 
 
Figure 7.68 Rate of reduction of resazruin of bBM-MSCs encapsulated fibrin and P17-fibringoen 
gels. Measurements were taken at day 1, 3, 7, 14, 17, and 20 of encapsulation.  N=1. 
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Figure 7.69 Rate of reduction of resazruin of bBM-MSC encapsulated fibrin and HyStem-
fibrinogen gels. Measurements were taken at day 1, 3, 7, 14, 17, and 20 of encapsulation.  N=1. 
 
 
Glycosaminoglycan content 
Total GAG content revealed high background values for P15 (image A Figure 7.70) 
and P17 (image B Figure 7.70) the cell free gels. The cell free values were subtracted 
from the cell encapsulated values to ensure a measure of ECM deposition. Total GAG 
content per gel suggests all P15, P17 and HyStem gels supported ECM synthesis (Figure 
7.71 to Figure 7.73).  
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Figure 7.70 Cell free gels incubated with DMB assay. P15-fibrinogen (A), P17-fibrinogen (B) 
and HySem-fibrinogen gels (C). Fibrin was used as a reference material (A, B, C).  Measurements 
were taken at day 21 of encapsulation.  N=1. 
 
 
Figure 7.71 Total GAG content per gel of bBM-MSC encapsulated fibrin, P15-fibrinogen 
gels. Measurements were taken at day 21 of encapsulation.  N=1. 
A 
B C 
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Figure 7.72 Total GAG content per gel of bBM-MSC encapsulated fibrin, P17-fibrinogen gels. 
Measurements were taken at day 21 of encapsulation.  N=1. 
 
 
Figure 7.73 Total GAG content per gel of bBM-MSC encapsulated fibrin, and HyStem-fibrinogen 
gels. Measurements were taken at day 21 of encapsulation.  N=1. 
 
 
Haematoxylin and Eosin staining  
H&E staining was carried out on cell free and bBM-MSC encapsulated hydrogels. 
From the cell free images (Figure 7.74) it is possible to observe that the P15, P17, and 
HyStem hydrogels stained pink and therefore ECM deposition cannot be fully observed 
(Figure 7.75 to Figure 7.77). From the H&E staining it is possible to see dense cellular 
and ECM deposition layers on the outer edges of the hydrogels, less ECM deposition can 
be observed in the centre of the gels.  
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Figure 7.74 Histological H&E staining of sections taken from cell free P15-fibrinogen gels 
formed from (A) P15 0.75 mg.mL-1, (B) P15 0.5 mg.mL-1, (C) P15 0.25 mg.mL-1, P17-fibrinogen 
gels formed from (D) P17 0.75 mg.mL-1, (E) P17 0.5 mg.mL-1, (F) P17 0.25 mg.mL-1, and 
HyStem-fibrinogen gels formed from (G) HyStem 1 mg.mL-1 and (H) HyStem 0.75 mg.mL-1. 
Images were taken with a magnification of x20. Scale bars are shown on the images. 
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Figure 7.75 Histological H&E stained sections taken from bBM-MSC encapsulated in P15-
fibrinogen gels formed from (A, B) P15 0.75 mg.mL-1, (C, D) P15 0.5 mg.mL-1, (E, F) P15 0.25 
mg.mL-1, for 21 days. Images were taken at a magnification of x20 (A, C, E) and x40 (B, D, F). 
Scale bars are shown on the images. 
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Figure 7.76 Histological H&E stained sections taken from bBM-MSC encapsulated in P17-
fibrinogen gels formed from (A, B) P17 0.75 mg.mL-1, (C, D) P17 0.5 mg.mL-1, (E, F) P17 0.25 
mg.mL-1, for 21 days. Images were taken at a magnification of x20 (A, C, E) and x40 (B, D, F). 
Scale bars are shown on the images. 
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Figure 7.77 Histological H&E stained sections taken from bBM-MSC encapsulated in HyStem-
fibrinogen gels formed from (A, B) HyStem 1 mg.mL-1, (C, D) HyStem 0.75 mg.mL-1, for 21 
days. Images were taken at a magnification of x20 (A, C) and x40 (B, D). Scale bars are shown 
on the images. 
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Toluidine blue staining 
Cell free gels (Figure 7.78) were stained with Toluidine blue giving the gel structure 
dark blue colour which made distinguishing the purple proteoglycan stain in the bBM-
MSC encapsulated gels more difficult. However, P17 gels (Figure 7.80) have more areas 
of dark purple staining that is suggesting proteoglycan formation in these gels in 
comparison to the P15 (Figure 7.79) and HyStem (Figure 7.81) gels bBM-MSC 
encapsulated gels. It is possible to see in HyStem 0.75 mg.mL-1 (images C and D, Figure 
7.81) more areas of bBM-MSC congregation within the pores of the gel, from the dark 
blue nucleic acid staining.  
 
Figure 7.78 Histological Toluidine blue staining of sections taken from cell free P15-fibrinogen 
gels formed from (A) P15 0.75 mg.mL-1, (B) P15 0.5 mg.mL-1, (C) P15 0.25 mg.mL-1, P17-
fibrinogen gels formed from (D) P17 0.75 mg.mL-1, (E) P17 0.5 mg.mL-1, (F) P17 0.25 mg.mL-1, 
and HyStem-fibrinogen gels formed from (G) HyStem 1 mg.mL-1 and (H) HyStem 0.75 mg.mL-1. 
Images were taken with a magnification of x20. Scale bars are shown on the images. 
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Figure 7.79 Histological Toluidine blue stained sections taken from bBM-MSC encapsulated in 
P15-fibrinogen gels formed from (A, B) P15 0.75 mg.mL-1, (C, D) P15 0.5 mg.mL-1, (E, F) P15 
0.25 mg.mL-1, for 21 days. Images were taken at a magnification of x20 (A, C, E) and x40 (B, D, 
F). Scale bars are shown on the images. 
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Figure 7.80 Histological Toluidine blue stained sections taken from bBM-MSC encapsulated in 
P17-fibrinogen gels formed from (A, B) P17 0.75 mg.mL-1, (C, D) P17 0.5 mg.mL-1, (E, F) P17 
0.25 mg.mL-1, for 21 days. Images were taken at a magnification of x20 (A, C, E) and x40 (B, D, 
F). Scale bars are shown on the images. 
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Figure 7.81 Histological Toluidine blue stained sections taken from bBM-MSC encapsulated in 
HyStem-fibrinogen gels formed from (A, B) HyStem 1 mg.mL-1, (C, D) HyStem 0.75 mg.mL-1, 
for 21 days. Images were taken at a magnification of x20 (A, C) and x40 (B, D). Scale bars are 
shown on the images. 
 
Key Summary 
• The cell activity, GAG content and histological staining suggested that bBM-
MSCs survived and differentiated when encapsulated in P15, P17 and HyStem 
– fibrinogen gels.  
• In the presence of aprotinin in serum-free conditions, HyStem – fibrinogen gels 
visibly degraded throughout the 21 day culture period.  
• bBM-MSC migration was observed in all P15, P17 and HyStem – fibrinogen 
gels. 
• Therefore, there is evidence to suggest that HyStem – fibrinogen gels at the 
concentrations investigated in this thesis, is not a suitable cell delivery system 
for cartilage repair.  
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7.7    MSC delivery to cartilage injury 
An injured articular cartilage model was developed as described in section 4.2.5,  
Figure 4.1, in which cell encapsulated gels could be held in the cartilage defect. bBM-
MSCs were encapsulated in fibrinogen -FPA 2.66 mg.mL-1 or fibrin gels at  300,000 cells 
per gel.  The MSC encapsulated gels were then transferred into the cartilage defect of the 
cartilage injury model (1 gel per defect) and the whole cartilage model co-cultured with 
the MSC encapsulated gels under chondrogenic conditions for 2 weeks. 
   
Cell activity 
Cell viability determinations using the PrestoBlue® showed that the cartilage-bBM-
MSC encapsulated gel systems remained viable over the 14 day incubation period. These 
results are shown in Figure 7.83. The culture medium removed from the cartilage – gel 
model showed very little resazurin dye reduction indicating that the culture medium 
contained little cells or cell debris from the cartilage – bBM-MSC encapsulated model, 
Figure 7.82.  
 
 
Figure 7.82 Rate of reduction of PrestoBlue® (shown as mean relative fluorescence units per 
minute) from the medium removed at day 1, 3, 7 and 10 from bBM-MSC encapsulated FPA-
fibrinogen 2.66 mg.mL-1and fibrin gels delivered to a cartilage injury model. N=1. 
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Figure 7.83 Rate of reduction of PrestoBlue® (shown as mean relative fluorescence units per 
minute) indicating the cell activity of bBM-MSC encapsulated FPA-fibrinogen 2.66 mg.mL-1and 
fibrin gels delivered to a cartilage injury model. N=1. 
 
Phase contrast images 
Phase contrast images taken at day 4 of culture of the bBM-MSC encapsulated gels 
delivered to an injured cartilage model showed bBM-MSCs had migrated from FPA-
fibrinogen 2.66 mg.mL-1 gels to the injured cartilage, refer to Figure 7.84 images A and 
B. In contrast, few bBM-MSCs appeared to migrate towards the injury site at day 4 of 
encapsulation in fibrin gels, refer to Figure 7.84 images C and D. However, bBM-MSC 
migration from the fibrin gels towards the cartilage injury occurred between day 4 and 
day 10 and were observed as confluent between the gel and the cartilage injury.  
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Figure 7.84 Phase contrast images of bBM MSC encapsulated in FPA-fibrinogen 2.66 mg.mL-1 
(A and B) and fibrin (C and D) gels, blue arrows, delivered to injured articular cartilage pieces, 
purple arrows. Migration of bBM-MSCs are represented by black arrows. Images taken at day 4 
of encapsulation at a magnification of x4 (A and C) and x20 (B and D). Scale bars are shown on 
the image. 
 
 
Key Summary 
• bBM-MSCs migrated from the FPA-fibrinogen and fibrin gels towards the 
injured cartilage. 
• Cartilage explant injury model can be used as an in vitro model for cartilage 
repair. 
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8.0 Discussion 
8.1  The formation and structure of gels 
The gelation method and rate of the novel fibrinogen cross-linked gels is particularly 
important for cell survival. Gels that require external factors such as heat or 
photopolymerisation are adding factors which could affect cellular survival and function, 
and also limits the use of these gels in a clinical setting. The method of gelation for the 
FBP carrier molecules with fibrinogen requires the two liquid precursors to combine, 
rapidly forming a gel. This is a very simple and effective gelation method overcoming 
limitations without the addition of further techniques for gelation. The novel cross-linked 
fibrinogen gels therefore, are advantageous in clinical settings in comparison to gels such 
as agarose. The gelation rates of the novel cross-linked fibrinogen gels and fibrin were 
analysed using KC4 coagulation analyser; P15, P17 and FPA had a quicker gelation time 
with fibrinogen in comparison to fibrin, section 5.1. In clinic, the novel cross-linked 
fibrinogen gels would be fabricated in situ and a specialised syringe would be required to 
ensure the FBP carrier molecules and fibrinogen do not have contact before the required 
gelation site. The advantage to this is that the cells would become entrapped in the gel 
quicker providing a safe encapsulation to keep cells localised at the injury site.  
The gels were fabricated using a NaCl buffer, the concentration of salt present during 
gelation can impact the structural properties of the gels. Davies et al found that increasing 
the salt concentration to 2.6 (w/v) % increased the mechanical properties of the gel and 
enhanced osteogenic differentiation [235]. This suggested that the gel had become much 
stiffer in comparison to the 0.9 (w/v) % of NaCl used during this project. Therefore, the 
use of higher salt concentrations may impinge chondrogenic differentiation because a 
softer environment is required. Also gelation in a non-physiological salt concentrations 
could also possibly have detrimental effects on some cell types. However, the novel cross-
linked fibrinogen gels could be tailored for use in osteogenic applications by increasing 
the NaCl concentration present during gelation.   
Cell survival and differentiation depends on the structural properties of the hydrogel 
in which it is encapsulated. Scanning electron microscopy (SEM) was chosen based on 
the success of dehydration methods and imaging of various hydrogels within the 
literature. Methods researched involved fixation of the gel in glutaraldehyde before the 
dehydration process with increased concentrations of ethanol, osmium tetroxide was used 
for fixing cell encapsulated gels and also provided a heavy metal stain for greater contrast 
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between cells and the material [194], [235], [236]. However, in this investigation it 
became evident that ethanol dehydration did not keep the integrity of the hydrogel 
structure intact. It can be seen from the SEM images in section 5.2 that clear defined 
fibres were not observed. Whereas, imaged gels after freeze drying enabled observations 
of a clear, defined structure of the gels and enabled the comparison of the FPA, P15, P17 
- fibrinogen and fibrin structure. However, due to the necessary dehydration step for all 
SEM, the surface structure observed may not fully represent that of the hydrated 
fibrinogen gels. The structures of the fibrin, FPA, P15 and P17 – fibrinogen gels have 
distinct differences as seen on the SEM images in section 5.2. Fibrin has clear, defined 
fibres whereas FPA-fibrinogen gels have a more foam-like structure with defined pores. 
Observations suggest P15 and P17 – fibrinogen gels had similar structures and display 
areas of both fibres and foam-like structures throughout the gels. Haemostatix Ltd. 
observed areas of fibres as well as areas of foam-like structures when carrying out SEM 
on the FPA – fibrinogen hydrogels, however areas of fibres were not found under the 
conditions used for this project.  
Areas of undefined fibres were observed within the FPA gels. Again, this may have 
been an artefact of the dehydration process. This is mostly observed on those samples 
dehydrated with ethanol and therefore could be a by-product of this dehydration method 
either an artefact or causing the structure to fuse together. This is more apparent in FPA 
gels at a concentration of 2 mg.mL-1. From previous dehydration techniques, it was found 
that freeze-drying preserved the structure of the gel to a greater extent than ethanol 
dehydration and therefore the fibrinogen gels formed from the peptides P15 and P17 were 
freeze-dried prior to imaging. Fibrinogen gels formed from P15 and P17 were imaged 
using a concentration of 0.75 mg.mL-1 of the FBP carriers because of the limited amounts 
of materials available. The peptide materials P15 and P17 (results shown in section 5.2) 
formed fibrinogen gels with a fibrous and foam-like structures within the hydrogels with 
both gels having very open and porous structure in comparison to the FPA-fibrinogen gel 
and fibrin gel structures. Also, the fibrinogen fibres appeared much bigger in the gels 
formed with P15 or P17 in comparison to the fibrin fibres in fibrin gels. It was observed 
that large areas of the fibrinogen gels formed from P15 or P17 did not have clear defined 
fibres and it was possible that the fibres fused together during the freeze-dried dehydration 
process.  
The porosity and cross-linking density of hydrogels may affect cellular survival and 
differentiation and therefore investigating a range of porosities will determine the 
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optimum structural properties for different cell types. The cross-linking density and 
porosity of the novel cross-linked fibrinogen gels can be modified by altering the 
concentration of FBP present during gelation. In theory, the higher the concentration of 
FBP present the more cross-linked the structure becomes. This is because more fibrinogen 
binding peptides are present to bind to the fibrinogen molecules creating a more compact 
and less porous structure. If less FBPs are present then less binding will occur creating a 
more open porous structure. However, from the SEM images it can be observed that 
fibrinogen gels formed from FPA at concentrations of 2.66 mg.mL-1, 2 mg.mL-1 and 
0.7 mg.mL-1 had larger pores giving a more open gel structure. In contrast fibrinogen gels 
formed using FPA at a concentration of 1.33 mg.mL-1 had smaller sized but a greater 
number of pores throughout the surface of the gel. This meant that the lowest 
concentration of binding peptides created a structure similar to that of the highest 
concentration of FPA-fibrinogen gels, providing the highest number of FBP. This 
phenomenon may have occurred because, as the number of FBPs was increased the 
number of binding peptides binding to the fibrinogen molecules plateaued. This 
information was provided by Haemostatix Ltd and can also be seen from the gelation 
times investigated using KC4 coagulation analyser, see section 5.1. It was found that the 
gelation rate of the FPA-fibrinogen gels plateaued giving evidence to suggest that there 
was a maximum number of binding peptides which could bind to the number of 
fibrinogen molecules present during gelation. The fibrinogen gels formed from FPA at a 
concentration of 0.7 mg.mL-1 created a more open porous structure due to two binding 
peptides available per fibrinogen molecule during gelation. Fibrinogen gels formed from 
FPA gels at a concentration of 1.33 mg.mL-1 had a more compact due to four binding 
peptides present per one molecule of fibrinogen during gelation. However, when the 
concentration of binding peptides of FPA gels is greater than 2 mg.mL-1 a more open 
porous structure is observed due to the plateau of binding from the FPA. Another potential 
reason for this observation could be due to the artefactual structure changes of the 
fibrinogen gel surfaces caused by the procedure of dehydration of the hydrogels. 
However, the impact of the dehydration procedure needed for SEM was reduced by 
fixation of the novel cross-linked fibrinogen gels prior to the dehydration methods.  
Due to the difficulties of measuring pore diameter with the SEM images, pore diameter 
was measured using the histological stained samples. The results showed that the gels had 
very similar pore diameters, but cell free gels had a much more open porous structure in 
comparison to cell encapsulated gels. Average pore diameter for cell free gels ranged 
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from 25 – 60 µm, whereas cell encapsulated gels ranged from 12 – 50 µm. A pore size of 
3 µm – 8 µm is reported to promote chondrogenic differentiation but a smaller pore size 
of 0.2 µm – 1.0 µm encourages chondrocytes to attain a fibroblast morphology [237]. 
These pore sizes are larger than the optimum range to encourage chondrogenic 
differentiation, however chondrogenic differentiation and ECM formation was observed 
in all FPA-fibrinogen and fibrin gels as discussed in greater detail in section 8.2. Highly 
cross-linked structures may not allow for sufficient room for the cells to synthesise 
extracellular matrix but larger pore sizes may result in cell migration from and through 
the gel. It is important to find the optimal conditions for each cell type to allow the cells 
to function to their full potential. The cross-linking density of the gels can have an effect 
on degradation rate. Gels with a higher cross-linking density tend to have a lower 
degradation rate in comparison to those gels with a lower cross-linking densities. This 
effect of cross-linking density has been shown with various different hydrogels [238].   
 
8.2 Chondrocyte encapsulation  
To determine cell survival within the hydrogels PrestoBlue® assays were carried out. 
PrestoBlue® is a resazurin based dye which can enter the mitochondria of healthy cells 
and is reduced to resorufin mainly by NADH and NADPH produced by enzymes of an 
active electron transport chain found in viable cells. The dye can also be reduced by 
reducing agent in the cell cytoplasm. The reduced dye, resorufin is fluorescent and can 
be measured spectrophotometrically. The higher the fluorescence the more active the cells 
and this is proportional to the number of viable cells in the gels [239]. However, 
artefactual values can also occur by dye reduction occurring by reducing agents in 
incubation medium or by dye binding to scaffold materials. Cell viability methods such 
as MTT assays and live/dead staining require each sample to be terminated at each time 
point. The advantage of using resazurin dye is that it is a vital dye and most cells do not 
have any toxic effects at concentrations of the gel needed to determine cell viability. 
Therefore, the viability of the same cells (in 2 or 3D culture) can be repeatedly assessed 
over extended time periods. This aspect is particularly advantageous when using 
expensive reagents and reagent in limited supply such as the TISEEL fibrinogen used for 
gelation and the FBP carriers. It has also been demonstrated that PrestoBlue® is more 
sensitive at detected live cells in comparison to MTT assays [240]. 
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As described in section 4.5, initial biocompatibility testing of the novel cross-linked 
fibrinogen gels was carried out by fabricating 100 µL gels with 50,000 chondrocytes 
encapsulated per gel using fibrinogen gels formed from FPA or PEG FBP carriers and 
fibrin gels. The gels were cast and cultured in an individual well in a 96-well culture plate. 
The gel formed a plug covering the entire bottom of the culture well, so that a maximum 
volume of 200 µL could be added on top of the gel. In this experimental style it was not 
possible to observe whether cells were adhering to the tissue culture plastic during the 
culture period. The cell viability results from the reduction of resazurin dye showed 
increasing levels of chondrocyte activity throughout the 21 day culture period for all novel 
cross-linked fibrinogen gels and fibrin gels. However, PEG 1 mg.mL-1 was significantly 
higher than fibrin throughout the 21 day culture period. Whereas gels formed from FPA 
2.66 mg.mL-1 was only significantly higher than fibrin at day 7 (P<0.0001) and day 14 
(P<0.01) of encapsulation. These results suggested that the fibrinogen-PEG 1 mg.mL-1 
supported the viability of chondrocytes to a greater degree than fibrin under the culture 
conditions used. Control experiments showed that the gels themselves did not interfere in 
the cell viability assay to cause artefactual results.  
The results showed that the FPA gels performed better than the PEG gels in terms of 
GAG accumulation in the gels. Interestingly, higher levels of GAG were found in the 
culture medium from the PEG-fibrinogen gels, which is suggestive that chondrocytes 
encapsulated in these gels were synthesising the GAG components but that they may not 
have been incorporated to the same degree as occurred in the FPA gels. The fibrin gels 
were comparable to the FPA-fibrinogen gels, in terms of GAG content per gel indicating 
that they both performed to the same degree in term of ECM accumulation of 
proteoglycans. This result suggested that the natural materials are able to support cell 
differentiation better than synthetic co-polymers. These results indicated that the gel 
structure and pore sizes of the fibrinogen-FPA and fibrinogen-PEG gels was appropriate 
since encapsulated chondrocytes had regained their chondrogenic phenotype within the 
fibrinogen based gels. Chondrocytes are well known to lose their chondrogenic phenotype 
during the monolayer culture needed to culture a sufficient number of cells for 
encapsulation. However, the type of collagen in the ECM formed in the chondrocyte 
encapsulated hydrogels needs to be investigated. Incorporation of collagen II into the 
ECM would confirm the chondrogenic phenotype of the encapsulated chondrocytes  
The structure of the fibrinogen gels formed with PEG and FPA would have differed, 
meaning that the porosity and pore sizes of the gels would likely to have been different. 
Differences in pore size could result in different cellular morphologies, as previously 
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discussed, smaller pore sizes tend to lead to a more fibroblast like morphology whereas 
larger pore size lead to cartilage formation and the formation of GAG’s. The differences 
in structure of PEG gels and FPA gels have not been analysed but this may be a possible 
reason as to why FPA gels were outperforming PEG in terms of chondrogenic 
differentiation.  
Interestingly, for chondrocytes encapsulated in fibrinogen gels formed from PEG 
analogues had higher cell viability results in comparison to FPA-fibrinogen gels. 
Dikovsky et al [204] created a PEGylated fibrinogen gel formed by ultraviolet light. 
Dikovsky et al reported that cell migration in his PEG: fibrinogen hydrogels was limited, 
and the higher the concentration of PEG the less the cells are able to migrate into the 
matrix of the gel. Not only this, but PEG may have a cytotoxic effect on cells. The 
cytotoxic effects reported by Dikovsky et al investigation contradict the viability data 
presented in this thesis. Also, other studies have shown PEG is cytocompatible and cell 
friendly, [203] and [141]. The main reason for the difference between Dikvosky and the 
results presented here is unclear and could lie within the differences in the very different 
structure of the PEG-fibrinogen gels. Analysis on the gel structure of PEG has not been 
investigated in this research. This was due to a commercial-based decision by 
Haemostatix Ltd. to cease all research on the PEG-fibrinogen binding peptide carrier. 
Therefore all further investigations were carried out continued with fibrinogen gels 
formed using FPA, P15, P17, HyStem fibrinogen binding peptide carriers with fibrin gels 
remaining as a reference material. 
The initial biocompatibility testing was promising however, it was observed that cell 
death occurred during/immediately after encapsulation in the novel cross-linked 
fibrinogen gels and fibrin gels approximately one in four times during experimental 
repeats. Therefore, one focus of this research was to optimise the gels for chondrocyte 
encapsulation and to understand what was causing the cell death. Two areas were 
investigated to create a more reliable and ‘cell friendly’ gel system. The first approach 
was to transfer the cell-encapsulated gels into larger culture wells to increase the volume 
of medium to promote nutrient availability and transfer. The second approach was to 
investigate the minimum concentration of calcium that was needed for gelation.   
The gels were originally cast and cultured in 96-well plates allowing only 200 µL of 
medium to be placed on the hydrogels. Cells require the exchange of nutrients and waste, 
nutrient depletion and waste accumulation can occur more rapidly with smaller volumes 
of culture medium (i.e. 200 µL) in relation to the cell number (50,000 cells per gel). The 
medium had to be changed daily and from day 14 onwards the medium ideally required 
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changing twice a day. This was not always a practical possibility and therefore nutrient 
depletion and waste build up could have affected chondrocyte survival and 
differentiation. Bioreactors were not used as a method for culture despite the added 
advantages of nutrient and waste exchange [241]. Due to the soft nature, the small volume 
of the fibrinogen gels and the difficulties with handling the gels, it was thought that the 
fibrinogen gels would not be able to withstand the forces in the bioreactor. Casting the 
gels in larger wells, for example a 24-well plate, resulted in a thin film of gel formation 
along the bottom of the well. As the two gel components fibrinogen and either FPA or 
thrombin (for fibrin gels) were combined the gelation was not fast enough to allow for a 
defined 3D gel pellet structure to form. The aim of the method development was to 
minimise handling of the gels to reduce the risk of infection and from exerting forces onto 
the gels that may affect cellular survival.  
The first approach was to form a layer of agarose in individual culture wells and cut a 
6 mm diameter wells in the agarose layer to form a mould in which to cast the fibrinogen 
and fibrin gels (as described in section 4.5.1). Ahearne et al also investigated the use of 
agarose moulds for fibrin casting, however he successfully removed the fibrin gel from 
the agarose well [242]. This agarose system was investigated because the cast gels would 
be exposed to larger volumes of culture medium (1 mL per well). The FPA-fibrinogen 
and fibrin gels were successfully cast in the centre of the agarose well, allowing a defined 
3D gel pellet to form. However, the cell viability of chondrocytes encapsulated in the 
fibrinogen gels, formed and cultured in this system, suggested that the cells were not 
surviving when encapsulated by this method. This result was unexpected as agarose gels 
have been used successfully for chondrocyte encapsulation by various laboratories [243] 
[244] and also shown in this thesis.  One possible reason for the failure to cast and culture 
chondrocyte encapsulated fibrinogen gels could be that 1 % agarose gels had an average 
pore size of 1 µm [245], this pore size may be too small to allow for sufficient nutrient 
transfer through the 1 % agarose gel surrounding the case gels thereby limiting nutrient 
and waste exchange on the sides and bottom areas of the gels. Removal of excess agarose 
gel after encapsulation of the chondrocytes in the FPA-fibrinogen and fibrin gels proved 
impractical as the gel could not be removed in one piece, leaving agarose gel pieces within 
the culture wells. When attempting to remove the agarose gel mould, it was noted that the 
FPA-fibrinogen gels were placed under stress and this may also contribute to reducing 
cell survival in the fibrinogen and fibrin gels. Therefore, this method of gel casting was 
abandoned and the use of PTFE well moulds was investigated to allow medium to 
surround all sides of the hydrogels to try to limit cell death. 
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As described in section 4.5.2, PTFE well moulds were formed from drilling 6 mm 
diameter holes into small, individual blocks of PTFE. PTFE was chosen due to its low 
friction coefficient to reduce stress placed on the gels during transfer and to encourage 
the gelation of the two liquid precursors. Cell free gels were tested for gelation in the 
PTFE wells and defined 3D gel pellets were formed within the well structures. Visually, 
the 3D pellet formed after gelation from this method and from casting the gels in 96-well 
culture plates were very similar. However, the removal of the gels from the PTFE moulds 
was difficult, the gels could not be transferred simply by turning the well upside down, 
as initially thought. Use of a sterile spatula was required to transfer the gels from the 
PTFE moulds into a well in a 24-well culture plate. However, after transfer 2 mL of 
medium was able to surround the gels in a well in a 24-well plate allowing for greater 
nutrient and waste exchange for the cells. This system was used successfully to cast fibrin 
and FPA-fibrinogen gels to investigate the effect of calcium concentration on cell 
survival, with successful results. However, it did become apparent that the PTFE well 
moulds were difficult to clean with increasing use because hydrogel residue built up in 
the bottom of the well. Cleaning techniques such as ultra-sonic water baths were used to 
remove the residue but this was unsuccessful. The PTFE moulds then became an infection 
risk and this method of casting was eventually abandoned. 
The most efficient method tried was to cast the fibrinogen gels in individual wells in a 
96-well culture plate and then transferring the gels to a well in a 24-well culture plate via 
a sterile spatula. These were then incubated with 2 mL of medium. This method, although 
labour-intensive, proved the most successful gelation method. The increased handling of 
the gels, increased the risk of physical damage to the gels and also increased the risk of 
bacterial and fungal contamination. These risks, however, outweighed the advantages of 
being able to incubate the cell encapsulated gels in a larger volume of medium.  Gelation 
formed a defined 3D gel pellet in the 96-well culture plate but had the added benefits of 
being transferred to a larger well providing a larger volume of medium to allow for 
sufficient nutrient transfer. Therefore, all further investigations formed gels by using this 
method.   
The calcium concentration used for the fibrinogen and fibrin gelation was investigated 
because it is known that a change in calcium ions can have an adverse effect on cells. A 
sudden exposure to calcium ions can trigger signalling pathways which lead to cell 
apoptosis [246]. Haemostatix Ltd. advised the use of 10 mM CaCl2 for gelation as this 
had been deemed necessary for gelation of FPA gels under the conditions used. The 
calcium concentration of culture medium such as DMEM is 1.82 mM and therefore 
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investigations into using lower calcium concentrations for gelation were carried out. A 
range of calcium concentrations between 0 and 20 mM were tested for cell free gelation 
of the FPA-fibrinogen and fibrin gelation see section 6.2.4. It was observed that calcium 
was essential for gelation as fibrinogen-FPA and fibrin gels did not form with 0 mM 
CaCl2 after 30 minutes of incubation at 37 ºC. However, 2 mM CaCl2 enabled gelation. 
Davies et al found that gelation of fibrin gels occurred without the presence of calcium 
using 40 mg.mL-1 fibrinogen however, the gels were too weak to be handled or analysed 
for cell encapsulation, [235]. The novel cross-linked fibrinogen gels fabricated with a 
range of calcium concentrations from 2 – 20 mM had very similar appearances and could 
all be handled and transferred with a sterile spatula to culture plates. Chondrocytes were 
encapsulated using 2 mM CaCl2 with successful results and compared with gels fabricated 
with the original 10 mM CaCl2. Cell viability results from chondrocytes encapsulated in 
fibrin and FPA-fibrinogen gels cast with 2 mM or 10 mM calcium did not have a 
detrimental effect on the gelation of the gels or chondrocyte survival within the novel 
cross-linked fibrinogen gels (see section 6.2.4). However, by using a calcium 
concentration closer to physiological levels would not expose the chondrocytes to 
supraphysiological calcium concentrations. It was concluded that lowering the calcium 
concentration to 2 mM would reduce the risk of apoptosis.  
Using the 2 mM calcium for gelation and casting gels as above, the effect of the 
numbers of chondrocytes that could be encapsulated in the 100 µL gels was also 
investigated to determine the optimum number of cells for encapsulation. Cell density of 
50.000 to 300, 000 cells per gel were investigated (see section 6.2.3). In all hydrogels cell 
densities of 300,000 chondrocytes per gel had significantly higher cell activity in 
comparison to 150,000 and 50,000 chondrocytes per gel. It was expected that the rate of 
cell activity would increase with higher cell numbers but the results showed that no 
significant cell death occurred with 300,000 chondrocytes encapsulated per gel over the 
21 day culture period. GAG production suggested that some ECM deposition had 
occurred within all chondrocyte encapsulated hydrogels at all cell densities of the 
encapsulated cells. The results suggested that 300,000 chondrocytes per gel was the 
optimum for the survival of chondrocytes over a 21 day period and ECM deposition and 
therefore was used for further investigations.  
The optimisation of the fabrication and chondrocyte encapsulation of the FPA-
fibrinogen gels reduced the variation in cell death and formed a more reliable, cell friendly 
system where chondrocyte death was minimised (refer to results in section 6.3). Using 
the ‘optimised’ parameter, fibrinogen gels formed from-FPA 2.66 mg.mL-1 were taken 
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forward for further investigation because from the previous results it was shown that this 
concentration of FPA supported chondrocyte survival and differentiation to a greater 
extent than the lower FPA concentrations. The FPA-fibrinogen gel formed from 
2.66 mg.mL-1 formed a larger gel that was easier to handle in comparison to the lower 
concentrations of FPA, this is another reason this concentration was taken forward. Also, 
the ‘optimised’ parameters 4% agarose gels were also encapsulated with 300,000 
chondrocytes per gel dispensed in 100 µL gels and used as a reference material for FPA 
and fibrin gels. Agarose gels were used as a comparator as is known that chondrocytes 
survive and differentiate in agarose gels [247].  
Chondrocytes were encapsulated in fibrin and fibrinogen-FPA (refer to results section 
6.3). The cells remained viable within in the fibrin and FPA-fibrinogen gels and produced 
GAG which indicated that the chondrocytes were synthesising proteoglycans indicative 
of some ECM formation. GAG formation was measured at day 21 of encapsulation and 
it was observed in all FPA-fibrinogen, fibrin and agarose gels (sections 6.3 and 6.4). Cell 
free gels exhibited high levels of GAG content suggesting interference with the assay. 
The total GAG content per gel had a high reading despite the background values from the 
cell free gels suggesting that the chondrocytes were producing GAG’s and therefore 
synthesising ECM. FPA-fibrinogen gels formed from FPA 2.66 mg.mL-1 and FPA 
1.33 mg.mL-1 were significantly higher than FPA 0.7 mg.mL-1, suggesting there is a 
higher degree of differentiation occurring in gels formed from these concentrations of 
FPA. The remaining concentrations of FPA-fibrinogen gels, fibrin and agarose had no 
significant differences between the data suggesting that all gels are supporting ECM 
deposition to a similar degree other than FPA 0.7 mg.mL-1. This could be due to FPA 
0.7 mg.mL-1 formed a smaller gel in comparison to the other concentrations. 
During expansion of chondrocytes to increase the cell number available for 
encapsulation, the cells are cultured in monolayer culture in which it is well known that 
the chondrocytes lose their phenotype. Dedifferentiated chondrocytes synthesise collagen 
I instead of collagen II and rapidly lose the ability to synthesise aggrecan, the major 
proteoglycan found in the ECM. The production of GAG by the encapsulated cells was 
also an indication that the chondrocytes had regained a chondrogenic phenotype. 
Confirmation of this would need the analysis of any extracellular collagen, the presence 
of collagen II would confirm full chondrocyte differentiation.  
Interestingly, a reproducible peak in cell activity was observed at day 10 of 
encapsulation. However, day 10 to day 21 a decrease in chondrocyte metabolic activity 
was usually observed in chondrocyte encapsulated FPA gels, fibrin gels and agarose gels, 
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(refer to section 6.4). This diminution in cell activity may possibly be related to the time 
at which the chondrocytes had regained their chondrogenic phenotype and began 
synthesis of ECM components rather than continued proliferation. This has been observed 
in osteoprogenitor cells; the first four days are required for cell proliferation, 
differentiation begins at day 5 with cell proliferation still occurring until the cells mature 
and ECM deposition occurs from day 15, it is at this point when the cells stop proliferating 
and carry out ECM synthesis [248]. Therefore, chondrocytes may have an increase in cell 
activity due to proliferation up to day 10 as the chondrocytes have fully matured, the 
metabolic activity was reduced from day 10 as ECM synthesis occurred. 
To determine whether cell death was responsible for the reduction in the cell activity 
at day 10, live/dead staining was carried out on fibrinogen gels formed using FPA at a 
concentration of 2.66 mg.mL-1 and fibrin gels at day 1 and day 21 of chondrocyte 
encapsulation. In this procedure, the cytoplasm of live cells is stained with a fluorescent 
green stain and the nuclei of dead cells fluoresce red due to uptake of propidium iodide. 
Cell free gels were also tested and found not to take up any dye. Confocal microscopy 
showed 98 % of cells were live and viable in the chondrocyte encapsulated fibrinogen- 
FPA and fibrin gels both day 1 and day 21 of encapsulation, (section 6.3.1, figures 6.28 
and 6.29). The gels at day 21 of encapsulation showed an increase of cell numbers in the 
areas of the gels nearest to the gel surface compared to day 1; suggesting that cell 
proliferation had occurred (see section 6.3.1, figures 6.30 and 6.31). Less than 2 % of 
cells were observed to be dead (i.e. red fluorescence). The gels were cut in half to observe 
staining in the central areas of the gels. However, no staining was observed in the inner 
areas of the gel suggesting that during encapsulation the chondrocytes were not dispersed 
in the central regions of the gel. However, H&E staining of the gels had shown that the 
cells are evenly dispersed throughout the gel. Therefore, it was probable that the live/dead 
stain did not penetrate the centre of the gel in the time period of exposure of the gels to 
the stain. A longer exposure time of the stain to the gel could solve this problem or 
exposing the centre of the gel to the stain. However, the live/dead stain had to be incubated 
on the cells before fixation and cutting the gels prior to staining would have created 
mechanical forces on the gels. This could potentially have had adverse effects on the 
chondrocytes and therefore an accurate representation of the live/dead staining would not 
be obtained from this method.  
ECM deposition was further analysed by histological staining with H&E and Toluidine 
blue (see section 6.3, Figures 6.36 and 6.38). Haematoxylin is positively charged and 
binds to negatively charged areas for example DNA, of the cell nucleus. Therefore, H&E 
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stain was used to investigate the cell distribution throughout the gel and ECM deposition. 
Cell free and cell encapsulated fibrin and FPA-fibrinogen gels stained. This is because 
fibrinogen is a glycoprotein and therefore could bind Eosin giving hydrogels a deep pink 
colour. It was possible to observe the stained nuclei of the chondrocytes in purple which 
show that the cells appeared to be evenly dispersed throughout the gels. A cell layer was 
observed on the outer gel edges of all concentrations of FPA-fibrinogen and fibrin gels 
with a pale purple staining surrounding the cells. This suggested that the cells were 
synthesising ECM on the edges of the gel and filling the pores of the gel with ECM. The 
chondrocytes in the centre of the FPA-fibrinogen and fibrin gels did not appear to have 
synthesised ECM and therefore may not have been receiving appropriate nutrient transfer. 
However some areas of ECM formation could be observed in more central regions of 
fibrinogen gels formed from FPA concentrations of 1.33 mg.mL-1 and 0.7 mg.mL-1.  
Agarose 4 % cell free gels did not stain and therefore any staining on the chondrocyte 
encapsulated gels is cell nuclei and ECM deposition. The chondrocytes did not look as 
evenly dispersed throughout the gel in comparison to FPA-fibrinogen and fibrin gels 
however, ECM deposition was observed in pale purple suggesting that the chondrocytes 
were differentiating in the agarose gels. Toluidine blue has a high affinity for acidic tissue 
and therefore stains nucleic acids dark blue and proteoglycans bind the dye causing a 
metachromic shift so that the dye appears purple. This stain was used to determine if 
proteoglycan formation had occurred within the fibrinogen gels providing further 
evidence for the GAG quantification data. The fibrin and fibrinogen gels was found to 
bind the toluidine blue giving a dark blue colour and therefore a high background staining. 
Areas of proteoglycan staining was observed in all chondrocyte encapsulated fibrinogen-
FPA gels, fibrin and agarose gels (refer sections 6.3 and 6.4), however this staining was 
much sparser in fibrin gels compared to FPA-fibrinogen gels.  FPA-fibrinogen gels at a 
concentration of 2.66 mg.mL-1 had areas of very dense purple showing proteoglycan 
formation incorporated within the gel. The chondrocytes appear to be surrounded by 
proteoglycans in this area. Fibrinogen gels formed from FPA at a concentration of 
0.7 mg.mL-1 appeared to have a more compact structure in comparison to the other FPA 
concentrations according to the dark blue staining which is inconsistent with SEM 
images. Agarose 4 % cell free gels stained slightly but chondrocyte encapsulated gels 
have stained purple on the edges of the gel but very dark blue in the centre of the gel, this 
suggested proteoglycan formation within the gels, section 6.4. It is interesting to note that 
from both the Toluidine blue and H&E staining that fibrin has much more closed structure 
in comparison to the porous fibrinogen-FPA structures. Less purple ECM staining was 
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visible in fibrin in comparison to the fibrinogen-FPA gels. This staining is consistent with 
the GAG quantitative analysis.  
Attempts were made to investigate the gene expression by quantitative real time 
polymerase chain reaction (qRT-PCR) over the 21 day incubation period for the collagen 
II and aggrecan which are major components of hyaline ECM. However, difficulties were 
found in extracting sufficient RNA from the hydrogels. TRIzol was used to extract RNA 
from the FPA-fibrinogen and fibrin gels with unsuccessful results. TRIzol was used due 
to being a popular RNA extraction method with fibrin gels having very successful results 
from extracted RNA from chondrocytes and MSCs with this method [249] [250] [251]. 
TRIzol is a phenol based extraction method and the RNA was contaminated with phenol 
during the extraction process this can be seen from the graphs of RNA extraction where 
the first peak represents phenol contamination in the sample, as described by Biomedical 
Genomics [252]. Contamination leads to a false RNA concentration result when analysing 
by NanoDrop. The phenol was removed by using a method by Krebs et al [253] to ensure 
minimised RNA losses from the samples. This method successfully reduced the phenol 
contamination yielding a purer RNA solution (section 6.3) but very low RNA yields of 
less than 3 ng.mL-1 of RNA were attained. qRT-PCR required RNA concentrations of 
more than 50 ng.mL-1. Therefore, three gel ‘pellets’ were combined for each RNA 
extraction and a non-phenol based Isolate II RNA mini kit was used. This RNA extraction 
kit used a filter centrifugation method to reduce the contaminants passing through from 
the hydrogel, the fibrinogen and FPA molecules should not be able to pass through the 
filter during centrifugation. Table 6.8 showed that with one gel per extraction 
11.9 ng.mL-1 of RNA was detected, however when three gels per extraction was carried 
out then 77.3 ng.mL-1 of RNA was detected giving a high enough value for qRT-PCR. 
The 260/280 OD aspect ratio is a measure of how pure the sample is, this value should be 
as close to two as possible. This value was improved dramatically by using the Isolate II 
RNA mini kit in comparison to the TRIzol reagent. However, with three gels per 
extraction this ratio was slightly lower suggesting that the gel fragments may be 
contaminating the sample. Several experimental repeats were carried out using fibrinogen 
gels formed with FPA 2.66 mg.mL-1 and fibrin gels with 300,000 chondrocytes 
encapsulated per gel. RNA was extracted at day 1, day 10 and day 21 of encapsulation. 
However, contamination of the extracted RNA was problematic and low yields of RNA 
were obtained. Unfortunately, due to limited amounts of the fibrinogen and fibrinogen 
binding peptides, available this area of research could not be carried on further. 
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Chondrocytes were encapsulated in fibrin gels and fibrinogen gels formed with FPA 
2.66 mg.mL-1, P15, P17 and HyStem gels. It was observed through light microscopy and 
Crystal violet staining, that some chondrocyte migration had occurred from the fibrinogen 
P15 and fibrinogen P17 during the incubation period as a ‘ring’ of chondrocytes had 
adhered to the tissue culture plastic surrounding the gels by the end of the 21 day culture 
period. The reasons for the migration are unknown, it could be due to breakdown of the 
gels, although macroscopically the gels had reduced in size. However, this could be due 
to chondrocytes being transferred on the outer surface of the gels on encapsulation and 
the chondrocytes then attached to the tissue culture plastic. Some adherence of 
chondrocytes was observed at day 1 of encapsulation giving some evidence for this 
hypothesis. The chondrocytes would then proliferate throughout the 21 day culture period 
on the tissue culture plastic. However, it is more probable that chondrocytes proliferating 
of the surface of the areas of the hydrogel in close proximity to the surface of the culture 
dish also became attached to the tissue culture plastic at these points.-. However, this 
experiment could not be repeated as the P15, P17 and HyStem materials were limited. 
Cell migration was not observed in previous experiments with chondrocyte encapsulated 
FPA gels and fibrin gels and it was not observed in future experiments. Park et al found 
that chondrocytes did cause degradation in fibrinogen gels and was inhibited by aprotinin 
[254]. The addition of hyaluronic acid into the scaffolds and in the presence of aprotinin 
inhibited gel degradation. However, this was not found in this study with HyStem gels 
and this could be due to the binding of the hyaluronic acid molecule to the fibrinogen 
molecule, further optimisation may be required.  
Following the cell viability of the encapsulated chondrocytes over the 21 day 
incubation period, the level of cell activity increased throughout the 21 day culture period, 
suggesting some cell proliferation. This was in contrast to chondrocytes encapsulated in 
fibrin and fibrinogen-FPA gels in which the level of cell activity peaked at day 10 which 
was observed in chondrocyte encapsulated FPA gels and fibrin gels previously. The 
apparent increase in cell activity could possibly have been due to chondrocytes which had 
migrated out of the gel adhering to the tissue culture plastic. The encapsulated 
chondrocytes were found to have synthesised GAGs during the incubation period. 
However, cells encapsulated in fibrin gels and fibrinogen-FPA gels (formed with 
2.66 mg.mL-1 FPA) had a higher mean GAG in comparison to the fibrinogen-P15 and 
fibrinogen-P17 gels at all concentrations and HyStem at a concentration of 1 mg.mL-1.  
Toluidine blue staining was not reflective of the GAG content determined by 
biochemical assay and no proteoglycan staining was detected. However, from all the 
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results obtained chondrocytes could be encapsulated in fibrinogen gels formed with P15 
and P17 and HyStem with good viability for a minimum period of 21 days. However, 
these must be considered preliminary results as there were very limited amounts of the 
fibrinogen binding peptises available for this research, hence all experiments need to be 
repeated to ensure the validity of the preliminary findings given in this thesis.   
Bovine articular cartilage pieces were removed from the metacarpophalangeal joint by 
using a 6 mm biopsy punch. These reproducible circular pieces of cartilage were injured 
by using a 3 mm biopsy punch to create a small circular defect in the centre of the 
cartilage, see Figure 4.1. These discs of cartilage were used as a novel cartilage injury 
model to deliver cells via the gels to determine if cartilage repair would occur in vitro. 
Injury models have been previously researched including the use of osteochondral plugs, 
in which a full thickness defect is created and attempted repair of the injury [255]. The 
disadvantage of using osteochondral plugs is the outgrowth of cells or release of factors 
into the medium which may have influenced the chondrocyte response to the injury [256]. 
To overcome this problem, agarose gel was used to surround the osteochondral plug. 
However, in this thesis cartilage only explants were used to create the injury model, to 
avoid the release of cells and factors from the bone explant. The cartilage – only explant 
injury model makes use of stiff tissue culture plastic to mimic the hardness of subchondral 
bone. Although this was preliminary data, chondrocyte encapsulated fibrinogen-FPA gels 
(FPA used at 2.66 mg.mL-1) demonstrated very encouraging results. It can be seen from 
the results presented in section 6.6 that microscopic observation and histological 
investigation of the tissues showed that the chondrocytes were induced to migrate from 
the gels towards the injured cartilage surface. This is particularly interesting because 
chondrocytes remained in encapsulation without the presence of injured cartilage. The 
presence of injured cartilage also appeared to promote ECM formation to a greater extent, 
in just 10 days, in comparison to chondrocyte encapsulated gels, cultured for 21 days. 
The results from the injury model are very promising for cell delivery as a treatment to 
aid in the regeneration of injured cartilage. This cartilage injury model has great potential 
to be used in vitro as research model in cartilage repair.  
 
8.2.1 Chondrocyte encapsulation summary 
The gelation conditions and incubation of the 100 µL fibrin and FPA-fibrinogen gels 
were developed to try to maximise the viability of the encapsulated chondrocytes by 
ensuring the novel cross-linked fibrinogen gels and fibrin gels had sufficient nutrient and 
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waste exchange for survival, and by reducing the calcium concentration needed for 
gelation to 2 mM to prevent the risk cell apoptosis. Under the incubation conditions, 
300,000 chondrocytes per gel could be encapsulated in the gels with good viability which 
was maintained over a period of at least 21 days. It has been shown that the chondrocytes 
remained in encapsulation and had survived a minimum 21 day culture period. During 
the incubation period the chondrocytes synthesised GAG indicating proteoglycan 
synthesis and probable ECM synthesis. These results showed that the FPA- fibrinogen 
hydrogels have great promise to be used in cell encapsulation and delivery applications. 
All results obtained with the FPA-fibrinogen gels were comparable to fibrin and agarose 
gels suggesting that the FPA-fibrinogen gels are comparable to the main competitor, 
fibrin in cell encapsulation and delivery applications. The successful cartilage injury 
model highlighted the potential for the novel cross-linked fibrinogen gels use in cell 
encapsulation and delivery to repair injured cartilage. 
P15, P17 and HyStem – fibrinogen gels have given encouraging preliminary results 
for chondrocyte encapsulation and delivery. Further research is needed to confirm the 
consistency and reliability of the data as these reagents were in very limited supply, 
enabling only preliminary data to be carried out.   
 
8.3  Mesenchymal stem cell encapsulation 
bBM-MSC encapsulation, and culture was carried out using the ‘optimised 
conditions’. 300,000 bBM-MSCs were encapsulated in fibrin and FPA-fibrinogen gels 
formed with 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1, and 0.7 mg.mL-1 FPA. After 3 days 
of encapsulation the bBM-MSCs  were observed adhering to the tissue culture plastic 
around the gels by phase contrast microscopy. All FPA-fibrinogen and fibrin gels showed 
initial signs of possible degradation, in that they appeared to be smaller. By day 15 of 
encapsulation the FPA-fibrinogen and fibrin gels had almost completely degraded, with 
high numbers of bBM-MSCs observed attached to the tissue culture plastic surrounding 
the gels (section 7.1). This was confirmed by using crystal violet to stain the attached 
cells at day 15 of encapsulation. The gels were not moved prior to staining to ensure the 
cells were not disturbed on the tissue culture plastic. Interestingly, gel degradation was 
not observed in any of the cell free FPA-fibrinogen and fibrin gels and therefore, the 
degradation of the fibrin and fibrinogen gels must be caused by the bBM-MSCs. Cell 
migration from the fibrin and fibrinogen gels was also observed when the osteoblastic-
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like cells, MG63 were encapsulated in the gels (section  7.1.1.).  Therefore, possible cell-
based mechanisms which could lead to the hydrogel dissolution and cell migration were 
considered and tested using fibrin and FPA-fibrinogen encapsulated bBM-MSCs. 
Previous studies have demonstrated that increasing the cell number can increase the 
degradation rate of fibrin gels suggesting that actions from the cells are causing the 
degradation of the gel [257].  
Cell-induced proteolytic degradation was the most likely cause of degradation of the 
fibrin and fibrinogen gels, and two possible types of proteinases were investigated: 
metalloproteinases (MMPs) and plasmin. MMP’s are endopeptidases which are secreted 
in an inactive form and when activated can degrade ECM and play an important role in 
cell migration [258]. MMP-2 and MMP-9 have been found to have a role in the 
degradation of articular cartilage [259] [260]. Plasmin is a serine proteinase which causes 
the breakdown of natural fibrin clots and therefore would also cause degradation of fibrin 
gels in vitro [261]. The precursor, inactive form of plasmin is plasminogen and this is 
present in serum and therefore was present in the serum-containing basic culture medium. 
When plasminogen is enzymatically activated to plasmin (by a suitable proteinase), gel 
degradation may occur. Plasmin also has the ability to activate pro-MMPs including 
MMP-2 and MMP-9 to cause the degradation of ECM [262]. Therefore, plasminogen 
activation to plasmin could also lead to MMP activation.  
To determine if MMPs were causing gel degradation and enabling cell migration the 
MMP inhibitor, Marimastat was incubated with bBM-MSC encapsulated in FPA-
fibrinogen and fibrin gels. Marimastat is known to inhibit a broad spectrum of MMPs 
including MMP-1, MMP-2, MMP-7, MMP-9, and MMP-14. To inhibit plasmin, 
aprotinin, a serine proteinase inhibitor, was incubated with bBM-MSC encapsulated in 
fibrinogen-FPA and fibrin gels to determine if the activation of plasminogen was causing 
gel degradation. Aprotinin was withdrawn from clinic in 2008 by Bayer HealthCare [263] 
due to safety concerns reported from studies investigating the use of the serine protease 
inhibitor in clinic [264] [265] [266]. These concerns included: an increased risk of death 
after administration of aprotinin; an increase in creatinine after the surgical procedure; 
and a high risk of anaphylaxes after second administration [267]. The withdrawal of 
aprotinin led to the use of tranexamic acid and aminocaproic acid [263]. Despite this, 
aprotinin is regularly used in vitro to inhibit fibrinolysis of fibrin gels. For example, 100 
KIU of aprotinin was used to supplement culture medium, cell encapsulated fibrin gels 
exhibited gel degradation over 7 days in culture [268]. Contradictory to the findings in 
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this thesis in which 204.48 KIU and 1226.48 KIU were incubated with the gels, it was 
observed that an activity of 130 KIU resulted in cell death, whereas a lower activity of 
aprotinin 65 KIU reduced degradation but enabled cells to proliferate [269]. Coffin et al 
reported that aprotinin activity as high as 628 KIU had no effect on MSC survival [270].   
Other studies have found that gel degradation occurs when MSCs are seeded onto 
fibrin sutures and this was inhibited with aprotinin up to 100 µg.mL-1 [271]. Mechanical 
testing confirmed that fibrin incubated without aprotinin is much weaker in comparison 
to the fibrin incubated with aprotinin at day 3 of seeding. It was also found that cell 
adhesion to the fibrin sutures had increased with the addition of aprotinin. There are 
several reports of the incubation of aprotinin with fibrin-encapsulated cells to inhibit 
fibrinolysis in vitro [272] [273] [274]. Interestingly, recombinant aprotinin was a 
component of the TISSEEL fibrinogen. 
300,000 bBM-MSCs were encapsulated in FPA-fibrinogen (using 2.66 mg.mL-1 FPA) 
and fibrin gels 24 hours and incubated with serum free medium containing 50 µM 
concentration of plasminogen in the presence of Marimastat or aprotinin. Gel degradation 
was observed in both fibrin and FPA-fibrinogen gels incubated with Marimastat (section 
7.1) and the encapsulated bBM-MSC control which contained no inhibitors, with cell 
migration occurring from the gels onto tissue culture plastic. The gels that were incubated 
with aprotinin did not degrade and crystal violet stain showed that very few cells had 
adhered to the tissue culture plastic in comparison to those gels incubated with no 
inhibitors and Marimastat. Therefore, by inhibiting plasmin activity (or another serine 
proteinase) degradation was inhibited and cell migration was reduced dramatically. To 
investigate if the encapsulated bBM-MSCs could activate plasminogen to plasmin, the 
level of plasmin activity in the culture medium from the cell encapsulated gels was 
analysed. It was found that plasmin activity was detected in all bBM-MSC encapsulated 
medium samples incubated without aprotinin and not in the samples incubated with 
aprotinin. Showing that the activation of plasminogen to plasmin was occurring in all 
samples apart from those incubated with aprotinin.  
In contrast, during incubation of the chondrocyte encapsulated fibrinogen gels, cell 
migration and gel degradation was not observed. Additionally, plasmin activity was not 
detected in the medium. However, Sitek et al found that without incubation with aprotinin 
or tranexamic acid to inhibit fibrinolysis, gel degradation occurred over a 28-day culture 
period [275]. Fibrinogen concentration for gel fabrication was 10 or 20 mg.mL-1, a higher 
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fibrinogen concentration such as 34 mg.mL-1, as used in this study, may decrease the rate 
of degradation and therefore it is not observed over the 21 day culture period. Regular 
microscopic examination of the encapsulated fibrin and FPA-fibrinogen gels was carried 
out and analysis of the culture medium from the gel cultures for resazurin reduction was 
performed. These experiments showed that the chondrocytes remained encapsulated in 
the all the fibrinogen-FPA and fibrin gels and did not migrate out of the gels. Therefore, 
there was evidence to suggest that plasmin was causing the bBM-MSC encapsulated 
fibrinogen gels to degrade.  
The activation of plasminogen was investigated by determining the levels of uPA and 
tPA in the medium. uPA and tPA are plasminogen activators. tPA and uPA have different 
roles in the activation of plasminogen: tPA activates plasminogen during fibrinolysis; 
whereas uPA activates plasminogen during cell migration [262]. uPA and tPA was not 
detected in any of the medium samples suggesting that another plasminogen activation 
process is taking place. It would not have been surprising if uPA was present in the 
medium during MSC migration, however it was found that this was not the case.  
Removing the source of plasminogen from the culture conditions, i.e. using serum free 
medium was then investigated. bBM-MSC encapsulated FPA-fibrinogen and fibrin gels 
incubated in serum free medium without aprotinin degraded over the 21 day culture 
period and cell migration occurred. However, the gels incubated with aprotinin did not 
degrade or exhibit signs of cell migration from the FPA-fibrinogen or fibrin gels. These 
results suggested that an aprotinin sensitive serine proteinase secreted by the cell surface 
of the bBM-MSCs caused the fibrinogen based gels to degrade. Therefore, activation of 
plasminogen to plasmin was not an essential requirement for fibrin and fibrinogen 
degradation by bBM-MSCs.  
In the presence of aprotinin bBM-MSCs were encapsulated in the FPA-fibrinogen and 
fibrin gels. The gels were continuously incubated in chondrogenic medium with aprotinin 
(added freshly at each medium change) for 21 days. Cell activity and GAG formation 
assays were able to be carried out on the gels. It was observed that cell free and medium 
samples showed very little resazurin reduction indicating no effect of the gels on the assay 
and little release of cells into the culture medium. However, there was a slight peak in 
resazurin reduction in the culture medium taken at day 3 of encapsulation on the medium. 
Interestingly, this peak occurred at the same time that the first migration of bBM-MSC 
was observed from the gels cultured in the absence of aprotinin. Therefore, the peak may 
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potentially may be the result of a small number of cells being detected in the sample 
medium. However, bBM-MSCs did not migrate onto to the tissue culture plastic 
throughout the 21 day culture. bBM-MSC encapsulated gels showed resazurin reduction 
of all gels suggesting all cells were viable and metabolically active throughout the 21 day 
culture period. Again, a peak in cell activity was observed at day 10 of encapsulation as 
described for encapsulated chondrocytes. All the bBM-MSC encapsulated gels were 
found to have synthesised GAGs suggesting all FPA-fibrinogen and fibrin gels are able 
to support bBM-MSC chondrogenic differentiation. No significant differences in GAG 
content were observed between the different FPA-fibrinogen formulations and fibrin gels 
for total GAG content suggesting that all gels supporting the BM-MSCs to a similar extent 
and were comparable to each and the main competitor fibrin.  
H&E staining showed that the bBM-MSCs behaved differently in the gels in 
comparison to chondrocytes. The cells appeared to congregate together in the pores of the 
gels rather than remaining as individual cells within the pores. Cell layers are observed 
on the edges of the gels but ECM formation again could not be seen due to high 
background staining from the gels. It was observed from the Toluidine blue staining that 
there were areas of congregated cells and proteoglycan formation, as well as cell layers 
at the edges of the gels.  
On encapsulation of bBM-MSCs in fibrinogen gels formed with P15, P17 and HyStem 
gels, cell migration and gel degradation occurred and was observed by phase contrast 
light microscopy images and a crystal violet stain confirming cell adhesion to tissue 
culture plastic, (section 7.4). P15 contains a RGD sequence which should encourage cell 
adhesion, however, the shape of the peptide backbone of P15 is unknown and therefore it 
is not known if the RGD sequence was available to the cells. It was observed that 
fibrinogen gels formed with P15 and P17 at 0.75 mg.mL-1 degraded slower and had not 
fully degraded by day 9 of encapsulation and less cell migration was observed whereas 
0.25 mg.mL-1 and 0.5 mg.mL-1 for both P15 and P17 degraded within 9 days of 
encapsulation and exhibited high numbers of cells migrating from the gels. As previously 
discussed, a higher cross-linking density results in a decreased degradation rate, the 
results from this thesis concur. HyStem formed very weak gels with fibrinogen when 
encapsulated with either bBM-MSCs or chondrocytes and both concentrations 
0.75 mg.mL-1 and 1 mg.mL-1 degraded to a thin layer on the bottom of the well plate with 
very high cell migration observed. To inhibit gel degradation aprotinin was incubated in 
the medium from day 3 of encapsulation. Aprotinin inhibited gel degradation and reduced 
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cell migration. Therefore, this permitted longer term incubation and enabled the cell 
viability and GAG accumulation to be assessed. Cell free gels and samples of medium 
incubated with the gels showed very little resazurin reduction and therefore did not 
interfere with the assay. Cell viability was observed in all fibrinogen gels formed from 
P15, P17 and HyStem at all concentrations of FBPs used. A peak in metabolic activity at 
day 14 was observed which was consistent in all gels and interestingly this peak in activity 
appears after the same incubation time in chondrogenic medium as with chondrocyte 
encapsulation in P15-fibrinogen, P17-fibrinogen, FPA-fibrinogen and HyStem-
fibrinogen and bBM-MSC encapsulation in FPA-fibrinogen gels. Total GAG content was 
determined in all the gels and all gels showed GAG accumulation in the hydrogels. 
However, some cell migration was observed in the gels over the 24 day incubation period. 
The HyStem-fibrinogen gels degraded throughout the culture period and therefore the 
bBM-MSC encapsulated gels were incubated with serum-free medium and aprotinin to 
inhibit the degradation of the HyStem-fibrinogen gels. Snyder et al found that when 
crosslinking hyaluronic acid with fibrinogen concentrations of 3 mg.mL-1 the gels would 
degrade within two days of encapsulating MSCs. However, when the fibrinogen 
concentration was increased to 6 mg.mL-1 and in the presence of aprotinin, gel 
degradation did not occur [276]. This may be due to the modification of hyaluronic acid 
with methacrylic anhydride and the exposure to UV light creating a stronger gel. This 
system also incorporated aprotinin into the gel fabrication steps instead of supplementing 
the medium with aprotinin. This does suggested that higher concentrations of HyStem 
should be investigated. HyStem gels still exhibited gel degradation and cell migration 
meaning that the gels are too weak to enable efficient cell encapsulation of bBM-MSCs 
for a 21 day period. This could account for the high cell activity results because the cells 
had adhered to the tissue culture plastic and these were contributing to the resazurin 
reduction results. Total GAG content per gel suggested that all gels have supported bBM-
MSC chondrogenic differentiation, however fibrin has a higher mean GAG content than 
all P15, P17 and HyStem gels. However, for chondrogenic differentiation to be confirmed 
further research must be done to determine if chondrogenic genes are expressed (such as 
for collagen II and aggrecan). 
H&E staining showed that the bBM-MSCs congregate within the pores of the gel and 
this was consistent with bBM-MSC encapsulated FPA-fibrinogen gels and fibrin gels as 
previously discussed. Cell layers can be observed on the edges of the gels with ECM 
deposition suggesting that these cells had exhibited a more differentiated state in 
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comparison to those cells in the centre of the gel. Toluidine blue stained gels indicating 
proteoglycan deposition in all gels. Greater areas of proteoglycan staining was found in 
fibrinogen gels formed from 0.75 mg.mL-1 concentrations of P15 and P17, suggesting 
that the gels formed from higher concentrations of P15 and P17 were supporting 
chondrogenic differentiation to a greater degree than the lower concentrations of P15 and 
P17. It was possible to section and stain HyStem at concentrations of 1 mg.mL-1 and 
0.75 mg.mL-1 due to a very small gel remained after 21 days in culture. The staining 
suggested proteoglycan formation in 0.75 mg.mL-1 but due to high background staining 
this was not observed in gels fabricated with 1 mg.mL-1 HyStem. 
   
8.3.1 Mesenchymal stem cell encapsulation summary 
On encapsulation of bBM-MSCs it became apparent that the cells behaved differently 
in comparison to chondrocytes. bBM-MSC migration was observed along with gel 
degradation. Due to the protein nature of the fibrin and fibrinogen gels. Cell-induced 
proteolytic degradation was the most likely cause of degradation of the fibrin and 
fibrinogen gels, and two possible types of proteinases were investigated: MMPs and 
plasmin.  Use of the MMP inhibitor Marimastat had no effect on gel degradation or cell 
migration. Inhibition of plasmin in serum containing medium with aprotinin was found 
to inhibit gel degradation and reduced cell migration. Therefore, the bBM-MSCs were 
able to produce a proteinase which could activate plasminogen to plasmin. Removing the 
source of the plasmin precursor, plasminogen, which is found in serum and incubating 
the bBM-MSC encapsulated gels in serum-free medium, did not stop cell migration or 
gel degradation. However, addition of aprotinin to these incubations inhibited cell 
migration and gel degradation. These results suggested the bBM-MSCs produced an 
aprotinin-sensitive serine protease which directly degraded the fibrinogen gels in addition 
to activating plasminogen to plasmin. In the presence of aprotinin, bBM-MSCs 
encapsulated in FPA-fibrinogen gels at all concentrations were able to survive and 
differentiate within the gels.  
bBM-MSC encapsulated HyStem-fibrinogen gels showed gel degradation occurred in 
the presence of aprotinin and therefore the gels were too weak to support long-term 
culture. However, these gels have shown promising results despite gel degradation. P15 
and P17 – fibrinogen gels had supported chondrogenic differentiation of the bBM-MSCs, 
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with concentrations of 0.75 mg.mL-1 of both fibrinogen –binding peptides showing 
greater promise due to a slower degradation rate. 
 
8.4 Overall discussion 
Although the novel cross-linked fibrinogen gels and fibrin gels were consistently 
similar when encapsulated with chondrocytes and MSCs throughout this thesis, the 
fibrinogen gels have added advantages which make them superior to fibrin for cell 
encapsulation and delivery. The FPA-fibrinogen gels were formed from reproducible 
synthetic carriers of the fibrinogen binding peptide sequence, removing batch to batch 
variation. Combined with the high quality, commercially available fibrinogen a more 
consistently reliable gel can be formed. The combination of synthetic and natural 
materials is highly advantageous to encourage cell differentiation but also has the added 
benefit of tailorability, as previously described. The cross-linking density of the novel 
fibrinogen gels can readily be modified by altering the number of fibrinogen binding 
peptides present during gelation. This added tailorability provides a more versatile gel 
suitable for many different applications. The gelation of novel cross-linked fibrinogen 
gels occurred by simply combining two liquid precursors (the FBP carrier and fibrinogen) 
and the fast gelation rate makes these novel fibrinogen gels ideal for clinical settings.   
A range of gels are being developed for use in cell delivery and encapsulation for 
cartilage repair. It has been demonstrated by Rahman et al that combining fibrin with 
PLGA, an enhanced cell viability and differentiation capability was achieved than just 
PLGA alone, providing evidence to suggest that a combination of natural and synthetic 
gels is beneficial to cellular survival [277]. Sheykhhasan et al found that fibrin gels 
encouraged chondrogenic differentiation greater than alginate or PLGA when 
encapsulated with MSCs [278]. In this study cross-linking the fibrinogen with synthetic 
carriers of FBPs did not significantly change chondrocyte or bBM-MSC activity and 
differentiation in comparison to pure fibrin gels. The range of FPA-fibrinogen gels 
investigated appeared to have similar porosities and if lower concentrations of the FPA 
carriers were investigated then a bigger difference in cellular survival and chondrogenic 
differentiation may have been observed.  
Other gel systems use a ceramic scaffold as an osteochondral plug to fill the defect and 
mimic the bone. Cells are then delivered on top of the plug via a gel such as fibrin to 
create the softer environment required for chondrogenic differentiation [279]. Successful 
 274 | P a g e  
 
C h a p t e r |  Discussion 
results have been demonstrated in vivo with the encapsulation of chondrocytes within the 
fibrin gel. Evidence suggested a hyaline-like cartilage repair. Providing further evidence 
for the suitability of the novel cross-linked fibrinogen gels in cell encapsulation and 
delivery for cartilage regeneration.    
In this study the differences in cellular behaviour between chondrocytes and 
mesenchymal stem cells was apparent. Chondrocytes remained in encapsulation whereas 
MSCs migrated out of the fibrinogen based gels and the gels degraded. This behaviour is 
not surprising because MSCs are required to migrate out of the stem cell niche in which 
the MSCs are contained in an enriched ECM [280] whereas chondrocytes are required to 
remain in the lacunae and synthesise ECM. By these behaviours being exhibited in the 
novel cross-linked fibrinogen gels the cells appear to be in environments similar to that 
of their natural environment. 
In summary, it has been demonstrated that the novel cross-linked fibrinogen gels have 
supported chondrocyte and MSC survival and differentiation over a 21 day culture period. 
Control over the degradation rate of the gels has been established with the addition of 
aprotinin to the culture medium reducing MSC migration. Therefore, these novel cross-
linked fibrinogen gels have potential for use in cell encapsulation and delivery for 
cartilage repair. 
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9.0 Conclusions 
As outlined in the literature review there is a need for cell therapies to repair injured 
cartilage. The research shown in this study has provided a solution with a novel 
cross-linked fibrinogen gel system for cell encapsulation and delivery applications. The 
fibrinogen based gels are formed by combining fibrinogen with novel carrier materials 
that have attached novel fibrinogen binding peptides. It is the interaction of the fibrinogen 
binding peptides with fibrinogen that leads to cross-linking of the protein to form a 
fibrinogen-FBP gel. A range of gels such as fibrin and agarose have been successfully 
investigated for cell encapsulation and delivery but have limitations. The novel cross-
linked fibrinogen gels overcome these limitations and have demonstrated considerable 
potential for cell encapsulation and delivery throughout this research. The main 
conclusions from this research are outlined below: 
• Confirmation of natural gel systems such as fibrin and agarose supported 
chondrocyte culture and therefore have potential for use in cell encapsulation and 
delivery despite the limitations discussed in the literature review. 
 
• More importantly, this research has demonstrated that novel cross-linked 
fibrinogen gels based on different carrier molecules bound to the fibrinogen 
binding peptide were also able to support articular chondrocyte and MSC survival 
for up to 21 days in culture.  
 
• Of these novel cross-linked fibrinogen gels, investigations into the encapsulation 
of FPA-fibrinogen gels was the main focus. FPA-fibrinogen gels at concentrations 
of 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1 and 0.7 mg.mL-1 supported 
chondrocyte survival and differentiation over a 21 day culture period and are 
comparable to the main competitor fibrin and agarose. Chondrocytes remained in 
encapsulation throughout the culture period. From H&E staining fibrin has a 
closed structure whereas FPA has pores in which the chondrocytes appear to 
reside individually. Concentration of FPA present during gelation did not appear 
to affect chondrocyte survival or differentiation, FPA 2.66 mg.mL-1 and FPA 1.33 
mg.mL-1 had a higher mean GAG formation compared to FPA 2 mg.mL-1, FPA 
0.7 mg.mL-1 and fibrin. This was also consistent with the Toluidine blue staining.     
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• It was noted that chondrocytes remained entrapped within the novel cross-linked 
fibrinogen gels throughout culture whereas MSCs migrated from the gels and gel 
degradation was observed. MSC migration occurred at day 3 of encapsulation and 
by day 15 the novel cross-linked fibrinogen gels had fully degraded (see section 
7.1). Gel degradation was inhibited and cell migration reduced when the 
fibrinogen gels were incubated with aprotinin (see section 7.3). On incubation 
with serum-free medium, cell migration and gel degradation also occurred but was 
inhibited by aprotinin. This suggested the production of an aprotinin sensitive 
serine protease which is able to activate plasminogen to plasmin and directly 
degrade the novel cross-linked fibrinogen gels. In the presence of aprotinin, FPA 
gels at concentrations of 2.66 mg.mL-1, 2 mg.mL-1, 1.33 mg.mL-1 and 0.7 mg.mL-1 
were able to support bBM-MSC survival and chondrogenic differentiation 
throughout a 21 day culture period. 
 
• The MSC-induced migration and gel degradation could focus MSC migration to 
a site of injury to aid in its repair, as shown from the cartilage injury model where 
bBM-MSCs can be observed migrating towards the injured cartilage, section 7.7. 
 
In conclusion, the ability of being able to control the rate of cross-linking of fibrinogen 
by using the novel fibrinogen binding peptide analogues described in this thesis is very 
advantageous and enables fine tuning of the porosity of the fibrinogen gels. This 
refinement of porosity is not as easily or reproducibly achieved by using traditional fibrin 
gels. This novel cross-linked fibrinogen gel system has great promise for use in cell 
encapsulation and delivery applications to tissue injury sites. 
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10.0 Future Work  
The research carried out in this thesis shows the potential for the use of novel cross-
linked fibrinogen gels in cell encapsulation and delivery applications. However, further 
work is required to be carried out: 
• P15 and P17 – fibrinogen gels at concentrations of 1 mg.mL-1 show promise 
for cell encapsulation, more repeats are required to determine if the data shown 
is an accurate representation of the gels. Further to this P17 contains DGEA 
sequence, developing a collagen binding assay would determine whether this 
sequence was available to the cells or blocked by the shape of the peptide.  
• P15, P17 and HyStem – fibrinogen gels encapsulated with chondrocytes 
showed inconsistent results with the GAG assay and the histological 
examination. This should be repeated to determine if the data shown in this 
thesis is an accurate representation of the encapsulation of chondrocytes in P15, 
P17, and HyStem – fibrinogen gels.  
• Histological examination showed that the fibrinogen gels stained and therefore 
high backgrounds were observed. Collagen II immunostaining is more specific 
and would allow the observation of collagen type II production which is present 
in articular cartilage. This should be investigated on chondrocyte and bBM-
MSC encapsulated gels. 
• RNA extraction requires further optimisation to ensure phenol contamination 
is removed from the FPA-fibrinogen and fibrin gels, once this has been 
achieved qRT-PCR could be carried out to determine if chondrogenic genes 
are being expressed. This will also help to determine if the decrease in 
chondrocyte and bBM-MSC activity at day 10 of encapsulation is due to 
differentiation.  
• The cartilage injury model has been optimised for the removal of cartilage from 
the metacarpophalangeal joint. The delivery of chondrocytes showed 
successful results. Experimental repeats for 21 days for the delivery of 
chondrocytes and bBM-MSC’s to the injury is required for accuracy of the 
data. 
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